group_name,group_level,strata_name,strata_level,window_name,variable,variable_type,variable_level,estimate_type,estimate,cdm_name,generated_by
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: LOCAL ANESTHETICS (21605096),binary,NA,count,96,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANDROGENS (21602506),binary,NA,count,313,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,1961,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: LOCAL ANESTHETICS (21605096),binary,NA,count,86,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,1456,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,13402,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: POSTERIOR PITUITARY LOBE HORMONES (21602697),binary,NA,count,63,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,7848,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,10259,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: BETA BLOCKING AGENTS, OTHER COMBINATIONS (21601738)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,404,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,1616,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: LIVER THERAPY, LIPOTROPICS (21600521)",binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,4004,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,332,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,8543,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,6575,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: UTEROTONICS (21602430),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,361,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,6166,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,1135,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: AMPHENICOLS (21602813),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: GONADOTROPINS AND OTHER OVULATION STIMULANTS (21602597),binary,NA,count,73,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,637,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,2208,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,870,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,1352,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,963,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,140,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: SURGICAL AIDS (21605112),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,1864,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,2616,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: OTHER HEMATOLOGICAL AGENTS (21601226),binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANABOLIC STEROIDS (21600915),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,431,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,283,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,199,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS (21602745)",binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,3123,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,6057,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,1399,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, COMBINATIONS (21601898)",binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,1593,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,11758,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,84,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANDROGENS (21602506),binary,NA,count,569,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,4696,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ULTRASOUND CONTRAST MEDIA (21605437),binary,NA,count,265,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES (21603728),binary,NA,count,173,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,2768,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,6380,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: CARDIOVASCULAR SYSTEM (21605509),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,9745,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANTIPSORIATICS FOR SYSTEMIC USE (21602044),binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,252,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ALLERGENS (21605214),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,507,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: OTHER RESPIRATORY SYSTEM PRODUCTS (21603531),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,723,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,13262,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,4201,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,325,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,1998,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: OTHER OTOLOGICALS (21605180),binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,1483,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE (21602318),binary,NA,count,77,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: GLYCOGENOLYTIC HORMONES (21602776),binary,NA,count,175,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,1225,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: CICATRIZANTS (21601986),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: AMPHENICOLS (21602813),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,1073,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, COMBINATIONS (21601898)",binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,1317,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,1545,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANTIADRENAL PREPARATIONS (21602748),binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: SURGICAL AIDS (21605112),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,denominator,binary,NA,count,49646,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,192,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE (21602318),binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,102,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,495,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,78,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ENZYMES (21601997),binary,NA,count,78,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,4742,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,278,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM (21601848),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,1135,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANABOLIC STEROIDS (21600915),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,1784,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,6669,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,758,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,402,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION (21600451),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,839,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: OPIOIDS (21604254),binary,NA,count,11172,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,1769,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,2284,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,7486,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,9892,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,2925,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: RENAL SYSTEM (21605462),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: OTHER RESPIRATORY SYSTEM PRODUCTS (21603531),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS (21601730)",binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,932,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS (21604911),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH ANALGESICS (21600220),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,13676,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: HYPOTHALAMIC HORMONES (21602709),binary,NA,count,63,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,377,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,909,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,491,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,155,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,394,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,83,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,1746,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: OTHER HEMATOLOGICAL AGENTS (21601226),binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION (21604787),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,144,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,8089,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,935,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,4596,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES (21602683),binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,1479,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: OTHER ANTIHYPERTENSIVES (21600438),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,20328,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: BLOOD AND RELATED PRODUCTS (21601137),binary,NA,count,47,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,1533,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: RENAL SYSTEM (21605462),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,3603,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,439,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,1081,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,8600,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,6924,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,301,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: CARDIOVASCULAR SYSTEM (21605509),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,7517,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,902,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,865,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,2830,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: OCULAR VASCULAR DISORDER AGENTS (21605119),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: GLYCOGENOLYTIC HORMONES (21602776),binary,NA,count,207,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: CICATRIZANTS (21601986),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,367,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,2296,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,7855,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: ECTOPARASITICIDES, INCL. SCABICIDES (21604968)",binary,NA,count,121,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,11494,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,1779,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANTACIDS (21600047),binary,NA,count,150,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,187,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,2068,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,3361,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,1277,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,306,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: OTHER PLAIN VITAMIN PREPARATIONS (21600840),binary,NA,count,61,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,4686,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,5060,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,1975,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,4255,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,17106,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,916,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: OTHER ANTIHYPERTENSIVES (21600438),binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,1865,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,5702,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,825,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,1293,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,2272,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,1488,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: X-RAY CONTRAST MEDIA, NON-IODINATED (21605414)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: VITAMIN K AND OTHER HEMOSTATICS (21601043),binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ALKYLATING AGENTS (21601388),binary,NA,count,268,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,4072,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,933,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,2337,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,278,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,242,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: OTHER OTOLOGICALS (21605180),binary,NA,count,44,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,1682,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTITREMATODALS (21604928),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION (21604787),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,1483,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,2514,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: OCULAR VASCULAR DISORDER AGENTS (21605119),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,2817,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,103,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,4931,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,2241,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,11619,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,240,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,306,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: CORTICOSTEROIDS (21605164),binary,NA,count,70,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,216,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: POTASSIUM (21600875),binary,NA,count,3006,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,13995,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,1908,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,487,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ALLERGENS (21605214),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION (21602558),binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,121,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: DIAGNOSTIC AGENTS (21605106),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,2771,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,415,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,4042,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,985,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTI-PARATHYROID AGENTS (21602785),binary,NA,count,91,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,623,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: OTHER THERAPEUTIC RADIOPHARMACEUTICALS (21605585),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM (21601848),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,3617,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,6639,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,243,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,6943,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,74,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,549,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: UTEROTONICS (21602430),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,2750,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,2917,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,5295,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,1415,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,1463,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,8275,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTIFIBRINOLYTICS (21601033),binary,NA,count,188,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,2866,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,1783,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,1671,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: CALCIUM (21600858),binary,NA,count,1491,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,4651,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,1068,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ALKYLATING AGENTS (21601388),binary,NA,count,76,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,57,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,5718,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,2195,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,13369,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,2135,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: COMBINATIONS OF ANTIBACTERIALS (21603035),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,993,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,2988,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,740,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,16738,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,217,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: SPECIFIC ANTIRHEUMATIC AGENTS (21604021),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,1761,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: BETA BLOCKING AGENTS AND OTHER DIURETICS (21601718),binary,NA,count,69,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS (21601730)",binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,3163,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,112,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,101,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,14083,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,150,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,1613,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,82,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,6508,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,56,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,2538,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: COMBINATIONS OF ANTIBACTERIALS (21603035),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,16890,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,445,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,64,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,7268,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,171,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,1659,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,1471,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,11021,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,829,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ESTROGENS (21602514),binary,NA,count,2102,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,6485,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: POSTERIOR PITUITARY LOBE HORMONES (21602697),binary,NA,count,79,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: CORTICOSTEROIDS (21605164),binary,NA,count,68,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,367,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,2594,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION (21600451),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,5586,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,1169,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION (21602558),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,9581,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ULTRASOUND CONTRAST MEDIA (21605437),binary,NA,count,296,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,494,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS (21604125)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,197,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,3582,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTACIDS (21600047),binary,NA,count,200,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,5540,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,1088,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,5376,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,2487,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: EMOLLIENTS AND PROTECTIVES (21601969),binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,710,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,3541,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,218,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,3576,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: HYPOTHALAMIC HORMONES (21602709),binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,2829,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,2393,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,336,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,339,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ENZYMES (21601997),binary,NA,count,89,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,2611,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: BETA BLOCKING AGENTS AND OTHER DIURETICS (21601718),binary,NA,count,61,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTIADRENAL PREPARATIONS (21602748),binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,166,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: MEDICATED DRESSINGS (21602262),binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,4592,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,104,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,8978,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,1469,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,90,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS (21604125)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: ECTOPARASITICIDES, INCL. SCABICIDES (21604968)",binary,NA,count,151,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: MEDICATED DRESSINGS (21602262),binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,1420,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,10500,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,2295,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,1837,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: POTASSIUM (21600875),binary,NA,count,2357,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,1333,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,644,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,144,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,97,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,295,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,158,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,5298,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,1744,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES (21603728),binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: OPIOIDS (21604254),binary,NA,count,13418,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,8381,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,16524,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: PROTECTIVES AGAINST UV-RADIATION (21601979),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,8776,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,118,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,1217,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,2483,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,248,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,26397,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,1130,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,3360,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,4508,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,4919,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: LIVER THERAPY, LIPOTROPICS (21600521)",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,4735,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,267,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,730,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANTIFIBRINOLYTICS (21601033),binary,NA,count,112,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,257,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: INTESTINAL ADSORBENTS (21600627),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,74,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: VITAMIN K AND OTHER HEMOSTATICS (21601043),binary,NA,count,87,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,1641,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ESTROGENS (21602514),binary,NA,count,3962,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,1420,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS (21600933),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,234,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,1911,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,2136,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,963,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,16137,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,6337,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,522,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,3700,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,828,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,123,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS (21602745)",binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,69,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,5704,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,2097,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,457,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,1977,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,954,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,2895,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,784,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,4485,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,893,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,5796,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,11384,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,232,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,3886,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,568,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS (21600933),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,152,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,290,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,157,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,1165,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTIPSORIATICS FOR SYSTEMIC USE (21602044),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,10818,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES (21602683),binary,NA,count,90,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,5007,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: OTHER DIURETICS (21601556),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,23159,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,1504,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: GONADOTROPINS AND OTHER OVULATION STIMULANTS (21602597),binary,NA,count,77,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: CALCIUM (21600858),binary,NA,count,1487,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,1321,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: EMOLLIENTS AND PROTECTIVES (21601969),binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: SPECIFIC ANTIRHEUMATIC AGENTS (21604021),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,1290,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,1359,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,258,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,3436,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,1027,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH ANALGESICS (21600220),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,121,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,989,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: BLOOD AND RELATED PRODUCTS (21601137),binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,787,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,3832,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,370,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: OTHER DIURETICS (21601556),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,4768,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,308,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,855,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,547,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,702,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,176,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,585,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,89,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,159,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,5950,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANTI-PARATHYROID AGENTS (21602785),binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,5521,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,53,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,690,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,1404,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,denominator,binary,NA,count,37497,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,1409,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,1051,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,346,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,11348,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,244,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,1544,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: DRUGS FOR TREATMENT OF LEPRA (21603121),binary,NA,count,121,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,408,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS (21604911),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,9635,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,3510,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,6068,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: DRUGS FOR TREATMENT OF LEPRA (21603121),binary,NA,count,92,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: OTHER PLAIN VITAMIN PREPARATIONS (21600840),binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,1262,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,1777,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION (21602558),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,485,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,1222,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: UTEROTONICS (21602430),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,594,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,1192,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, COMBINATIONS (21601898)",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,3359,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,76,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,431,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: GLYCOGENOLYTIC HORMONES (21602776),binary,NA,count,88,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,677,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,2559,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS (21600933),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,461,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,867,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: CICATRIZANTS (21601986),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,1007,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: RENAL SYSTEM (21605462),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS (21602745)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,9113,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTI-PARATHYROID AGENTS (21602785),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: EMOLLIENTS AND PROTECTIVES (21601969),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER THERAPEUTIC RADIOPHARMACEUTICALS (21605585),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,123,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,1368,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,272,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,1148,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: MEDICATED DRESSINGS (21602262),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTI-PARATHYROID AGENTS (21602785),binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS (21602745)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE (21602318),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,2197,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,936,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ALKYLATING AGENTS (21601388),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: POTASSIUM (21600875),binary,NA,count,199,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,1048,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,2420,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,242,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,349,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: SURGICAL AIDS (21605112),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,344,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,472,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,4805,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: LIVER THERAPY, LIPOTROPICS (21600521)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,688,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,8190,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,1315,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,1314,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,5792,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,159,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,745,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,4334,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION (21600451),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: CALCIUM (21600858),binary,NA,count,746,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,79,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,75,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,119,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,5074,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,2630,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,4388,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,1971,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES (21603728),binary,NA,count,85,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,709,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTITREMATODALS (21604928),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,859,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,5341,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,798,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,916,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIADRENAL PREPARATIONS (21602748),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,544,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,801,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,380,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH ANALGESICS (21600220),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, COMBINATIONS (21601898)",binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,721,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,399,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION (21600451),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,2029,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,351,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,1397,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,1122,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,426,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS (21604911),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,222,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,1085,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,194,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH ANALGESICS (21600220),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES (21603728),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: GONADOTROPINS AND OTHER OVULATION STIMULANTS (21602597),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: BETA BLOCKING AGENTS AND OTHER DIURETICS (21601718),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,3572,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,433,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES (21603728),binary,NA,count,66,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,449,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,333,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,4746,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,9286,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,1366,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,968,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,2473,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,314,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,2556,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,662,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,1054,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,200,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: LIVER THERAPY, LIPOTROPICS (21600521)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER ANTIHYPERTENSIVES (21600438),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,154,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTACIDS (21600047),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS (21604125)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS (21601730)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,73,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM (21601848),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: UTEROTONICS (21602430),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,314,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,801,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: DRUGS FOR TREATMENT OF LEPRA (21603121),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,751,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OPIOIDS (21604254),binary,NA,count,5569,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION (21602558),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,368,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,245,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,1147,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS (21604911),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,421,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS (21601730)",binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,237,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,1316,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,374,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,664,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,159,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,127,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,5202,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,509,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,3000,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: X-RAY CONTRAST MEDIA, NON-IODINATED (21605414)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: VITAMIN K AND OTHER HEMOSTATICS (21601043),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,120,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,1570,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,84,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,731,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,83,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,3829,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: SURGICAL AIDS (21605112),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,66,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,107,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,1022,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,400,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,74,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,148,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OPIOIDS (21604254),binary,NA,count,5858,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,1296,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,174,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: GLYCOGENOLYTIC HORMONES (21602776),binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER RESPIRATORY SYSTEM PRODUCTS (21603531),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,871,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,48,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, COMBINATIONS (21601898)",binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIPSORIATICS FOR SYSTEMIC USE (21602044),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,1067,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,451,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTACIDS (21600047),binary,NA,count,92,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,79,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,1666,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: VITAMIN K AND OTHER HEMOSTATICS (21601043),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,99,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANABOLIC STEROIDS (21600915),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,411,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,975,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,1163,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,5940,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,159,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIFIBRINOLYTICS (21601033),binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,479,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,3248,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,430,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,746,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: BETA BLOCKING AGENTS AND OTHER DIURETICS (21601718),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,442,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS (21601730)",binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,181,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,67,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,415,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,554,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,101,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,785,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,207,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,573,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER HEMATOLOGICAL AGENTS (21601226),binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,79,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,1429,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,2474,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,499,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,213,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: INTESTINAL ADSORBENTS (21600627),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,112,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,194,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,6789,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,2083,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,2355,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM (21601848),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,3779,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,1992,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,915,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIADRENAL PREPARATIONS (21602748),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,911,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OCULAR VASCULAR DISORDER AGENTS (21605119),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,6806,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH ANALGESICS (21600220),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIPSORIATICS FOR SYSTEMIC USE (21602044),binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: CICATRIZANTS (21601986),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,698,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANABOLIC STEROIDS (21600915),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,124,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,178,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,379,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,568,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH ANALGESICS (21600220),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER HEMATOLOGICAL AGENTS (21601226),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,1760,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,151,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,3153,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,1044,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,12279,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,277,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ENZYMES (21601997),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,270,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,198,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTITREMATODALS (21604928),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,2402,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,3094,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,1980,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,69,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,235,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,2200,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,833,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,1311,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,850,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,109,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: CORTICOSTEROIDS (21605164),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,102,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,701,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: SURGICAL AIDS (21605112),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: GONADOTROPINS AND OTHER OVULATION STIMULANTS (21602597),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,169,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,226,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: BETA BLOCKING AGENTS AND OTHER DIURETICS (21601718),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,615,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ALKYLATING AGENTS (21601388),binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,1213,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: POSTERIOR PITUITARY LOBE HORMONES (21602697),binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,denominator,binary,NA,count,9565,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,120,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,5322,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER HEMATOLOGICAL AGENTS (21601226),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,89,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,87,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,167,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,342,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,811,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,577,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,1864,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,3885,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,4221,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,73,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: POSTERIOR PITUITARY LOBE HORMONES (21602697),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,198,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ULTRASOUND CONTRAST MEDIA (21605437),binary,NA,count,125,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,923,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,443,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,575,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,776,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,559,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,2210,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,1432,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,122,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES (21602683),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, COMBINATIONS (21601898)",binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,778,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: CICATRIZANTS (21601986),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,51,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTI-PARATHYROID AGENTS (21602785),binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,154,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,158,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,353,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,1330,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES (21603728),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: ECTOPARASITICIDES, INCL. SCABICIDES (21604968)",binary,NA,count,48,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,806,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER PLAIN VITAMIN PREPARATIONS (21600840),binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANABOLIC STEROIDS (21600915),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,110,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,1657,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,588,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,705,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,745,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,286,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,142,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,1382,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,327,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,131,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,2233,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,127,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS (21601730)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIADRENAL PREPARATIONS (21602748),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER THERAPEUTIC RADIOPHARMACEUTICALS (21605585),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM (21601848),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,276,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: LOCAL ANESTHETICS (21605096),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,3060,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,778,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS (21601730)",binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,118,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,1035,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,544,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,102,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,647,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,1514,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTI-PARATHYROID AGENTS (21602785),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,109,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIPSORIATICS FOR SYSTEMIC USE (21602044),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,221,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,1746,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,163,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,10367,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,146,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,852,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,1087,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: COMBINATIONS OF ANTIBACTERIALS (21603035),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,85,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: EMOLLIENTS AND PROTECTIVES (21601969),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,335,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,2919,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,161,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: CORTICOSTEROIDS (21605164),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANDROGENS (21602506),binary,NA,count,138,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ENZYMES (21601997),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: VITAMIN K AND OTHER HEMOSTATICS (21601043),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,577,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,195,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,583,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,967,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS (21604125)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES (21602683),binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,132,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,909,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,75,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: RENAL SYSTEM (21605462),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANDROGENS (21602506),binary,NA,count,117,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION (21600451),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER OTOLOGICALS (21605180),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: ECTOPARASITICIDES, INCL. SCABICIDES (21604968)",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,799,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: RENAL SYSTEM (21605462),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,56,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: LIVER THERAPY, LIPOTROPICS (21600521)",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,202,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,975,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,255,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,1482,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,3176,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,4331,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,1295,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,2934,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER ANTIHYPERTENSIVES (21600438),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,678,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,562,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,2641,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,1767,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,124,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,503,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,788,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,3758,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: LIVER THERAPY, LIPOTROPICS (21600521)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,10990,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER HEMATOLOGICAL AGENTS (21601226),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,73,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,366,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,573,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS (21604911),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: AMPHENICOLS (21602813),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: LOCAL ANESTHETICS (21605096),binary,NA,count,48,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,91,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,1848,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIPSORIATICS FOR SYSTEMIC USE (21602044),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,483,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,180,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,3544,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,284,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ULTRASOUND CONTRAST MEDIA (21605437),binary,NA,count,107,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,136,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,2196,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,64,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,1780,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,2676,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: BLOOD AND RELATED PRODUCTS (21601137),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,139,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,106,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,69,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIFIBRINOLYTICS (21601033),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,679,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ENZYMES (21601997),binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: BETA BLOCKING AGENTS, OTHER COMBINATIONS (21601738)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,1047,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,98,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,2184,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: GONADOTROPINS AND OTHER OVULATION STIMULANTS (21602597),binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER ANTIHYPERTENSIVES (21600438),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,391,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,96,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,3966,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,2285,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,283,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,165,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,165,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,533,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS (21600933),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,125,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,182,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,608,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,4698,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,540,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,556,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: BLOOD AND RELATED PRODUCTS (21601137),binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,475,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: BETA BLOCKING AGENTS AND OTHER DIURETICS (21601718),binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,937,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,1161,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,478,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: CALCIUM (21600858),binary,NA,count,631,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,107,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: X-RAY CONTRAST MEDIA, NON-IODINATED (21605414)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,140,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,268,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,676,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ESTROGENS (21602514),binary,NA,count,843,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,2685,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS (21600933),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,61,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,1649,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,720,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,625,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,1216,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,3061,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,282,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,1296,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,607,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,195,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,131,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,61,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,115,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,4104,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,71,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,2485,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,1968,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,2272,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,295,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,625,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,205,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,115,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,1188,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,650,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,449,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,321,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,186,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,2476,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: POTASSIUM (21600875),binary,NA,count,442,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,551,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION (21600451),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: HYPOTHALAMIC HORMONES (21602709),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,1421,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,7797,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,728,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,3354,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,99,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,329,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION (21604787),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: COMBINATIONS OF ANTIBACTERIALS (21603035),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,286,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,352,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,838,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER DIURETICS (21601556),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,416,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,4737,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,1889,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,75,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,416,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,71,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,1692,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: EMOLLIENTS AND PROTECTIVES (21601969),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ESTROGENS (21602514),binary,NA,count,1060,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: CORTICOSTEROIDS (21605164),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,459,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ESTROGENS (21602514),binary,NA,count,715,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,2961,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,2050,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,83,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,96,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,173,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,1121,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,1469,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,294,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: DRUGS FOR TREATMENT OF LEPRA (21603121),binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE (21602318),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: GLYCOGENOLYTIC HORMONES (21602776),binary,NA,count,65,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION (21604787),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,319,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,338,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,7602,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: ECTOPARASITICIDES, INCL. SCABICIDES (21604968)",binary,NA,count,56,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,162,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,1842,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ENZYMES (21601997),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,605,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ESTROGENS (21602514),binary,NA,count,1524,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: CALCIUM (21600858),binary,NA,count,616,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,351,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,166,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,65,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ALLERGENS (21605214),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,1597,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ALKYLATING AGENTS (21601388),binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER DIURETICS (21601556),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,2369,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,674,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTACIDS (21600047),binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,67,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,2920,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,1018,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: VITAMIN K AND OTHER HEMOSTATICS (21601043),binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,1664,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,707,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,2276,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: MEDICATED DRESSINGS (21602262),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,53,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,2880,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,646,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,473,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,96,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION (21602558),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,89,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,975,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,114,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER OTOLOGICALS (21605180),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,526,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,70,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,2499,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,464,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,2189,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,227,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,214,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,481,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: CICATRIZANTS (21601986),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,126,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,367,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: AMPHENICOLS (21602813),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: CORTICOSTEROIDS (21605164),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: BETA BLOCKING AGENTS AND OTHER DIURETICS (21601718),binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,142,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,1490,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,190,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTACIDS (21600047),binary,NA,count,123,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE (21602318),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER ANTIHYPERTENSIVES (21600438),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: EMOLLIENTS AND PROTECTIVES (21601969),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,132,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,138,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTACIDS (21600047),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,1708,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,177,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,5054,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,473,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,1176,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,87,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE (21602318),binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,112,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,73,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,93,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,2946,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES (21602683),binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,544,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,436,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,740,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,298,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ALKYLATING AGENTS (21601388),binary,NA,count,113,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,810,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: GONADOTROPINS AND OTHER OVULATION STIMULANTS (21602597),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER OTOLOGICALS (21605180),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER ANTIHYPERTENSIVES (21600438),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,434,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANDROGENS (21602506),binary,NA,count,148,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,107,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,2196,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,67,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: RENAL SYSTEM (21605462),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,2800,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,880,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: LOCAL ANESTHETICS (21605096),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,284,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,4526,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: LOCAL ANESTHETICS (21605096),binary,NA,count,56,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,388,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,603,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,172,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,503,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,747,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ULTRASOUND CONTRAST MEDIA (21605437),binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,530,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,244,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIADRENAL PREPARATIONS (21602748),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ALKYLATING AGENTS (21601388),binary,NA,count,125,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,1117,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,121,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,725,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,137,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,296,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: EMOLLIENTS AND PROTECTIVES (21601969),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,737,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,668,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES (21602683),binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,4059,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,1338,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,4575,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,299,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,1887,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: GLYCOGENOLYTIC HORMONES (21602776),binary,NA,count,83,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,4724,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,110,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,591,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,358,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,139,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,859,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE (21602318),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,256,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,1023,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,61,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,161,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,1126,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,364,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: GLYCOGENOLYTIC HORMONES (21602776),binary,NA,count,106,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,4708,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,2080,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ULTRASOUND CONTRAST MEDIA (21605437),binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,529,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,116,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,1945,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,1028,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: BLOOD AND RELATED PRODUCTS (21601137),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,73,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,2931,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OPIOIDS (21604254),binary,NA,count,1069,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,333,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,446,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,379,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: CICATRIZANTS (21601986),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,714,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,2578,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,56,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: CALCIUM (21600858),binary,NA,count,657,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,1999,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,2122,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,494,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ENZYMES (21601997),binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE (21602318),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: POTASSIUM (21600875),binary,NA,count,996,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS (21600933),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,170,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER HEMATOLOGICAL AGENTS (21601226),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,3900,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANABOLIC STEROIDS (21600915),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,629,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,2727,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: CARDIOVASCULAR SYSTEM (21605509),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: POSTERIOR PITUITARY LOBE HORMONES (21602697),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: SURGICAL AIDS (21605112),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,330,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,201,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,330,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,244,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,751,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,77,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,189,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,4072,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTACIDS (21600047),binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,6392,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,1033,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,2542,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION (21602558),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,1400,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: HYPOTHALAMIC HORMONES (21602709),binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,2604,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,214,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,265,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,62,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,846,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,98,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: HYPOTHALAMIC HORMONES (21602709),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,521,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: DRUGS FOR TREATMENT OF LEPRA (21603121),binary,NA,count,64,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,6162,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OCULAR VASCULAR DISORDER AGENTS (21605119),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,547,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,1238,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER OTOLOGICALS (21605180),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS (21602745)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,741,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,763,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,640,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,139,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIFIBRINOLYTICS (21601033),binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,1758,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,376,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER RESPIRATORY SYSTEM PRODUCTS (21603531),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,1170,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,804,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,463,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,2079,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,1233,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,109,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OCULAR VASCULAR DISORDER AGENTS (21605119),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,1112,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,690,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,156,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,232,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,485,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER DIURETICS (21601556),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,289,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION (21602558),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,212,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,336,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,527,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,2438,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,1415,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: CORTICOSTEROIDS (21605164),binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,314,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,183,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,399,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,189,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: EMOLLIENTS AND PROTECTIVES (21601969),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,664,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,405,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ALKYLATING AGENTS (21601388),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,3451,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,161,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,2691,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,712,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,599,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: UTEROTONICS (21602430),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,2284,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,554,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,7083,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES (21602683),binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,492,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,1233,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,1011,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,2237,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER OTOLOGICALS (21605180),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,5241,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,133,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,63,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER PLAIN VITAMIN PREPARATIONS (21600840),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: DRUGS FOR TREATMENT OF LEPRA (21603121),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,683,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM (21601848),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION (21600451),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,151,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,168,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,339,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,196,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,147,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,96,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS (21601730)",binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,117,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,64,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,1271,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: POSTERIOR PITUITARY LOBE HORMONES (21602697),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,415,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,329,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,798,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,190,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,241,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,812,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,1159,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,6495,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,161,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,5639,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,999,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,1195,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,882,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OPIOIDS (21604254),binary,NA,count,4245,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,108,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,737,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,2017,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,655,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS (21604911),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,311,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS (21604125)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,260,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,1435,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,2098,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,66,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: RENAL SYSTEM (21605462),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ALLERGENS (21605214),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,135,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: ECTOPARASITICIDES, INCL. SCABICIDES (21604968)",binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,3234,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: SPECIFIC ANTIRHEUMATIC AGENTS (21604021),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,506,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,470,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,1100,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIADRENAL PREPARATIONS (21602748),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,363,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,421,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,2231,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,4540,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,102,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,5200,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,1255,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,175,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,432,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,592,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,1132,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,85,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,722,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,172,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,110,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES (21602683),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,2422,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,3005,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH ANALGESICS (21600220),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIADRENAL PREPARATIONS (21602748),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,384,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,887,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM (21601848),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,548,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: DIAGNOSTIC AGENTS (21605106),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM (21601848),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,2038,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER PLAIN VITAMIN PREPARATIONS (21600840),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ULTRASOUND CONTRAST MEDIA (21605437),binary,NA,count,117,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ENZYMES (21601997),binary,NA,count,44,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,2122,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: HYPOTHALAMIC HORMONES (21602709),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,440,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,1165,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,461,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,582,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,946,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,93,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,4060,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER PLAIN VITAMIN PREPARATIONS (21600840),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,4489,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,622,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,329,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,1082,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,81,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,404,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: LOCAL ANESTHETICS (21605096),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,7057,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,denominator,binary,NA,count,18770,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,676,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,2013,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION (21600451),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: LIVER THERAPY, LIPOTROPICS (21600521)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES (21603728),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,568,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,449,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: MEDICATED DRESSINGS (21602262),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,3578,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: UTEROTONICS (21602430),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,373,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,613,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANDROGENS (21602506),binary,NA,count,314,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: UTEROTONICS (21602430),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: DRUGS FOR TREATMENT OF LEPRA (21603121),binary,NA,count,48,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,721,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION (21604787),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,596,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: VITAMIN K AND OTHER HEMOSTATICS (21601043),binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS (21604911),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,322,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,1641,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,699,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,157,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,179,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,4343,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,62,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,168,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIPSORIATICS FOR SYSTEMIC USE (21602044),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,527,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: MEDICATED DRESSINGS (21602262),binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,944,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,3599,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS (21600933),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,572,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,denominator,binary,NA,count,22836,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,1486,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,2860,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: HYPOTHALAMIC HORMONES (21602709),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,118,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,673,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,505,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: POSTERIOR PITUITARY LOBE HORMONES (21602697),binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER PLAIN VITAMIN PREPARATIONS (21600840),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,282,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,238,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OPIOIDS (21604254),binary,NA,count,2102,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: BLOOD AND RELATED PRODUCTS (21601137),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,1745,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,343,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANDROGENS (21602506),binary,NA,count,130,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: SPECIFIC ANTIRHEUMATIC AGENTS (21604021),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,100,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANDROGENS (21602506),binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,107,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,1343,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,1036,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,1081,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,1515,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: PROTECTIVES AGAINST UV-RADIATION (21601979),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,2148,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,1420,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER RESPIRATORY SYSTEM PRODUCTS (21603531),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,560,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,156,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,126,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,443,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,290,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,83,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,735,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,82,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: POTASSIUM (21600875),binary,NA,count,1162,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: MEDICATED DRESSINGS (21602262),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,185,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,48,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,3713,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OPIOIDS (21604254),binary,NA,count,5747,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,2868,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTI-PARATHYROID AGENTS (21602785),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,838,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,301,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: POSTERIOR PITUITARY LOBE HORMONES (21602697),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: GONADOTROPINS AND OTHER OVULATION STIMULANTS (21602597),binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,56,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,748,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,420,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ALLERGENS (21605214),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,1277,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,378,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIFIBRINOLYTICS (21601033),binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,260,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,5598,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,2831,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,76,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,248,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,66,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,668,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,2062,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER OTOLOGICALS (21605180),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,denominator,binary,NA,count,3521,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: CALCIUM (21600858),binary,NA,count,214,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: SPECIFIC ANTIRHEUMATIC AGENTS (21604021),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,127,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,316,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,5255,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,230,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,11970,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION (21604787),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,238,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,4974,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,1267,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,11673,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,217,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: LOCAL ANESTHETICS (21605096),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ALLERGENS (21605214),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS (21602745)",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,247,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,419,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES (21603728),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,4298,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,591,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,1172,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,642,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,717,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,1003,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,652,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,1418,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,denominator,binary,NA,count,15206,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: POTASSIUM (21600875),binary,NA,count,1176,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,145,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,1402,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS (21602745)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,2382,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,53,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,134,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,886,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,263,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,498,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,652,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,1934,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,65,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,92,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: POTASSIUM (21600875),binary,NA,count,1388,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,110,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,1194,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,1886,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,1577,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTI-PARATHYROID AGENTS (21602785),binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,427,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,70,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: BLOOD AND RELATED PRODUCTS (21601137),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,672,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,1323,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANABOLIC STEROIDS (21600915),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,411,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ESTROGENS (21602514),binary,NA,count,199,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,1825,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,2908,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,1568,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: UTEROTONICS (21602430),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIFIBRINOLYTICS (21601033),binary,NA,count,105,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,148,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: BETA BLOCKING AGENTS AND OTHER DIURETICS (21601718),binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,664,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS (21602745)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,106,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,1019,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: HYPOTHALAMIC HORMONES (21602709),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: CALCIUM (21600858),binary,NA,count,114,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER ANTIHYPERTENSIVES (21600438),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,497,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: RENAL SYSTEM (21605462),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,502,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,1578,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION (21604787),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,699,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,3663,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,629,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,263,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,1018,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,10373,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,1789,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,2589,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,236,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: GLYCOGENOLYTIC HORMONES (21602776),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,124,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: CORTICOSTEROIDS (21605164),binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ULTRASOUND CONTRAST MEDIA (21605437),binary,NA,count,141,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,2885,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,93,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,716,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,429,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,4163,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,467,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION (21602558),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER HEMATOLOGICAL AGENTS (21601226),binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,251,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,2776,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,706,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,487,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,421,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTITREMATODALS (21604928),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,182,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,1636,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,739,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: VITAMIN K AND OTHER HEMOSTATICS (21601043),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS (21604911),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,denominator,binary,NA,count,17245,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,660,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,116,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER PLAIN VITAMIN PREPARATIONS (21600840),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,185,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,160,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,1147,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,1975,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,582,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,150,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS (21604125)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,1050,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,3942,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: LIVER THERAPY, LIPOTROPICS (21600521)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,492,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,1404,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIFIBRINOLYTICS (21601033),binary,NA,count,63,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,895,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,3320,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,200,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,227,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,71,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,394,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,1713,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,466,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,1824,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: DRUGS FOR TREATMENT OF LEPRA (21603121),binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,171,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,195,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,237,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,80,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,4263,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,131,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: GONADOTROPINS AND OTHER OVULATION STIMULANTS (21602597),binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,2313,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,645,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,391,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: BETA BLOCKING AGENTS, OTHER COMBINATIONS (21601738)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,1471,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,2534,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,2398,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,331,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ESTROGENS (21602514),binary,NA,count,1723,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: BLOOD AND RELATED PRODUCTS (21601137),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,192,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: ECTOPARASITICIDES, INCL. SCABICIDES (21604968)",binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS (21600933),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,3797,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,1277,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,3213,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,1427,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,604,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,88,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,114,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,1579,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,201,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: MEDICATED DRESSINGS (21602262),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,62,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,5942,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,400,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ALLERGENS (21605214),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: CARDIOVASCULAR SYSTEM (21605509),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,861,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,334,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,458,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OCULAR VASCULAR DISORDER AGENTS (21605119),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,67,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: COMBINATIONS OF ANTIBACTERIALS (21603035),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,401,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: ECTOPARASITICIDES, INCL. SCABICIDES (21604968)",binary,NA,count,65,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,180,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,535,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH ANALGESICS (21600220),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIPSORIATICS FOR SYSTEMIC USE (21602044),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,68,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,259,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,1432,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,672,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, COMBINATIONS (21601898)",binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,163,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,1354,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,151,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,5228,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION (21604787),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,144,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,51,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: X-RAY CONTRAST MEDIA, NON-IODINATED (21605414)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,265,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER HEMATOLOGICAL AGENTS (21601226),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,6143,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,955,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANTIPSORIATICS FOR SYSTEMIC USE (21602044),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: SURGICAL AIDS (21605112),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,15434,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,-365 to -1,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,2602,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,10796,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,714,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS (21604125)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: CALCIUM (21600858),binary,NA,count,704,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS (21601730)",binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,2283,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,-365 to -1,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER HEMATOLOGICAL AGENTS (21601226),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,-365 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,554,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,1301,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,6499,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,231,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,1201,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,1764,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS (21600933),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,887,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,1326,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION (21602558),binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,674,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIADRENAL PREPARATIONS (21602748),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, COMBINATIONS (21601898)",binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,-365 to -1,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,3259,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,-365 to -1,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ANDROGENS (21602506),binary,NA,count,175,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,48,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,181,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,2316,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,3109,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,-365 to -1,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,144,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,694,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,251,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: SPECIFIC ANTIRHEUMATIC AGENTS (21604021),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,48,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,86,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,57,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: ANTIFIBRINOLYTICS (21601033),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: CICATRIZANTS (21601986),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,1188,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,811,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,-365 to -1,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,579,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER PLAIN VITAMIN PREPARATIONS (21600840),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,1728,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,2626,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,258,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,-365 to -1,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,2258,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,473,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: POTASSIUM (21600875),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,715,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: SPECIFIC ANTIRHEUMATIC AGENTS (21604021),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,303,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,766,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: OTHER RESPIRATORY SYSTEM PRODUCTS (21603531),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,-365 to -1,ATC 3rd: CORTICOSTEROIDS (21605164),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,127,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,-365 to -1,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: POSTERIOR PITUITARY LOBE HORMONES (21602697),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, COMBINATIONS (21601898)",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES (21603728),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,48,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,1065,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,936,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,868,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,245,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,-365 to -1,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANTIADRENAL PREPARATIONS (21602748),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,447,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,1729,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,3560,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,2289,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: CALCIUM (21600858),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,-365 to -1,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,4389,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,237,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,591,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,1445,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,-365 to -1,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,901,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,557,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,73,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,70,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,120,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,824,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,denominator,binary,NA,count,18247,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,144,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,-365 to -1,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: ANDROGENS (21602506),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,113,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,1751,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,122,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: CARDIOVASCULAR SYSTEM (21605509),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: ANABOLIC STEROIDS (21600915),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,-365 to -1,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,51,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,307,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: GLYCOGENOLYTIC HORMONES (21602776),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,2095,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"ATC 3rd: BETA BLOCKING AGENTS, OTHER COMBINATIONS (21601738)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION (21602558),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,429,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,3317,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,1041,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,56,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,1333,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, COMBINATIONS (21601898)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: OPIOIDS (21604254),binary,NA,count,7867,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,528,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,104,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: ANDROGENS (21602506),binary,NA,count,67,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,145,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,780,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,-365 to -1,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,607,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,-365 to -1,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,228,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,839,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,68,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,143,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,445,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,90,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,1409,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS (21604911),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE (21602318),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: BLOOD AND RELATED PRODUCTS (21601137),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,96,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,1034,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,503,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,350,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,62,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: ANTIFIBRINOLYTICS (21601033),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,782,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION (21600451),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: OCULAR VASCULAR DISORDER AGENTS (21605119),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,168,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,2552,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,927,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,96,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: ECTOPARASITICIDES, INCL. SCABICIDES (21604968)",binary,NA,count,83,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,945,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,1347,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,71,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,2774,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: LOCAL ANESTHETICS (21605096),binary,NA,count,44,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,47,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: POSTERIOR PITUITARY LOBE HORMONES (21602697),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ENZYMES (21601997),binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OPIOIDS (21604254),binary,NA,count,5993,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,129,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,-365 to -1,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,1909,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,112,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,722,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,1195,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,528,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,2569,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,1009,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,1428,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,4902,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,225,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,89,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,406,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: OTHER HEMATOLOGICAL AGENTS (21601226),binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,165,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,667,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE (21602318),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,61,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: HYPOTHALAMIC HORMONES (21602709),binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,845,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,2059,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,646,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,478,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,925,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,173,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,-365 to -1,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,4338,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: POSTERIOR PITUITARY LOBE HORMONES (21602697),binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,297,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIFIBRINOLYTICS (21601033),binary,NA,count,64,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,550,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,1259,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,996,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: VITAMIN K AND OTHER HEMOSTATICS (21601043),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,307,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,257,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS (21600933),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,428,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,423,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,209,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,231,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,1995,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,775,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,9919,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,1872,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,73,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION (21604787),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ALKYLATING AGENTS (21601388),binary,NA,count,238,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,364,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,-365 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ENZYMES (21601997),binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,595,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: OTHER PLAIN VITAMIN PREPARATIONS (21600840),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,68,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: CALCIUM (21600858),binary,NA,count,749,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,-365 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: POSTERIOR PITUITARY LOBE HORMONES (21602697),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: POSTERIOR PITUITARY LOBE HORMONES (21602697),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,1877,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,1306,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: POTASSIUM (21600875),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,348,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANABOLIC STEROIDS (21600915),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,620,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,66,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,-365 to -1,denominator,binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,151,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: ALKYLATING AGENTS (21601388),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,-365 to -1,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: ENZYMES (21601997),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: ANTIPSORIATICS FOR SYSTEMIC USE (21602044),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,-365 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,80,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,78,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,56,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES (21603728),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,940,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,-365 to -1,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,2294,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,12602,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: CARDIOVASCULAR SYSTEM (21605509),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,88,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,833,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: BETA BLOCKING AGENTS, OTHER COMBINATIONS (21601738)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: ECTOPARASITICIDES, INCL. SCABICIDES (21604968)",binary,NA,count,95,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,1026,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,2098,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: X-RAY CONTRAST MEDIA, NON-IODINATED (21605414)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,1591,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,56,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,231,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,5909,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,143,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: OTHER OTOLOGICALS (21605180),binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,204,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: ENZYMES (21601997),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,156,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS (21600933),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: BETA BLOCKING AGENTS AND OTHER DIURETICS (21601718),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,7441,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,790,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,66,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,945,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: ESTROGENS (21602514),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,633,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: ECTOPARASITICIDES, INCL. SCABICIDES (21604968)",binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,582,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,192,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,2529,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,535,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,3900,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,745,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,6922,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,350,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,594,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,1681,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"ATC 3rd: ECTOPARASITICIDES, INCL. SCABICIDES (21604968)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,denominator,binary,NA,count,19120,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,2999,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OCULAR VASCULAR DISORDER AGENTS (21605119),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: ANDROGENS (21602506),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,208,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,1580,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,137,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,388,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,515,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,136,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,125,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ESTROGENS (21602514),binary,NA,count,970,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,5560,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,628,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,4298,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,884,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,64,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,denominator,binary,NA,count,15075,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,273,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,677,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,3480,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: EMOLLIENTS AND PROTECTIVES (21601969),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,3430,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,96,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,572,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,292,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,2696,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,-365 to -1,denominator,binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,149,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,155,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,992,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,2916,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: UTEROTONICS (21602430),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,62,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: BLOOD AND RELATED PRODUCTS (21601137),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,5216,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,-365 to -1,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,121,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,724,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,68,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,219,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: GONADOTROPINS AND OTHER OVULATION STIMULANTS (21602597),binary,NA,count,70,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,576,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,285,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,-365 to -1,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,95,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,356,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANABOLIC STEROIDS (21600915),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: DRUGS FOR TREATMENT OF LEPRA (21603121),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,1610,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: CICATRIZANTS (21601986),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,645,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,705,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,73,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,72,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,5134,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,630,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,243,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,1912,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: MEDICATED DRESSINGS (21602262),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,3233,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: COMBINATIONS OF ANTIBACTERIALS (21603035),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,-365 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,79,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,677,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ALKYLATING AGENTS (21601388),binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,1677,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ALLERGENS (21605214),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,966,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,89,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,136,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS (21601730)",binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,-365 to -1,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION (21602558),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,2262,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,654,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,150,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,138,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,670,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,357,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: RENAL SYSTEM (21605462),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: CALCIUM (21600858),binary,NA,count,1020,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,1610,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,323,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,258,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: ESTROGENS (21602514),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,480,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,1708,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,919,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,797,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: UTEROTONICS (21602430),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES (21603728),binary,NA,count,155,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,118,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,2975,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION (21600451),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, COMBINATIONS (21601898)",binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,363,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,319,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,1246,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,2053,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,3791,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,-365 to -1,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ULTRASOUND CONTRAST MEDIA (21605437),binary,NA,count,145,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS (21604911),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,470,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION (21600451),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ALKYLATING AGENTS (21601388),binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,1016,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,909,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: ESTROGENS (21602514),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,4825,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OPIOIDS (21604254),binary,NA,count,5005,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,239,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,389,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,549,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS (21604911),binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,476,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: OTHER THERAPEUTIC RADIOPHARMACEUTICALS (21605585),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANDROGENS (21602506),binary,NA,count,136,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: CALCIUM (21600858),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: BLOOD AND RELATED PRODUCTS (21601137),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,631,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,-365 to -1,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,464,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,1663,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,2177,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,2715,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,180,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: OTHER ANTIHYPERTENSIVES (21600438),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,56,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,247,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,750,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,5475,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,-365 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,66,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,5572,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,106,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,denominator,binary,NA,count,2453,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,1828,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,3511,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTACIDS (21600047),binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER THERAPEUTIC RADIOPHARMACEUTICALS (21605585),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,56,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,121,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,150,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,368,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,625,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: ANTIADRENAL PREPARATIONS (21602748),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,1463,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS (21601730)",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,943,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,342,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,2726,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,2045,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,291,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,3201,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,91,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,71,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,494,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,500,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,144,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,-365 to -1,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,denominator,binary,NA,count,70,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,2275,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS (21602745)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: LOCAL ANESTHETICS (21605096),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,456,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,721,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,226,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,1074,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,1056,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,1880,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,4392,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,206,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER ANTIHYPERTENSIVES (21600438),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,135,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,3236,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,986,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,564,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,304,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: HYPOTHALAMIC HORMONES (21602709),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,7670,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,4624,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,361,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: SURGICAL AIDS (21605112),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,2202,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,1262,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: MEDICATED DRESSINGS (21602262),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,657,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,6042,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: GONADOTROPINS AND OTHER OVULATION STIMULANTS (21602597),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,505,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,1514,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,47,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,96,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,1372,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANTITREMATODALS (21604928),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,640,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,2442,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,2338,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,1869,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,385,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,513,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,2166,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: OTHER PLAIN VITAMIN PREPARATIONS (21600840),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,1565,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,163,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,348,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,269,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTI-PARATHYROID AGENTS (21602785),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,84,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,3322,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,627,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,297,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,-365 to -1,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,603,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,1656,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,156,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,1299,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,-365 to -1,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,444,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: GONADOTROPINS AND OTHER OVULATION STIMULANTS (21602597),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS (21600933),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,780,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,68,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,1274,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,420,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,1902,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,797,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS (21604911),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: GLYCOGENOLYTIC HORMONES (21602776),binary,NA,count,134,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,1544,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,213,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,1687,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: CALCIUM (21600858),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,1736,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,279,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,65,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,351,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,7877,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,65,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,465,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,-365 to -1,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: OPIOIDS (21604254),binary,NA,count,503,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: UTEROTONICS (21602430),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,3582,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,344,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,424,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,1163,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ESTROGENS (21602514),binary,NA,count,1127,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: OPIOIDS (21604254),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,954,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,176,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER RESPIRATORY SYSTEM PRODUCTS (21603531),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,-365 to -1,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: ANTACIDS (21600047),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,187,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: LIVER THERAPY, LIPOTROPICS (21600521)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,298,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: CALCIUM (21600858),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH ANALGESICS (21600220),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: GLYCOGENOLYTIC HORMONES (21602776),binary,NA,count,65,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: OTHER PLAIN VITAMIN PREPARATIONS (21600840),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,-365 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,1470,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,51,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,597,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,67,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,332,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,1271,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,-365 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,170,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: COMBINATIONS OF ANTIBACTERIALS (21603035),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,4070,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: GONADOTROPINS AND OTHER OVULATION STIMULANTS (21602597),binary,NA,count,61,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: ENZYMES (21601997),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: EMOLLIENTS AND PROTECTIVES (21601969),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,1578,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,2422,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,768,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: AMPHENICOLS (21602813),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION (21604787),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,1145,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,256,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIPSORIATICS FOR SYSTEMIC USE (21602044),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,1312,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIPSORIATICS FOR SYSTEMIC USE (21602044),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: HYPOTHALAMIC HORMONES (21602709),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,137,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,-365 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: LOCAL ANESTHETICS (21605096),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,410,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ANTACIDS (21600047),binary,NA,count,91,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,449,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,2329,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,"ATC 3rd: BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS (21601730)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,61,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: EMOLLIENTS AND PROTECTIVES (21601969),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,111,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,246,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,561,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ANTIFIBRINOLYTICS (21601033),binary,NA,count,48,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,80,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: RENAL SYSTEM (21605462),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,133,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: SURGICAL AIDS (21605112),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,4962,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,106,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,3444,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,702,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,1508,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,207,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,1640,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: MEDICATED DRESSINGS (21602262),binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,2577,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,2164,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: OTHER OTOLOGICALS (21605180),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,1899,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS (21602745)",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,721,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,341,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: RENAL SYSTEM (21605462),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,127,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,577,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,6552,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,3247,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: PROTECTIVES AGAINST UV-RADIATION (21601979),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,7170,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,2091,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,9930,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: BETA BLOCKING AGENTS AND OTHER DIURETICS (21601718),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,-365 to -1,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,3026,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,3997,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,182,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,61,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,127,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,8429,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,272,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,93,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,2292,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ALLERGENS (21605214),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,260,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: LOCAL ANESTHETICS (21605096),binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,1055,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,139,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,858,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,284,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS (21602745)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH ANALGESICS (21600220),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,64,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,2858,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,5897,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,165,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,516,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: OTHER DIURETICS (21601556),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,362,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANTACIDS (21600047),binary,NA,count,124,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,483,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,118,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: OPIOIDS (21604254),binary,NA,count,5138,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,122,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: EMOLLIENTS AND PROTECTIVES (21601969),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,544,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ANTIADRENAL PREPARATIONS (21602748),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,6442,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,62,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,4080,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,83,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,2922,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,-365 to -1,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,90,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,1094,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"ATC 3rd: BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS (21601730)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: UTEROTONICS (21602430),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,973,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: ANTI-PARATHYROID AGENTS (21602785),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM (21601848),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANTIFIBRINOLYTICS (21601033),binary,NA,count,105,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,-365 to -1,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ALLERGENS (21605214),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,1334,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,-365 to -1,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,6139,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,758,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,902,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,602,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,120,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,315,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,6091,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,1620,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION (21602558),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: HYPOTHALAMIC HORMONES (21602709),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: ENZYMES (21601997),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,-365 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,973,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION (21604787),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES (21602683),binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: LIVER THERAPY, LIPOTROPICS (21600521)",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER ANTIHYPERTENSIVES (21600438),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,125,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTACIDS (21600047),binary,NA,count,62,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,557,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,2540,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,61,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: CARDIOVASCULAR SYSTEM (21605509),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: CICATRIZANTS (21601986),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: ANTACIDS (21600047),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,5616,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES (21603728),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,166,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,417,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: INTESTINAL ADSORBENTS (21600627),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: CORTICOSTEROIDS (21605164),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: BETA BLOCKING AGENTS AND OTHER DIURETICS (21601718),binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,415,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,2703,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,3454,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,417,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,150,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,224,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS (21600933),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,-365 to -1,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,48,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: HYPOTHALAMIC HORMONES (21602709),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,558,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: POTASSIUM (21600875),binary,NA,count,1321,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ULTRASOUND CONTRAST MEDIA (21605437),binary,NA,count,117,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,-365 to -1,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,1775,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,47,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,3440,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,745,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"ATC 3rd: LIVER THERAPY, LIPOTROPICS (21600521)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,1845,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES (21603728),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,1841,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,72,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,824,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,456,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: OCULAR VASCULAR DISORDER AGENTS (21605119),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,378,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ENZYMES (21601997),binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: GLYCOGENOLYTIC HORMONES (21602776),binary,NA,count,106,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,6145,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,573,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,315,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,156,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,79,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS (21604911),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,647,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,denominator,binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,700,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,144,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER OTOLOGICALS (21605180),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: LIVER THERAPY, LIPOTROPICS (21600521)",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS (21600933),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: OPIOIDS (21604254),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,-365 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: OTHER ANTIHYPERTENSIVES (21600438),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,2652,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,-365 to -1,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,416,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,444,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,370,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,626,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,12680,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: LOCAL ANESTHETICS (21605096),binary,NA,count,51,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,5996,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,474,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES (21602683),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,383,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: OTHER DIURETICS (21601556),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: BETA BLOCKING AGENTS AND OTHER DIURETICS (21601718),binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,3754,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,375,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,2235,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: RENAL SYSTEM (21605462),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: VITAMIN K AND OTHER HEMOSTATICS (21601043),binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,221,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,904,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,3252,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,5566,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANDROGENS (21602506),binary,NA,count,388,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: CALCIUM (21600858),binary,NA,count,466,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES (21602683),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,167,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE (21602318),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,8964,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ALLERGENS (21605214),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,691,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,7922,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANTI-PARATHYROID AGENTS (21602785),binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,4141,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,259,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER OTOLOGICALS (21605180),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS (21602745)",binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,2352,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,938,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,160,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,-365 to -1,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,10519,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER DIURETICS (21601556),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,733,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER RESPIRATORY SYSTEM PRODUCTS (21603531),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,972,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,73,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,193,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,51,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,104,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ESTROGENS (21602514),binary,NA,count,2740,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: ALKYLATING AGENTS (21601388),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,3528,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ESTROGENS (21602514),binary,NA,count,1108,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,1117,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: BLOOD AND RELATED PRODUCTS (21601137),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,7440,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,1200,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE (21602318),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,519,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: LIVER THERAPY, LIPOTROPICS (21600521)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,67,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,62,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,830,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,411,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,149,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES (21603728),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,1302,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,842,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: OTHER PLAIN VITAMIN PREPARATIONS (21600840),binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: ULTRASOUND CONTRAST MEDIA (21605437),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,2985,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,966,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: CORTICOSTEROIDS (21605164),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: CORTICOSTEROIDS (21605164),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,111,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: OTHER HEMATOLOGICAL AGENTS (21601226),binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,-365 to -1,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,2537,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,1583,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH ANALGESICS (21600220),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: ESTROGENS (21602514),binary,NA,count,107,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,377,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: VITAMIN K AND OTHER HEMOSTATICS (21601043),binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,1845,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,688,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,3568,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,339,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,6238,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,681,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,923,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,-365 to -1,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ENZYMES (21601997),binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: BETA BLOCKING AGENTS, OTHER COMBINATIONS (21601738)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: GLYCOGENOLYTIC HORMONES (21602776),binary,NA,count,73,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: POTASSIUM (21600875),binary,NA,count,1017,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,1688,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,5065,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,3667,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANDROGENS (21602506),binary,NA,count,112,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,-365 to -1,"ATC 3rd: ECTOPARASITICIDES, INCL. SCABICIDES (21604968)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,94,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,2557,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTITREMATODALS (21604928),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM (21601848),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,165,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,1010,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: CORTICOSTEROIDS (21605164),binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,621,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS (21604125)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER PLAIN VITAMIN PREPARATIONS (21600840),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,7892,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,287,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: BLOOD AND RELATED PRODUCTS (21601137),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: VITAMIN K AND OTHER HEMOSTATICS (21601043),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,5012,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,1979,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,354,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,340,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,314,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ULTRASOUND CONTRAST MEDIA (21605437),binary,NA,count,176,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,4388,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,4462,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,76,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,694,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,236,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: CORTICOSTEROIDS (21605164),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,2688,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: POTASSIUM (21600875),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,1188,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,2575,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,269,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,denominator,binary,NA,count,31995,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,-365 to -1,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,-365 to -1,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,874,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH ANALGESICS (21600220),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: MEDICATED DRESSINGS (21602262),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,128,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,97,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,146,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,9826,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,818,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: ULTRASOUND CONTRAST MEDIA (21605437),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,92,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,548,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,2279,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,3037,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,308,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: BETA BLOCKING AGENTS AND OTHER DIURETICS (21601718),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,2714,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,814,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,468,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM (21601848),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,478,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,-365 to -1,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: OTHER HEMATOLOGICAL AGENTS (21601226),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,2819,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ANTIPSORIATICS FOR SYSTEMIC USE (21602044),binary,NA,count,47,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,1489,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,718,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTI-PARATHYROID AGENTS (21602785),binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,-365 to -1,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,111,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: ANTIADRENAL PREPARATIONS (21602748),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: LOCAL ANESTHETICS (21605096),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,976,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,735,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,1500,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,1608,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: COMBINATIONS OF ANTIBACTERIALS (21603035),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,4024,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,166,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,83,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,1233,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,4294,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,343,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,248,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,1440,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES (21602683),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,134,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,4024,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,2762,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,241,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,5310,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,10384,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,1761,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,983,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ULTRASOUND CONTRAST MEDIA (21605437),binary,NA,count,109,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS (21601730)",binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: POSTERIOR PITUITARY LOBE HORMONES (21602697),binary,NA,count,56,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,84,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,1305,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,331,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,684,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,133,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,81,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,305,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,1505,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: AMPHENICOLS (21602813),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,1356,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: HYPOTHALAMIC HORMONES (21602709),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,431,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,671,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,-365 to -1,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,835,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,2131,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: DRUGS FOR TREATMENT OF LEPRA (21603121),binary,NA,count,79,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,204,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: OTHER OTOLOGICALS (21605180),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,163,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,127,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,denominator,binary,NA,count,116,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,427,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,389,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: ULTRASOUND CONTRAST MEDIA (21605437),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,633,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: LOCAL ANESTHETICS (21605096),binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,56,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ALKYLATING AGENTS (21601388),binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,563,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,53,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,558,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: BETA BLOCKING AGENTS AND OTHER DIURETICS (21601718),binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,257,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,4353,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,139,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,2817,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,3314,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,547,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,2768,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,541,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,47,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,7798,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: OPIOIDS (21604254),binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: ULTRASOUND CONTRAST MEDIA (21605437),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,1265,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,1985,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,321,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION (21600451),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,457,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: VITAMIN K AND OTHER HEMOSTATICS (21601043),binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: OTHER HEMATOLOGICAL AGENTS (21601226),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE (21602318),binary,NA,count,64,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,7494,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,6080,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,5485,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: CORTICOSTEROIDS (21605164),binary,NA,count,51,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,4883,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,95,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: MEDICATED DRESSINGS (21602262),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,355,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: DIAGNOSTIC AGENTS (21605106),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,515,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,517,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIADRENAL PREPARATIONS (21602748),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,117,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,6396,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,186,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIFIBRINOLYTICS (21601033),binary,NA,count,75,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,429,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,70,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: DRUGS FOR TREATMENT OF LEPRA (21603121),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM (21601848),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS (21602745)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,505,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"ATC 3rd: LIVER THERAPY, LIPOTROPICS (21600521)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ANTI-PARATHYROID AGENTS (21602785),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: POTASSIUM (21600875),binary,NA,count,1642,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANABOLIC STEROIDS (21600915),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: POTASSIUM (21600875),binary,NA,count,1241,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,940,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,264,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,506,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,1174,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,1487,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,601,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,75,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,3201,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: DRUGS FOR TREATMENT OF LEPRA (21603121),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,144,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,3212,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,82,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,220,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: ANTIPSORIATICS FOR SYSTEMIC USE (21602044),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,695,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES (21602683),binary,NA,count,67,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OCULAR VASCULAR DISORDER AGENTS (21605119),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,796,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,122,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,112,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,84,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: ECTOPARASITICIDES, INCL. SCABICIDES (21604968)",binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,1298,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,970,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,51,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,2995,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,2264,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION (21602558),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: POTASSIUM (21600875),binary,NA,count,106,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,390,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: DRUGS FOR TREATMENT OF LEPRA (21603121),binary,NA,count,105,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-365 to -1,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,1331,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, COMBINATIONS (21601898)",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION (21600451),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ANTIPSORIATICS FOR SYSTEMIC USE (21602044),binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ALLERGENS (21605214),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,140,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: OTHER RESPIRATORY SYSTEM PRODUCTS (21603531),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,152,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,933,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,2797,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,253,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,471,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: OTHER OTOLOGICALS (21605180),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE (21602318),binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,423,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: GLYCOGENOLYTIC HORMONES (21602776),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,549,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: AMPHENICOLS (21602813),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,256,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, COMBINATIONS (21601898)",binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,199,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,312,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ANTIADRENAL PREPARATIONS (21602748),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,denominator,binary,NA,count,49614,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,120,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE (21602318),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,47,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,311,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ENZYMES (21601997),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,3667,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,192,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,203,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM (21601848),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ANABOLIC STEROIDS (21600915),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,551,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,493,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,975,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,163,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION (21600451),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,173,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,327,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,403,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: OPIOIDS (21604254),binary,NA,count,3736,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,1657,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,6041,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,1818,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: RENAL SYSTEM (21605462),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS (21601730)",binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: OTHER RESPIRATORY SYSTEM PRODUCTS (21603531),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,323,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS (21604911),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH ANALGESICS (21600220),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,10939,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: HYPOTHALAMIC HORMONES (21602709),binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,256,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,240,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,276,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,89,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,118,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: OTHER HEMATOLOGICAL AGENTS (21601226),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,1202,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION (21604787),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,53,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,2515,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,678,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,2829,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES (21602683),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,954,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: OTHER ANTIHYPERTENSIVES (21600438),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,12246,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: BLOOD AND RELATED PRODUCTS (21601137),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,992,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: RENAL SYSTEM (21605462),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,632,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,169,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,191,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,2277,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,2293,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,121,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,1158,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,160,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,174,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,576,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: OCULAR VASCULAR DISORDER AGENTS (21605119),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: GLYCOGENOLYTIC HORMONES (21602776),binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: CICATRIZANTS (21601986),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,68,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,370,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,5251,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: ECTOPARASITICIDES, INCL. SCABICIDES (21604968)",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,1949,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,134,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,155,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ANTACIDS (21600047),binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,409,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,902,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,151,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: OTHER PLAIN VITAMIN PREPARATIONS (21600840),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,1604,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,1356,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,694,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,1207,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,2025,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,431,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: OTHER ANTIHYPERTENSIVES (21600438),binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,276,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,2577,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,470,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,189,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,267,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,207,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: X-RAY CONTRAST MEDIA, NON-IODINATED (21605414)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: VITAMIN K AND OTHER HEMOSTATICS (21601043),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ALKYLATING AGENTS (21601388),binary,NA,count,168,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,2628,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,380,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,1557,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,150,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: OTHER OTOLOGICALS (21605180),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,479,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION (21604787),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,712,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,540,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: OCULAR VASCULAR DISORDER AGENTS (21605119),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,657,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,68,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,1179,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,602,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,9006,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,89,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,212,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: CORTICOSTEROIDS (21605164),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,76,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: POTASSIUM (21600875),binary,NA,count,1764,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,6397,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,81,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,953,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION (21602558),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,88,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,1389,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,3240,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANTI-PARATHYROID AGENTS (21602785),binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,678,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,154,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM (21601848),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,2019,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,4775,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,3265,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: UTEROTONICS (21602430),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,146,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,421,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,1414,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,4085,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,112,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,909,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,1663,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANTIFIBRINOLYTICS (21601033),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,1354,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,1311,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,236,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: CALCIUM (21600858),binary,NA,count,910,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,1108,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ALKYLATING AGENTS (21601388),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,173,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,600,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,1182,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,1565,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,1575,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,147,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,763,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,288,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,6964,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,47,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: SPECIFIC ANTIRHEUMATIC AGENTS (21604021),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,971,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: BETA BLOCKING AGENTS AND OTHER DIURETICS (21601718),binary,NA,count,48,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS (21601730)",binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,687,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,71,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,61,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,8622,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,93,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,1229,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,1381,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,488,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,7106,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,166,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,2335,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,340,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,375,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,7388,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,165,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ESTROGENS (21602514),binary,NA,count,1250,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: POSTERIOR PITUITARY LOBE HORMONES (21602697),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,1538,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,61,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: CORTICOSTEROIDS (21605164),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,702,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION (21600451),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,821,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,364,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION (21602558),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,8329,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ULTRASOUND CONTRAST MEDIA (21605437),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,321,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS (21604125)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANTACIDS (21600047),binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,1205,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,4453,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,840,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,4281,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,1610,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: EMOLLIENTS AND PROTECTIVES (21601969),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,280,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,2433,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,610,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: HYPOTHALAMIC HORMONES (21602709),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,1409,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,620,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,66,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ENZYMES (21601997),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,1266,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: BETA BLOCKING AGENTS AND OTHER DIURETICS (21601718),binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANTIADRENAL PREPARATIONS (21602748),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: MEDICATED DRESSINGS (21602262),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,2656,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,2774,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,461,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,48,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS (21604125)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: ECTOPARASITICIDES, INCL. SCABICIDES (21604968)",binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: MEDICATED DRESSINGS (21602262),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,1051,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,7124,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,1515,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,1057,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: POTASSIUM (21600875),binary,NA,count,1412,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,275,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,51,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,113,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,65,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,94,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,1623,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,318,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES (21603728),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: OPIOIDS (21604254),binary,NA,count,4069,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,3484,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,6576,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,3379,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,47,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,883,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,1238,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,88,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,10370,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,270,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,822,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,1307,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,2329,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: LIVER THERAPY, LIPOTROPICS (21600521)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,3921,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,184,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ANTIFIBRINOLYTICS (21601033),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: VITAMIN K AND OTHER HEMOSTATICS (21601043),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ESTROGENS (21602514),binary,NA,count,2407,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,1154,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,592,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS (21600933),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,296,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,1438,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,179,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,12170,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,333,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,5507,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,2273,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,185,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,102,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS (21602745)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,3755,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,331,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,348,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,297,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,88,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,280,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,925,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,2058,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,1584,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,243,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,9234,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,617,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,126,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,115,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS (21600933),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,94,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,82,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,865,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANTIPSORIATICS FOR SYSTEMIC USE (21602044),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES (21602683),binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,7866,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,992,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: OTHER DIURETICS (21601556),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,701,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,10705,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: GONADOTROPINS AND OTHER OVULATION STIMULANTS (21602597),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: CALCIUM (21600858),binary,NA,count,942,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,216,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: EMOLLIENTS AND PROTECTIVES (21601969),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: SPECIFIC ANTIRHEUMATIC AGENTS (21604021),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,265,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,214,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,1092,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH ANALGESICS (21600220),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,193,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,586,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: BLOOD AND RELATED PRODUCTS (21601137),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,584,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,2571,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,157,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: OTHER DIURETICS (21601556),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,1872,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,213,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,172,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,624,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,106,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,74,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,64,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,2070,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ANTI-PARATHYROID AGENTS (21602785),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,3403,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,458,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,denominator,binary,NA,count,37471,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,1035,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,988,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,237,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,775,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,2749,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,97,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,398,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,44,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: DRUGS FOR TREATMENT OF LEPRA (21603121),binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS (21604911),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,7516,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,2453,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,4625,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: DRUGS FOR TREATMENT OF LEPRA (21603121),binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: OTHER PLAIN VITAMIN PREPARATIONS (21600840),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,184,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,1311,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: LOCAL ANESTHETICS (21605096),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ANDROGENS (21602506),binary,NA,count,191,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,272,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: LOCAL ANESTHETICS (21605096),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,312,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,8821,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: POSTERIOR PITUITARY LOBE HORMONES (21602697),binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,7462,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,1176,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,169,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: LIVER THERAPY, LIPOTROPICS (21600521)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,488,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,85,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,3871,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,1599,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: UTEROTONICS (21602430),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,1895,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,816,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: GONADOTROPINS AND OTHER OVULATION STIMULANTS (21602597),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,248,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,1290,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,397,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,166,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,159,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: SURGICAL AIDS (21605112),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,1029,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,516,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: OTHER HEMATOLOGICAL AGENTS (21601226),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANABOLIC STEROIDS (21600915),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,238,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,156,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,93,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS (21602745)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,440,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,716,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,2492,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, COMBINATIONS (21601898)",binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,1071,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,2810,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANDROGENS (21602506),binary,NA,count,324,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,2707,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ULTRASOUND CONTRAST MEDIA (21605437),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES (21603728),binary,NA,count,107,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,429,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,4868,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,3820,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,194,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: GLYCOGENOLYTIC HORMONES (21602776),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,179,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS (21600933),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,2205,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,558,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,337,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,798,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS (21602745)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,1392,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTI-PARATHYROID AGENTS (21602785),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,348,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,573,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: MEDICATED DRESSINGS (21602262),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTI-PARATHYROID AGENTS (21602785),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS (21602745)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE (21602318),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,279,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,601,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ALKYLATING AGENTS (21601388),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: POTASSIUM (21600875),binary,NA,count,114,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,276,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,1092,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,161,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,119,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,759,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,334,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,5541,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,110,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,233,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,600,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,1257,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,66,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,697,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION (21600451),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: CALCIUM (21600858),binary,NA,count,478,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,486,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,884,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,2971,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES (21603728),binary,NA,count,57,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,473,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,148,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,550,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,432,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,656,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,4183,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIADRENAL PREPARATIONS (21602748),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,466,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,210,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,284,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH ANALGESICS (21600220),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, COMBINATIONS (21601898)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,336,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,78,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,1682,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,139,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,578,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,279,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,92,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,125,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,151,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES (21603728),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,587,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,329,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES (21603728),binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,212,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,3840,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,211,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,4341,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,141,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,1960,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,123,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,1585,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,566,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,310,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: LIVER THERAPY, LIPOTROPICS (21600521)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OTHER ANTIHYPERTENSIVES (21600438),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTACIDS (21600047),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM (21601848),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: UTEROTONICS (21602430),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,124,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,169,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: DRUGS FOR TREATMENT OF LEPRA (21603121),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,198,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OPIOIDS (21604254),binary,NA,count,1749,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION (21602558),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,64,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,159,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,577,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS (21601730)",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,155,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,358,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,102,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,484,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,3601,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,86,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,460,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: VITAMIN K AND OTHER HEMOSTATICS (21601043),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,86,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,1358,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,205,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,44,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,588,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,150,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,282,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OPIOIDS (21604254),binary,NA,count,1966,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,581,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: GLYCOGENOLYTIC HORMONES (21602776),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OTHER RESPIRATORY SYSTEM PRODUCTS (21603531),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,93,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, COMBINATIONS (21601898)",binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIPSORIATICS FOR SYSTEMIC USE (21602044),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,506,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,69,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTACIDS (21600047),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,44,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,1154,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,146,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,581,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,175,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,1361,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIFIBRINOLYTICS (21601033),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,67,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,1103,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,205,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,406,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: BETA BLOCKING AGENTS AND OTHER DIURETICS (21601718),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,298,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS (21601730)",binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,76,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,122,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,150,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,425,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OTHER HEMATOLOGICAL AGENTS (21601226),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,290,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,551,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,364,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,87,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,3070,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,497,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,493,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM (21601848),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,2497,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,272,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,1610,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIADRENAL PREPARATIONS (21602748),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,192,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: OCULAR VASCULAR DISORDER AGENTS (21605119),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,5208,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIPSORIATICS FOR SYSTEMIC USE (21602044),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,165,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANABOLIC STEROIDS (21600915),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,231,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH ANALGESICS (21600220),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,549,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,2108,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,792,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,8950,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ENZYMES (21601997),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,57,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,115,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,1823,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,692,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,1129,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,69,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,647,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,957,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,235,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,149,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: CORTICOSTEROIDS (21605164),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,140,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: GONADOTROPINS AND OTHER OVULATION STIMULANTS (21602597),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,106,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: BETA BLOCKING AGENTS AND OTHER DIURETICS (21601718),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,147,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ALKYLATING AGENTS (21601388),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,842,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: POSTERIOR PITUITARY LOBE HORMONES (21602697),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,denominator,binary,NA,count,9565,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,1151,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: OTHER HEMATOLOGICAL AGENTS (21601226),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,65,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,113,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,126,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,76,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,440,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,1599,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,646,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: POSTERIOR PITUITARY LOBE HORMONES (21602697),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,111,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ULTRASOUND CONTRAST MEDIA (21605437),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,129,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,397,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,553,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,87,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,1385,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,891,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES (21602683),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, COMBINATIONS (21601898)",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,162,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTI-PARATHYROID AGENTS (21602785),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,117,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,134,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,373,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES (21603728),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: ECTOPARASITICIDES, INCL. SCABICIDES (21604968)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,66,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OTHER PLAIN VITAMIN PREPARATIONS (21600840),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANABOLIC STEROIDS (21600915),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,69,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,140,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,705,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,535,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,484,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,169,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,950,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,74,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,56,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,88,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,335,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS (21601730)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIADRENAL PREPARATIONS (21602748),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM (21601848),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,48,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: LOCAL ANESTHETICS (21605096),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,2429,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,589,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS (21601730)",binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,86,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,403,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,103,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,1042,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTI-PARATHYROID AGENTS (21602785),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIPSORIATICS FOR SYSTEMIC USE (21602044),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,95,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,690,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,115,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,4234,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,109,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,483,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,218,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: EMOLLIENTS AND PROTECTIVES (21601969),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,99,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,147,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: CORTICOSTEROIDS (21605164),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANDROGENS (21602506),binary,NA,count,73,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ENZYMES (21601997),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: VITAMIN K AND OTHER HEMOSTATICS (21601043),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,172,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,79,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,111,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,613,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES (21602683),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS (21604125)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,260,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: RENAL SYSTEM (21605462),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANDROGENS (21602506),binary,NA,count,75,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION (21600451),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: OTHER OTOLOGICALS (21605180),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: ECTOPARASITICIDES, INCL. SCABICIDES (21604968)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,550,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: RENAL SYSTEM (21605462),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: LIVER THERAPY, LIPOTROPICS (21600521)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,63,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,506,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,529,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,160,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,1488,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,2910,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,353,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,2253,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OTHER ANTIHYPERTENSIVES (21600438),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,197,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,395,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,807,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,972,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,80,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,110,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,3079,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: LIVER THERAPY, LIPOTROPICS (21600521)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,6885,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OTHER HEMATOLOGICAL AGENTS (21601226),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,155,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,140,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS (21604911),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: AMPHENICOLS (21602813),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: LOCAL ANESTHETICS (21605096),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,1476,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIPSORIATICS FOR SYSTEMIC USE (21602044),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,139,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,72,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,1102,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,107,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ULTRASOUND CONTRAST MEDIA (21605437),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,99,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,311,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,291,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,1934,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIFIBRINOLYTICS (21601033),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,105,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ENZYMES (21601997),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,521,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,61,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,670,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: GONADOTROPINS AND OTHER OVULATION STIMULANTS (21602597),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: OTHER ANTIHYPERTENSIVES (21600438),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,282,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,1517,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,1425,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,47,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,110,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,126,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS (21600933),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,67,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,356,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,2461,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,259,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,169,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: BLOOD AND RELATED PRODUCTS (21601137),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,106,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: BETA BLOCKING AGENTS AND OTHER DIURETICS (21601718),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,171,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,180,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,111,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: CALCIUM (21600858),binary,NA,count,363,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: X-RAY CONTRAST MEDIA, NON-IODINATED (21605414)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,81,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,171,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,452,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ESTROGENS (21602514),binary,NA,count,508,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,2179,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS (21600933),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,606,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,547,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,140,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,994,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,623,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,79,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,235,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,437,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,116,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,89,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,56,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,1299,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,600,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,1147,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,444,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,1891,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,192,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,138,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,78,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,339,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,1993,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: POTASSIUM (21600875),binary,NA,count,256,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,194,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION (21600451),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: HYPOTHALAMIC HORMONES (21602709),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,997,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,5823,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,144,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,2280,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION (21604787),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,229,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,509,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,124,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,1215,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,1489,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,177,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,1347,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: EMOLLIENTS AND PROTECTIVES (21601969),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ESTROGENS (21602514),binary,NA,count,630,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: CORTICOSTEROIDS (21605164),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ESTROGENS (21602514),binary,NA,count,442,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,970,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,1025,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,183,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,44,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,988,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,203,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: DRUGS FOR TREATMENT OF LEPRA (21603121),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE (21602318),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: GLYCOGENOLYTIC HORMONES (21602776),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION (21604787),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,57,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,218,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,3122,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: ECTOPARASITICIDES, INCL. SCABICIDES (21604968)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,724,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ENZYMES (21601997),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,399,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ESTROGENS (21602514),binary,NA,count,922,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: CALCIUM (21600858),binary,NA,count,397,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,72,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,783,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ALKYLATING AGENTS (21601388),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: OTHER DIURETICS (21601556),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,305,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,371,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTACIDS (21600047),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,711,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: VITAMIN K AND OTHER HEMOSTATICS (21601043),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,206,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,309,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,104,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,1752,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: MEDICATED DRESSINGS (21602262),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,139,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,416,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,267,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,68,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION (21602558),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,680,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: OTHER OTOLOGICALS (21605180),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,350,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,914,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,91,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,864,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,64,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,137,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,117,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: CICATRIZANTS (21601986),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,85,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,96,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: CORTICOSTEROIDS (21605164),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: BETA BLOCKING AGENTS AND OTHER DIURETICS (21601718),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,93,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,911,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,103,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTACIDS (21600047),binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE (21602318),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OTHER ANTIHYPERTENSIVES (21600438),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: EMOLLIENTS AND PROTECTIVES (21601969),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,100,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTACIDS (21600047),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,1060,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,3394,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,146,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,431,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE (21602318),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,573,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES (21602683),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,94,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,62,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,382,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,224,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ALKYLATING AGENTS (21601388),binary,NA,count,66,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,123,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: GONADOTROPINS AND OTHER OVULATION STIMULANTS (21602597),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: OTHER ANTIHYPERTENSIVES (21600438),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,348,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANDROGENS (21602506),binary,NA,count,98,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,519,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,300,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,573,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: LOCAL ANESTHETICS (21605096),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,51,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,62,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: LOCAL ANESTHETICS (21605096),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,283,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,392,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,57,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,114,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ULTRASOUND CONTRAST MEDIA (21605437),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,130,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,163,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIADRENAL PREPARATIONS (21602748),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,290,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ALKYLATING AGENTS (21601388),binary,NA,count,86,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,87,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,210,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: EMOLLIENTS AND PROTECTIVES (21601969),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,216,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,284,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,533,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES (21602683),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,1843,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,347,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,1183,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,94,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,1200,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: GLYCOGENOLYTIC HORMONES (21602776),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,83,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,149,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,283,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,95,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,514,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,108,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,794,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,209,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,224,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: GLYCOGENOLYTIC HORMONES (21602776),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,3781,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,234,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ULTRASOUND CONTRAST MEDIA (21605437),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,351,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,225,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: BLOOD AND RELATED PRODUCTS (21601137),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,290,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,94,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: OPIOIDS (21604254),binary,NA,count,332,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,1167,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,102,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,80,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,1198,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,493,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: CALCIUM (21600858),binary,NA,count,414,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,1193,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,509,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,76,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ENZYMES (21601997),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE (21602318),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: POTASSIUM (21600875),binary,NA,count,589,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS (21600933),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,78,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OTHER HEMATOLOGICAL AGENTS (21601226),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,800,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANABOLIC STEROIDS (21600915),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,218,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,2139,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: POSTERIOR PITUITARY LOBE HORMONES (21602697),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: SURGICAL AIDS (21605112),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,48,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,76,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,63,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,167,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,91,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,81,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,2904,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTACIDS (21600047),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,2591,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,173,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,514,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION (21602558),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,648,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: HYPOTHALAMIC HORMONES (21602709),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,1196,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,48,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,142,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,53,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,558,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: HYPOTHALAMIC HORMONES (21602709),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,71,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: DRUGS FOR TREATMENT OF LEPRA (21603121),binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,4068,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OCULAR VASCULAR DISORDER AGENTS (21605119),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,121,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,767,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OTHER OTOLOGICALS (21605180),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS (21602745)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,253,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,369,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,133,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,92,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIFIBRINOLYTICS (21601033),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,563,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: OTHER RESPIRATORY SYSTEM PRODUCTS (21603531),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,219,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,668,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,222,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,534,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,415,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OCULAR VASCULAR DISORDER AGENTS (21605119),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,496,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,137,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,367,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OTHER DIURETICS (21601556),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,69,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION (21602558),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,185,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,419,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,906,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,791,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: CORTICOSTEROIDS (21605164),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,47,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,146,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,125,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: EMOLLIENTS AND PROTECTIVES (21601969),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,104,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,225,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ALKYLATING AGENTS (21601388),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,891,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,805,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,121,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,276,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,1771,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,424,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,3221,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES (21602683),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,312,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,799,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,1416,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OTHER OTOLOGICALS (21605180),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,3560,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OTHER PLAIN VITAMIN PREPARATIONS (21600840),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: DRUGS FOR TREATMENT OF LEPRA (21603121),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,123,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM (21601848),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,108,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,145,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,127,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,113,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS (21601730)",binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,874,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: POSTERIOR PITUITARY LOBE HORMONES (21602697),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,181,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,80,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,597,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,83,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,555,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,5198,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,47,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,4592,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,802,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,620,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,196,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OPIOIDS (21604254),binary,NA,count,1438,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,77,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,529,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,1576,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,82,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS (21604911),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,72,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS (21604125)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,114,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,294,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,1260,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,97,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: ECTOPARASITICIDES, INCL. SCABICIDES (21604968)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,2836,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: SPECIFIC ANTIRHEUMATIC AGENTS (21604021),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,380,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,359,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,750,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIADRENAL PREPARATIONS (21602748),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,304,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,324,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,759,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,489,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,814,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,99,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,261,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,230,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,66,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,474,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,57,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES (21602683),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,576,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,998,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,163,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,125,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM (21601848),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,146,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM (21601848),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,520,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ULTRASOUND CONTRAST MEDIA (21605437),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OTHER PLAIN VITAMIN PREPARATIONS (21600840),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ENZYMES (21601997),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,301,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: HYPOTHALAMIC HORMONES (21602709),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,254,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,272,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,133,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,289,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,160,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,1344,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OTHER PLAIN VITAMIN PREPARATIONS (21600840),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,3478,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,350,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,72,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,165,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,200,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: LOCAL ANESTHETICS (21605096),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,denominator,binary,NA,count,18744,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,1034,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,99,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,1222,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION (21600451),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: LIVER THERAPY, LIPOTROPICS (21600521)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES (21603728),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,104,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: MEDICATED DRESSINGS (21602262),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,334,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,2852,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: UTEROTONICS (21602430),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,222,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,260,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANDROGENS (21602506),binary,NA,count,176,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: UTEROTONICS (21602430),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: DRUGS FOR TREATMENT OF LEPRA (21603121),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,206,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,430,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: VITAMIN K AND OTHER HEMOSTATICS (21601043),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS (21604911),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,120,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,1104,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,123,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,1537,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIPSORIATICS FOR SYSTEMIC USE (21602044),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,102,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: MEDICATED DRESSINGS (21602262),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,464,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,1125,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS (21600933),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,126,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,denominator,binary,NA,count,22836,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,352,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,1253,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: HYPOTHALAMIC HORMONES (21602709),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,243,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,123,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: POSTERIOR PITUITARY LOBE HORMONES (21602697),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: OTHER PLAIN VITAMIN PREPARATIONS (21600840),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,208,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: OPIOIDS (21604254),binary,NA,count,587,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: BLOOD AND RELATED PRODUCTS (21601137),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,358,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,184,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANDROGENS (21602506),binary,NA,count,70,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: SPECIFIC ANTIRHEUMATIC AGENTS (21604021),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,81,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANDROGENS (21602506),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,440,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,234,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,173,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,1015,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,389,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,632,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OTHER RESPIRATORY SYSTEM PRODUCTS (21603531),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,129,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,116,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,181,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,61,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,51,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,141,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: POTASSIUM (21600875),binary,NA,count,709,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: MEDICATED DRESSINGS (21602262),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,3279,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OPIOIDS (21604254),binary,NA,count,1733,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,2198,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTI-PARATHYROID AGENTS (21602785),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,66,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,143,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: POSTERIOR PITUITARY LOBE HORMONES (21602697),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: GONADOTROPINS AND OTHER OVULATION STIMULANTS (21602597),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,431,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,67,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ALLERGENS (21605214),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,70,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,435,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIFIBRINOLYTICS (21601033),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,2576,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,920,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,456,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,1566,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OTHER OTOLOGICALS (21605180),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,denominator,binary,NA,count,3521,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: CALCIUM (21600858),binary,NA,count,131,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: SPECIFIC ANTIRHEUMATIC AGENTS (21604021),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,167,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,174,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,4029,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,4792,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION (21604787),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,3716,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,241,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,5407,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,82,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: LOCAL ANESTHETICS (21605096),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS (21602745)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,162,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,100,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES (21603728),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,3692,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,94,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,770,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,97,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,92,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,142,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,261,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,483,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,denominator,binary,NA,count,15206,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: POTASSIUM (21600875),binary,NA,count,735,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,112,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,405,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,685,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,76,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,316,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,91,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,104,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,354,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,56,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: POTASSIUM (21600875),binary,NA,count,773,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,607,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,1054,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,272,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTI-PARATHYROID AGENTS (21602785),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,82,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: BLOOD AND RELATED PRODUCTS (21601137),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,289,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,665,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANABOLIC STEROIDS (21600915),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,80,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ESTROGENS (21602514),binary,NA,count,112,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,592,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,1186,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,621,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIFIBRINOLYTICS (21601033),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: BETA BLOCKING AGENTS AND OTHER DIURETICS (21601718),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,212,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS (21602745)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,710,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: HYPOTHALAMIC HORMONES (21602709),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: CALCIUM (21600858),binary,NA,count,69,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OTHER ANTIHYPERTENSIVES (21600438),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: RENAL SYSTEM (21605462),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,254,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,302,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION (21604787),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,541,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,1034,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,78,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,63,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,654,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,6519,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,318,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,1124,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: GLYCOGENOLYTIC HORMONES (21602776),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: CORTICOSTEROIDS (21605164),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ULTRASOUND CONTRAST MEDIA (21605437),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,1998,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,440,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,336,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,189,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,1215,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION (21602558),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OTHER HEMATOLOGICAL AGENTS (21601226),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,73,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,699,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,473,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,89,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,298,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,353,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,396,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: VITAMIN K AND OTHER HEMOSTATICS (21601043),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS (21604911),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,denominator,binary,NA,count,17213,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,418,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: OTHER PLAIN VITAMIN PREPARATIONS (21600840),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,125,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,280,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,696,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,341,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,102,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS (21604125)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,787,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,646,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: LIVER THERAPY, LIPOTROPICS (21600521)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,139,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,181,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIFIBRINOLYTICS (21601033),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,252,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,1454,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,113,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,89,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,123,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,277,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,80,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,558,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: DRUGS FOR TREATMENT OF LEPRA (21603121),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,53,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,130,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,1986,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: GONADOTROPINS AND OTHER OVULATION STIMULANTS (21602597),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,485,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,441,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,201,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,196,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,1064,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,1766,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,73,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ESTROGENS (21602514),binary,NA,count,1043,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: BLOOD AND RELATED PRODUCTS (21601137),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: ECTOPARASITICIDES, INCL. SCABICIDES (21604968)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS (21600933),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,585,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,645,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,1079,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,429,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,65,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,1023,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,156,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,4581,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ALLERGENS (21605214),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,477,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,61,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OCULAR VASCULAR DISORDER AGENTS (21605119),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,112,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: ECTOPARASITICIDES, INCL. SCABICIDES (21604968)",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,255,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIPSORIATICS FOR SYSTEMIC USE (21602044),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,164,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,95,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,315,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, COMBINATIONS (21601898)",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION (21602558),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: UTEROTONICS (21602430),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,120,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, COMBINATIONS (21601898)",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,853,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,2412,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,952,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,1936,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION (21604787),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,95,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,108,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OTHER HEMATOLOGICAL AGENTS (21601226),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,2689,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,246,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ANTIPSORIATICS FOR SYSTEMIC USE (21602044),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,5581,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,1226,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,4169,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,130,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS (21604125)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: CALCIUM (21600858),binary,NA,count,429,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS (21601730)",binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,397,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,-30 to -1,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OTHER HEMATOLOGICAL AGENTS (21601226),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,-30 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,97,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,129,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,1829,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,160,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,216,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,259,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS (21600933),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,460,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,670,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION (21602558),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,344,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIADRENAL PREPARATIONS (21602748),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, COMBINATIONS (21601898)",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,518,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: ANDROGENS (21602506),binary,NA,count,111,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,1765,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,457,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,492,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,206,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: SPECIFIC ANTIRHEUMATIC AGENTS (21604021),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: CICATRIZANTS (21601986),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,747,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,605,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,142,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OTHER PLAIN VITAMIN PREPARATIONS (21600840),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,628,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,2040,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,171,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,498,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,97,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: POTASSIUM (21600875),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,142,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: SPECIFIC ANTIRHEUMATIC AGENTS (21604021),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,197,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,64,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: OTHER RESPIRATORY SYSTEM PRODUCTS (21603531),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,62,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, COMBINATIONS (21601898)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES (21603728),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,231,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,309,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,140,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,185,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ANTIADRENAL PREPARATIONS (21602748),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,184,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,788,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,2868,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,1871,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: CALCIUM (21600858),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,2965,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,179,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,251,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,109,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,167,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,94,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,denominator,binary,NA,count,18234,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,558,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: ANDROGENS (21602506),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,51,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,1384,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,1610,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION (21602558),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,104,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,765,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,2645,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,884,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, COMBINATIONS (21601898)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: OPIOIDS (21604254),binary,NA,count,2134,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,353,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,69,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: ANDROGENS (21602506),binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,561,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,-30 to -1,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,327,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,153,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,150,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,329,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,68,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,117,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS (21604911),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE (21602318),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: BLOOD AND RELATED PRODUCTS (21601137),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,172,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,136,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,153,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: ANTIFIBRINOLYTICS (21601033),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,261,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: OCULAR VASCULAR DISORDER AGENTS (21605119),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,116,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,572,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,140,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,401,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: ECTOPARASITICIDES, INCL. SCABICIDES (21604968)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,729,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,1852,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: LOCAL ANESTHETICS (21605096),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: POSTERIOR PITUITARY LOBE HORMONES (21602697),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: ENZYMES (21601997),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OPIOIDS (21604254),binary,NA,count,2102,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,617,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,119,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,171,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,296,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,643,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,626,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,373,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,3913,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,169,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,71,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: OTHER HEMATOLOGICAL AGENTS (21601226),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,103,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE (21602318),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: HYPOTHALAMIC HORMONES (21602709),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,241,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,1241,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,474,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,358,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,76,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,1102,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: POSTERIOR PITUITARY LOBE HORMONES (21602697),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIFIBRINOLYTICS (21601033),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,137,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,745,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,144,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: VITAMIN K AND OTHER HEMOSTATICS (21601043),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,148,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS (21600933),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,92,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,236,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,125,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,1384,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,421,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,7420,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,750,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION (21604787),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: ALKYLATING AGENTS (21601388),binary,NA,count,156,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,56,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ENZYMES (21601997),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,144,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: OTHER PLAIN VITAMIN PREPARATIONS (21600840),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: CALCIUM (21600858),binary,NA,count,489,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,-30 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: POSTERIOR PITUITARY LOBE HORMONES (21602697),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,517,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,230,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: POTASSIUM (21600875),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,71,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ANABOLIC STEROIDS (21600915),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,89,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,-30 to -1,denominator,binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,113,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: ANTIPSORIATICS FOR SYSTEMIC USE (21602044),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,-30 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES (21603728),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,596,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,1748,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,7430,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,591,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: ECTOPARASITICIDES, INCL. SCABICIDES (21604968)",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,263,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,288,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: X-RAY CONTRAST MEDIA, NON-IODINATED (21605414)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,1170,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,136,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,704,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: OTHER OTOLOGICALS (21605180),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,128,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS (21600933),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: BETA BLOCKING AGENTS AND OTHER DIURETICS (21601718),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,1782,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,124,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,455,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: ESTROGENS (21602514),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,100,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: ECTOPARASITICIDES, INCL. SCABICIDES (21604968)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,222,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,332,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,241,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,491,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,555,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,5162,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,98,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,435,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,525,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,"ATC 3rd: ECTOPARASITICIDES, INCL. SCABICIDES (21604968)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,denominator,binary,NA,count,19107,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,1094,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OCULAR VASCULAR DISORDER AGENTS (21605119),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,768,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,256,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,131,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: ESTROGENS (21602514),binary,NA,count,581,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,2465,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,93,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,1392,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,181,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,denominator,binary,NA,count,15057,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,95,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,465,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,1011,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: EMOLLIENTS AND PROTECTIVES (21601969),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,360,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,68,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,112,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,101,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,880,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,-30 to -1,denominator,binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,721,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,1298,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: BLOOD AND RELATED PRODUCTS (21601137),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,968,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,-30 to -1,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,372,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: GONADOTROPINS AND OTHER OVULATION STIMULANTS (21602597),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,146,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,75,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,-30 to -1,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,144,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANABOLIC STEROIDS (21600915),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: DRUGS FOR TREATMENT OF LEPRA (21603121),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,445,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,82,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,140,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,56,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,1019,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,462,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,363,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: MEDICATED DRESSINGS (21602262),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,945,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,-30 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,97,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ALKYLATING AGENTS (21601388),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,1038,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ALLERGENS (21605214),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,252,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS (21601730)",binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION (21602558),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,610,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,162,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,48,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,235,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,73,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: RENAL SYSTEM (21605462),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: CALCIUM (21600858),binary,NA,count,628,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,482,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,142,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,88,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,221,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,710,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,642,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,621,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: UTEROTONICS (21602430),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES (21603728),binary,NA,count,101,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,514,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION (21600451),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,76,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, COMBINATIONS (21601898)",binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,57,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,192,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,514,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,572,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: ULTRASOUND CONTRAST MEDIA (21605437),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION (21600451),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ALKYLATING AGENTS (21601388),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,678,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,642,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: ESTROGENS (21602514),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,1467,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OPIOIDS (21604254),binary,NA,count,1778,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,162,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,82,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,161,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS (21604911),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,81,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANDROGENS (21602506),binary,NA,count,79,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: CALCIUM (21600858),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: BLOOD AND RELATED PRODUCTS (21601137),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,98,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,315,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,260,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,681,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,1041,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,57,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: OTHER ANTIHYPERTENSIVES (21600438),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,531,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,4167,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,-30 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,4279,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,denominator,binary,NA,count,2453,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,1473,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,500,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTACIDS (21600047),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,72,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,78,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,119,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,720,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS (21601730)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,689,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,242,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,223,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,1313,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,136,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,1980,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,145,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,352,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,88,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,-30 to -1,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,denominator,binary,NA,count,70,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,1843,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,348,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,91,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,140,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,272,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,567,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,889,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,3203,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,146,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OTHER ANTIHYPERTENSIVES (21600438),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,2225,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,216,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,85,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,74,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: HYPOTHALAMIC HORMONES (21602709),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,4791,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,3352,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: SURGICAL AIDS (21605112),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,415,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,884,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: MEDICATED DRESSINGS (21602262),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,348,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,995,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: GONADOTROPINS AND OTHER OVULATION STIMULANTS (21602597),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,73,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,808,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,281,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,117,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,1499,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,531,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,367,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,150,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,329,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,1000,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: OTHER PLAIN VITAMIN PREPARATIONS (21600840),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,1005,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,100,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,221,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,141,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTI-PARATHYROID AGENTS (21602785),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,2649,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,89,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,44,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,349,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,581,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,244,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,340,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: GONADOTROPINS AND OTHER OVULATION STIMULANTS (21602597),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS (21600933),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,254,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,358,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,312,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,1505,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,124,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: GLYCOGENOLYTIC HORMONES (21602776),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,344,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,152,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,275,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: CALCIUM (21600858),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,859,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,68,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,137,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,4982,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,-30 to -1,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,345,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: OPIOIDS (21604254),binary,NA,count,141,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,592,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,139,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,155,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,329,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ESTROGENS (21602514),binary,NA,count,666,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: OPIOIDS (21604254),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,234,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,133,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OTHER RESPIRATORY SYSTEM PRODUCTS (21603531),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,-30 to -1,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: ANTACIDS (21600047),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,86,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: LIVER THERAPY, LIPOTROPICS (21600521)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,80,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: CALCIUM (21600858),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH ANALGESICS (21600220),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: GLYCOGENOLYTIC HORMONES (21602776),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,-30 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,549,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,442,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,108,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,761,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,1842,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: GONADOTROPINS AND OTHER OVULATION STIMULANTS (21602597),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: ENZYMES (21601997),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: EMOLLIENTS AND PROTECTIVES (21601969),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,401,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,2028,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,404,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION (21604787),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,720,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,79,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIPSORIATICS FOR SYSTEMIC USE (21602044),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,205,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIPSORIATICS FOR SYSTEMIC USE (21602044),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,96,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,-30 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,94,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: ANTACIDS (21600047),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,280,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,247,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,"ATC 3rd: BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS (21601730)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,228,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: ANTIFIBRINOLYTICS (21601033),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: RENAL SYSTEM (21605462),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,87,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,3473,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,556,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,554,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,341,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,130,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,305,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: MEDICATED DRESSINGS (21602262),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,613,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,481,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,501,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS (21602745)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,507,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,82,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,66,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,4359,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,2852,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,804,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,1205,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,4021,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: BETA BLOCKING AGENTS AND OTHER DIURETICS (21601718),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,543,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,51,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,1372,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,47,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,1887,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,728,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,71,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: LOCAL ANESTHETICS (21605096),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,483,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,93,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,123,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,232,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS (21602745)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH ANALGESICS (21600220),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,1024,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,2792,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,353,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: OTHER DIURETICS (21601556),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,75,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ANTACIDS (21600047),binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,77,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,66,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: OPIOIDS (21604254),binary,NA,count,1622,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: EMOLLIENTS AND PROTECTIVES (21601969),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,134,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: ANTIADRENAL PREPARATIONS (21602748),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,5287,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,2776,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,1851,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,-30 to -1,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,67,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,184,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,"ATC 3rd: BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS (21601730)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: UTEROTONICS (21602430),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,563,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: ANTI-PARATHYROID AGENTS (21602785),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM (21601848),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ANTIFIBRINOLYTICS (21601033),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,745,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,-30 to -1,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,3635,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,156,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,616,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,103,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,80,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,4796,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,1164,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION (21602558),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: ENZYMES (21601997),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,-30 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,227,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION (21604787),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES (21602683),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: LIVER THERAPY, LIPOTROPICS (21600521)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OTHER ANTIHYPERTENSIVES (21600438),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTACIDS (21600047),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,203,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,1637,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,4279,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES (21603728),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,56,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: CORTICOSTEROIDS (21605164),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: BETA BLOCKING AGENTS AND OTHER DIURETICS (21601718),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,146,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,819,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,2619,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,81,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,65,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,-30 to -1,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: HYPOTHALAMIC HORMONES (21602709),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,408,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: POTASSIUM (21600875),binary,NA,count,805,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ULTRASOUND CONTRAST MEDIA (21605437),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,325,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,509,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,130,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,281,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,507,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,119,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,249,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: OCULAR VASCULAR DISORDER AGENTS (21605119),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,122,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ENZYMES (21601997),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: GLYCOGENOLYTIC HORMONES (21602776),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,752,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,428,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,47,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,454,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,denominator,binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,439,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OTHER OTOLOGICALS (21605180),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,63,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: LIVER THERAPY, LIPOTROPICS (21600521)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS (21600933),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: OPIOIDS (21604254),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,-30 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: OTHER ANTIHYPERTENSIVES (21600438),binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,2273,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,140,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,111,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,179,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,459,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: LOCAL ANESTHETICS (21605096),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,5925,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,5188,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,81,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,263,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: OTHER DIURETICS (21601556),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: BETA BLOCKING AGENTS AND OTHER DIURETICS (21601718),binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,2850,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,227,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,391,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: RENAL SYSTEM (21605462),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: VITAMIN K AND OTHER HEMOSTATICS (21601043),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,87,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,188,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,1137,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,3858,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ANDROGENS (21602506),binary,NA,count,216,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES (21602683),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: CALCIUM (21600858),binary,NA,count,279,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,118,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE (21602318),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,3646,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,462,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,6332,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ANTI-PARATHYROID AGENTS (21602785),binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,3379,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,107,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OTHER OTOLOGICALS (21605180),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS (21602745)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,481,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,541,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,1229,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OTHER DIURETICS (21601556),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,362,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OTHER RESPIRATORY SYSTEM PRODUCTS (21603531),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,542,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,119,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,78,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ESTROGENS (21602514),binary,NA,count,1650,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ESTROGENS (21602514),binary,NA,count,681,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,2312,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,185,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,1238,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,716,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE (21602318),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,243,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: LIVER THERAPY, LIPOTROPICS (21600521)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,79,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,81,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,98,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,590,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,380,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: OTHER PLAIN VITAMIN PREPARATIONS (21600840),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,2324,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,99,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: CORTICOSTEROIDS (21605164),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: CORTICOSTEROIDS (21605164),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: OTHER HEMATOLOGICAL AGENTS (21601226),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,-30 to -1,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,1244,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,742,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: ESTROGENS (21602514),binary,NA,count,69,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,322,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: VITAMIN K AND OTHER HEMOSTATICS (21601043),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,239,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,520,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,916,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,254,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,2827,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,298,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,183,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ENZYMES (21601997),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: GLYCOGENOLYTIC HORMONES (21602776),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: POTASSIUM (21600875),binary,NA,count,595,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,453,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,2025,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,3218,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANDROGENS (21602506),binary,NA,count,66,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,1741,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM (21601848),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,242,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: CORTICOSTEROIDS (21605164),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,493,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS (21604125)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OTHER PLAIN VITAMIN PREPARATIONS (21600840),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,4960,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,118,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: BLOOD AND RELATED PRODUCTS (21601137),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: VITAMIN K AND OTHER HEMOSTATICS (21601043),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,4019,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,1164,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,65,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,136,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,269,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ULTRASOUND CONTRAST MEDIA (21605437),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,831,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,2186,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,82,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,56,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,493,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: POTASSIUM (21600875),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,821,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,801,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,denominator,binary,NA,count,31981,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,-30 to -1,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,-30 to -1,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,104,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: MEDICATED DRESSINGS (21602262),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,86,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,4258,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,606,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: ULTRASOUND CONTRAST MEDIA (21605437),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,116,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,1754,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,458,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,166,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: BETA BLOCKING AGENTS AND OTHER DIURETICS (21601718),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,446,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,484,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,360,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM (21601848),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,1065,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: ANTIPSORIATICS FOR SYSTEMIC USE (21602044),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,331,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,108,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTI-PARATHYROID AGENTS (21602785),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: ANTIADRENAL PREPARATIONS (21602748),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,154,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,169,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,699,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,337,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,597,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,770,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,125,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,2915,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,44,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,215,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES (21602683),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,820,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,1270,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,1500,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,4723,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,1039,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,750,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ULTRASOUND CONTRAST MEDIA (21605437),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS (21601730)",binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: POSTERIOR PITUITARY LOBE HORMONES (21602697),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,850,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,48,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,199,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,987,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: AMPHENICOLS (21602813),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,354,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: HYPOTHALAMIC HORMONES (21602709),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,67,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,121,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,111,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,1311,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: DRUGS FOR TREATMENT OF LEPRA (21603121),binary,NA,count,44,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,158,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: OTHER OTOLOGICALS (21605180),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,63,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,denominator,binary,NA,count,116,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,340,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,141,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,483,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: LOCAL ANESTHETICS (21605096),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ALKYLATING AGENTS (21601388),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,56,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,65,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: BETA BLOCKING AGENTS AND OTHER DIURETICS (21601718),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,153,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,1478,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,477,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,1440,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,122,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,1580,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,249,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,3682,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: OPIOIDS (21604254),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,641,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,1405,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,239,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION (21600451),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: VITAMIN K AND OTHER HEMOSTATICS (21601043),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,151,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: OTHER HEMATOLOGICAL AGENTS (21601226),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE (21602318),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,2929,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,1698,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,1893,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: CORTICOSTEROIDS (21605164),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,3231,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,56,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: MEDICATED DRESSINGS (21602262),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,171,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,358,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,327,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIADRENAL PREPARATIONS (21602748),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,4645,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,78,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIFIBRINOLYTICS (21601033),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,63,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: DRUGS FOR TREATMENT OF LEPRA (21603121),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM (21601848),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,107,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,"ATC 3rd: LIVER THERAPY, LIPOTROPICS (21600521)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: ANTI-PARATHYROID AGENTS (21602785),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: POTASSIUM (21600875),binary,NA,count,960,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: POTASSIUM (21600875),binary,NA,count,743,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,74,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,179,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,330,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,171,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,329,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,85,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,2550,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: DRUGS FOR TREATMENT OF LEPRA (21603121),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,98,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,1163,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,166,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES (21602683),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OCULAR VASCULAR DISORDER AGENTS (21605119),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,162,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: ECTOPARASITICIDES, INCL. SCABICIDES (21604968)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,792,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,253,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,1346,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,519,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION (21602558),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: POTASSIUM (21600875),binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,137,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: DRUGS FOR TREATMENT OF LEPRA (21603121),binary,NA,count,51,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,-30 to -1,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,197,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, COMBINATIONS (21601898)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION (21600451),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ANTIPSORIATICS FOR SYSTEMIC USE (21602044),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ALLERGENS (21605214),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,114,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: OTHER RESPIRATORY SYSTEM PRODUCTS (21603531),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,74,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,1543,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,651,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,244,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,293,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: OTHER OTOLOGICALS (21605180),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE (21602318),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,271,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: GLYCOGENOLYTIC HORMONES (21602776),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,478,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: AMPHENICOLS (21602813),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,167,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: LIPID MODIFYING AGENTS, COMBINATIONS (21601898)",binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,76,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,184,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: SURGICAL AIDS (21605112),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ANTIADRENAL PREPARATIONS (21602748),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,denominator,binary,NA,count,49054,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,105,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE (21602318),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,267,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ENZYMES (21601997),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,3403,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,68,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM (21601848),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ANABOLIC STEROIDS (21600915),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,381,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,210,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,445,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,141,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,105,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,233,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,134,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: OPIOIDS (21604254),binary,NA,count,2270,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,784,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,5580,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,1587,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS (21601730)",binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: OTHER RESPIRATORY SYSTEM PRODUCTS (21603531),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,238,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH ANALGESICS (21600220),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,10383,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: HYPOTHALAMIC HORMONES (21602709),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,231,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,78,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,236,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,79,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,70,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: OTHER HEMATOLOGICAL AGENTS (21601226),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,1105,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION (21604787),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,44,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,1949,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,634,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,2442,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES (21602683),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,914,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: OTHER ANTIHYPERTENSIVES (21600438),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,37032,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: BLOOD AND RELATED PRODUCTS (21601137),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,833,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,256,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,922,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,108,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,1613,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,1643,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,110,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,288,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,104,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,81,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,226,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: GLYCOGENOLYTIC HORMONES (21602776),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,77,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,148,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,4604,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"ATC 3rd: ECTOPARASITICIDES, INCL. SCABICIDES (21604968)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,730,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,123,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ANTACIDS (21600047),binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,232,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,707,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: OTHER PLAIN VITAMIN PREPARATIONS (21600840),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,1324,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,196,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,1272,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,587,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,240,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,367,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: OTHER ANTIHYPERTENSIVES (21600438),binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,149,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,1823,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,405,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,153,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: VITAMIN K AND OTHER HEMOSTATICS (21601043),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ALKYLATING AGENTS (21601388),binary,NA,count,192,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,2466,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,302,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,1449,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,134,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: OTHER OTOLOGICALS (21605180),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,299,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION (21604787),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,834,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,298,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: OCULAR VASCULAR DISORDER AGENTS (21605119),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,430,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,61,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,740,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,379,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,8328,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,70,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,192,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: CORTICOSTEROIDS (21605164),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: POTASSIUM (21600875),binary,NA,count,1564,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,5275,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,792,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION (21602558),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,81,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,1205,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,3032,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ANTI-PARATHYROID AGENTS (21602785),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,627,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,154,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM (21601848),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,1978,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,4646,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,3231,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,78,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,178,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,956,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,3815,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,875,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,823,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ANTIFIBRINOLYTICS (21601033),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,1021,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,1182,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,66,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,460,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: CALCIUM (21600858),binary,NA,count,871,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ALKYLATING AGENTS (21601388),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,51,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,1004,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,243,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,1336,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,61,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,456,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,230,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,36947,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: SPECIFIC ANTIRHEUMATIC AGENTS (21604021),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,819,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"ATC 3rd: BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS (21601730)",binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: BETA BLOCKING AGENTS AND OTHER DIURETICS (21601718),binary,NA,count,47,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,418,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,62,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,51,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,16206,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,78,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,1088,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,887,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,249,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,6097,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,110,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,1540,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,268,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,227,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,6712,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,91,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ESTROGENS (21602514),binary,NA,count,1062,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: POSTERIOR PITUITARY LOBE HORMONES (21602697),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,1085,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: CORTICOSTEROIDS (21605164),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,516,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION (21600451),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,377,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,288,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION (21602558),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,7920,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,293,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS (21604125)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ANTACIDS (21600047),binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,947,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,4161,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,770,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,4029,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,1442,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: EMOLLIENTS AND PROTECTIVES (21601969),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,218,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,2242,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,323,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: HYPOTHALAMIC HORMONES (21602709),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,1187,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,404,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ENZYMES (21601997),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,1096,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: BETA BLOCKING AGENTS AND OTHER DIURETICS (21601718),binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ANTIADRENAL PREPARATIONS (21602748),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: MEDICATED DRESSINGS (21602262),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,2666,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,2043,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,307,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"ATC 3rd: MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS (21604125)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: ECTOPARASITICIDES, INCL. SCABICIDES (21604968)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: MEDICATED DRESSINGS (21602262),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,971,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,6559,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,1331,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,1055,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: POTASSIUM (21600875),binary,NA,count,1235,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,158,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,1088,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,133,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: OPIOIDS (21604254),binary,NA,count,2582,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,2805,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,49275,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,3241,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,824,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,965,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,88,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,10381,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,299,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,345,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,1000,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,1900,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,3653,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,157,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ANTIFIBRINOLYTICS (21601033),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: VITAMIN K AND OTHER HEMOSTATICS (21601043),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ESTROGENS (21602514),binary,NA,count,2148,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,1046,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,583,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS (21600933),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,130,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,1274,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,83,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,11508,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,296,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,5199,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,2061,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,122,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,100,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS (21602745)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,3682,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,129,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,320,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,116,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,236,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,456,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,1894,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,1160,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,164,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,8602,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,193,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,94,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,109,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS (21600933),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,71,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,76,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,794,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ANTIPSORIATICS FOR SYSTEMIC USE (21602044),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES (21602683),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,15888,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,289,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: OTHER DIURETICS (21601556),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,551,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,9733,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: GONADOTROPINS AND OTHER OVULATION STIMULANTS (21602597),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: CALCIUM (21600858),binary,NA,count,892,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,86,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: EMOLLIENTS AND PROTECTIVES (21601969),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: SPECIFIC ANTIRHEUMATIC AGENTS (21604021),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,168,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,81,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,710,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,65,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH ANALGESICS (21600220),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,65,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,503,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: BLOOD AND RELATED PRODUCTS (21601137),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,541,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,2338,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,105,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: OTHER DIURETICS (21601556),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,1482,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,185,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,595,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,138,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,1434,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ANTI-PARATHYROID AGENTS (21602785),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,3014,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,419,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,denominator,binary,NA,count,36871,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,939,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,835,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: INTESTINAL ADSORBENTS (21600627),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,648,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,5550,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,111,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,272,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: DRUGS FOR TREATMENT OF LEPRA (21603121),binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS (21604911),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,7042,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,2254,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,4385,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: DRUGS FOR TREATMENT OF LEPRA (21603121),binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: OTHER PLAIN VITAMIN PREPARATIONS (21600840),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,1235,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: LOCAL ANESTHETICS (21605096),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ANDROGENS (21602506),binary,NA,count,128,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,137,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: LOCAL ANESTHETICS (21605096),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,172,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,8285,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,287,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: POSTERIOR PITUITARY LOBE HORMONES (21602697),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,6908,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: LIVER THERAPY, LIPOTROPICS (21600521)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,146,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,64,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,2951,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,1759,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: UTEROTONICS (21602430),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,1271,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,743,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: GONADOTROPINS AND OTHER OVULATION STIMULANTS (21602597),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,171,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,1180,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,306,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,914,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,497,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: OTHER HEMATOLOGICAL AGENTS (21601226),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ANABOLIC STEROIDS (21600915),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,176,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,73,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,71,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS (21602745)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,159,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,498,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,1936,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"ATC 3rd: LIPID MODIFYING AGENTS, COMBINATIONS (21601898)",binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,986,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,1778,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ANDROGENS (21602506),binary,NA,count,225,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,2763,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES (21603728),binary,NA,count,77,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,175,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,4674,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,3205,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,169,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: GLYCOGENOLYTIC HORMONES (21602776),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,106,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS (21600933),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,2079,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,479,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,307,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,743,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS (21602745)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,156,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTI-PARATHYROID AGENTS (21602785),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,292,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,450,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: MEDICATED DRESSINGS (21602262),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTI-PARATHYROID AGENTS (21602785),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE (21602318),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,92,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,519,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: POTASSIUM (21600875),binary,NA,count,103,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ALKYLATING AGENTS (21601388),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,220,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,886,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,136,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,86,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: SURGICAL AIDS (21605112),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,343,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,308,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,8384,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,106,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,730,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,501,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,204,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION (21600451),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: CALCIUM (21600858),binary,NA,count,430,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,65,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,615,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,2689,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES (21603728),binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,286,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,75,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,1452,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,345,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,630,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,3823,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIADRENAL PREPARATIONS (21602748),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,140,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,449,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,273,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: LIPID MODIFYING AGENTS, COMBINATIONS (21601898)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,256,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,1580,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,112,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,438,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,197,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,48,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,117,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,202,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,299,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES (21603728),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,184,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,3604,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,87,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,4262,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,1852,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,97,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,1438,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,218,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,512,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"ATC 3rd: LIVER THERAPY, LIPOTROPICS (21600521)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: OTHER ANTIHYPERTENSIVES (21600438),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTACIDS (21600047),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM (21601848),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,98,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: DRUGS FOR TREATMENT OF LEPRA (21603121),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,123,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: OPIOIDS (21604254),binary,NA,count,1061,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION (21602558),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,140,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,518,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"ATC 3rd: BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS (21601730)",binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,141,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,64,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,227,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,413,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,3254,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,127,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: VITAMIN K AND OTHER HEMOSTATICS (21601043),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,1300,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,121,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,132,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,66,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,271,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: OPIOIDS (21604254),binary,NA,count,1151,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,465,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: GLYCOGENOLYTIC HORMONES (21602776),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: OTHER RESPIRATORY SYSTEM PRODUCTS (21603531),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"ATC 3rd: LIPID MODIFYING AGENTS, COMBINATIONS (21601898)",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIPSORIATICS FOR SYSTEMIC USE (21602044),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,460,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTACIDS (21600047),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,1081,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,133,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,70,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,491,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,762,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTIFIBRINOLYTICS (21601033),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,897,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,170,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,409,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: BETA BLOCKING AGENTS AND OTHER DIURETICS (21601718),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,275,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"ATC 3rd: BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS (21601730)",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,89,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,381,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: OTHER HEMATOLOGICAL AGENTS (21601226),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,143,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,317,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,298,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,85,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,2590,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,154,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,183,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM (21601848),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,2145,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,176,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,1510,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIADRENAL PREPARATIONS (21602748),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,121,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,8256,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH ANALGESICS (21600220),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIPSORIATICS FOR SYSTEMIC USE (21602044),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,109,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANABOLIC STEROIDS (21600915),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,222,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH ANALGESICS (21600220),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,268,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,6180,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,753,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,18305,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,99,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,1746,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,439,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,1270,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,56,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,61,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,561,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,931,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,81,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,62,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: CORTICOSTEROIDS (21605164),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,101,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: GONADOTROPINS AND OTHER OVULATION STIMULANTS (21602597),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,90,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: BETA BLOCKING AGENTS AND OTHER DIURETICS (21601718),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,118,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: ALKYLATING AGENTS (21601388),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,802,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: POSTERIOR PITUITARY LOBE HORMONES (21602697),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,denominator,binary,NA,count,9565,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,593,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,88,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,316,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,1299,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,167,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: POSTERIOR PITUITARY LOBE HORMONES (21602697),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,93,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,347,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,497,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,1169,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,764,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES (21602683),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,80,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: LIPID MODIFYING AGENTS, COMBINATIONS (21601898)",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTI-PARATHYROID AGENTS (21602785),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,112,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,105,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,263,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: ECTOPARASITICIDES, INCL. SCABICIDES (21604968)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: OTHER PLAIN VITAMIN PREPARATIONS (21600840),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANABOLIC STEROIDS (21600915),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,66,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,110,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,3521,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,502,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,434,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,148,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,872,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,72,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,77,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,104,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS (21601730)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM (21601848),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: LOCAL ANESTHETICS (21605096),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,2268,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,516,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS (21601730)",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,369,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,961,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTI-PARATHYROID AGENTS (21602785),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIPSORIATICS FOR SYSTEMIC USE (21602044),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,79,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,397,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,110,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,3340,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,97,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,413,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,114,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: EMOLLIENTS AND PROTECTIVES (21601969),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANDROGENS (21602506),binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ENZYMES (21601997),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: VITAMIN K AND OTHER HEMOSTATICS (21601043),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,114,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,69,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,575,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES (21602683),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,163,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANDROGENS (21602506),binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: OTHER OTOLOGICALS (21605180),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: ECTOPARASITICIDES, INCL. SCABICIDES (21604968)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,514,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: LIVER THERAPY, LIPOTROPICS (21600521)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,411,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,441,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,138,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,1812,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,2730,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,242,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,2175,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: OTHER ANTIHYPERTENSIVES (21600438),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,164,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,363,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,529,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,971,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,2812,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,18220,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: OTHER HEMATOLOGICAL AGENTS (21601226),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,122,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,91,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS (21604911),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: AMPHENICOLS (21602813),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: LOCAL ANESTHETICS (21605096),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,1370,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTIPSORIATICS FOR SYSTEMIC USE (21602044),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,238,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,79,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,721,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,81,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,88,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,72,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,162,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,1921,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: ENZYMES (21601997),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,431,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,451,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: GONADOTROPINS AND OTHER OVULATION STIMULANTS (21602597),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: OTHER ANTIHYPERTENSIVES (21600438),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,264,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,1758,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,1428,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,72,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,71,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS (21600933),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,375,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,6334,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,267,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,107,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: BLOOD AND RELATED PRODUCTS (21601137),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,75,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: BETA BLOCKING AGENTS AND OTHER DIURETICS (21601718),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,80,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,57,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,67,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: CALCIUM (21600858),binary,NA,count,376,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,156,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,418,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ESTROGENS (21602514),binary,NA,count,426,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,2048,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS (21600933),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,465,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,516,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,84,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: INTESTINAL ADSORBENTS (21600627),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,420,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,718,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,44,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,91,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,399,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,99,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,1059,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,379,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,1095,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,412,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,1742,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,88,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,80,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,316,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,1882,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: POTASSIUM (21600875),binary,NA,count,214,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,126,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,907,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,5568,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,78,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,2026,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION (21604787),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,217,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,472,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,839,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,1390,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,146,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,1264,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: ESTROGENS (21602514),binary,NA,count,537,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ESTROGENS (21602514),binary,NA,count,402,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,629,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,830,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,88,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,881,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,183,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: DRUGS FOR TREATMENT OF LEPRA (21603121),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE (21602318),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: GLYCOGENOLYTIC HORMONES (21602776),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION (21604787),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,199,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,2754,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"ATC 3rd: ECTOPARASITICIDES, INCL. SCABICIDES (21604968)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,533,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ENZYMES (21601997),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,395,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: ESTROGENS (21602514),binary,NA,count,807,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: CALCIUM (21600858),binary,NA,count,387,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,64,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,727,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ALKYLATING AGENTS (21601388),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: OTHER DIURETICS (21601556),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,68,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,318,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTACIDS (21600047),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,1187,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,120,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: VITAMIN K AND OTHER HEMOSTATICS (21601043),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,1599,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,111,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,89,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,229,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION (21602558),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,651,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: OTHER OTOLOGICALS (21605180),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,316,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,753,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,44,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,731,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,126,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,81,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS (21604125)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,78,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,67,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: CORTICOSTEROIDS (21605164),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: BETA BLOCKING AGENTS AND OTHER DIURETICS (21601718),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,825,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTACIDS (21600047),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE (21602318),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: OTHER ANTIHYPERTENSIVES (21600438),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: EMOLLIENTS AND PROTECTIVES (21601969),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTACIDS (21600047),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,969,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,3095,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,108,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,353,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE (21602318),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,211,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES (21602683),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,316,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,196,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: ALKYLATING AGENTS (21601388),binary,NA,count,79,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,66,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: GONADOTROPINS AND OTHER OVULATION STIMULANTS (21602597),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: OTHER ANTIHYPERTENSIVES (21600438),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,331,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANDROGENS (21602506),binary,NA,count,62,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,249,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,497,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,15206,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,261,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,361,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,96,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,145,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIADRENAL PREPARATIONS (21602748),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ALKYLATING AGENTS (21601388),binary,NA,count,83,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,165,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,87,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,153,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: EMOLLIENTS AND PROTECTIVES (21601969),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,205,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,218,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,500,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES (21602683),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,1571,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,220,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,3360,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,71,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,1173,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: GLYCOGENOLYTIC HORMONES (21602776),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,22836,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,78,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,113,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,258,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,74,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,511,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,73,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,741,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,128,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,207,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,3567,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,289,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,78,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,199,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,127,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: OPIOIDS (21604254),binary,NA,count,215,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,918,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,862,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,443,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: CALCIUM (21600858),binary,NA,count,385,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,1069,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,248,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ENZYMES (21601997),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE (21602318),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: POTASSIUM (21600875),binary,NA,count,508,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS (21600933),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,69,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: OTHER HEMATOLOGICAL AGENTS (21601226),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,469,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANABOLIC STEROIDS (21600915),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,150,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,1980,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: POSTERIOR PITUITARY LOBE HORMONES (21602697),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,62,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,148,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,64,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,2736,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTACIDS (21600047),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,15206,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,70,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,217,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION (21602558),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,431,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: HYPOTHALAMIC HORMONES (21602709),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,928,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,137,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,53,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,500,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: DRUGS FOR TREATMENT OF LEPRA (21603121),binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,3932,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,73,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,685,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS (21602745)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,179,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,312,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,76,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIFIBRINOLYTICS (21601033),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,418,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: OTHER RESPIRATORY SYSTEM PRODUCTS (21603531),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,138,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,592,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,164,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,264,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,310,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: OCULAR VASCULAR DISORDER AGENTS (21605119),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,414,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,135,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,337,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: OTHER DIURETICS (21601556),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,56,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION (21602558),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,163,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,375,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,799,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,679,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: CORTICOSTEROIDS (21605164),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,120,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,117,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: EMOLLIENTS AND PROTECTIVES (21601969),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,194,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ALKYLATING AGENTS (21601388),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,593,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,748,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,51,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,240,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,1666,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,377,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,2609,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES (21602683),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,222,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,757,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,1422,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: OTHER OTOLOGICALS (21605180),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,3284,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: OTHER PLAIN VITAMIN PREPARATIONS (21600840),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: DRUGS FOR TREATMENT OF LEPRA (21603121),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,70,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM (21601848),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,106,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,120,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,114,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,102,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS (21601730)",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,792,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: POSTERIOR PITUITARY LOBE HORMONES (21602697),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,168,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,547,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,423,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,4964,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,4235,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,763,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,1488,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,349,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: OPIOIDS (21604254),binary,NA,count,904,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,75,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,495,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,1488,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS (21604911),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"ATC 3rd: MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS (21604125)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,77,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,108,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,1097,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,89,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"ATC 3rd: ECTOPARASITICIDES, INCL. SCABICIDES (21604968)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,2671,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: SPECIFIC ANTIRHEUMATIC AGENTS (21604021),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,356,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,307,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,665,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTIADRENAL PREPARATIONS (21602748),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,257,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,101,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,420,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,92,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,723,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,53,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,198,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,101,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,64,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,433,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,350,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,670,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,916,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,74,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM (21601848),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,119,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM (21601848),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,333,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: OTHER PLAIN VITAMIN PREPARATIONS (21600840),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: ENZYMES (21601997),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,174,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: HYPOTHALAMIC HORMONES (21602709),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,216,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,169,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,84,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,233,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,62,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,1023,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: OTHER PLAIN VITAMIN PREPARATIONS (21600840),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,3278,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,241,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,63,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,173,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: LOCAL ANESTHETICS (21605096),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,denominator,binary,NA,count,18144,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,147,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,1081,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION (21600451),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: MEDICATED DRESSINGS (21602262),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,310,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,2669,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: UTEROTONICS (21602430),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,192,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,321,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANDROGENS (21602506),binary,NA,count,131,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: DRUGS FOR TREATMENT OF LEPRA (21603121),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,134,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,400,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: VITAMIN K AND OTHER HEMOSTATICS (21601043),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS (21604911),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,100,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,1005,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,117,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,1295,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: MEDICATED DRESSINGS (21602262),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,343,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,734,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,71,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,denominator,binary,NA,count,22836,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,241,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,943,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: HYPOTHALAMIC HORMONES (21602709),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,208,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,71,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: POSTERIOR PITUITARY LOBE HORMONES (21602697),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: OTHER PLAIN VITAMIN PREPARATIONS (21600840),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,200,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: OPIOIDS (21604254),binary,NA,count,368,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,191,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,147,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANDROGENS (21602506),binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: SPECIFIC ANTIRHEUMATIC AGENTS (21604021),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANDROGENS (21602506),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,78,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,339,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,177,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,915,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,220,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,494,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: OTHER RESPIRATORY SYSTEM PRODUCTS (21603531),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,75,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,104,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,144,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,77,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: POTASSIUM (21600875),binary,NA,count,624,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,3099,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: OPIOIDS (21604254),binary,NA,count,1153,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,2089,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTI-PARATHYROID AGENTS (21602785),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,105,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: POSTERIOR PITUITARY LOBE HORMONES (21602697),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: GONADOTROPINS AND OTHER OVULATION STIMULANTS (21602597),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,398,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: ALLERGENS (21605214),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,307,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIFIBRINOLYTICS (21601033),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,2165,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,1948,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,381,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,1479,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,denominator,binary,NA,count,3521,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: CALCIUM (21600858),binary,NA,count,120,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: SPECIFIC ANTIRHEUMATIC AGENTS (21604021),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,53,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,150,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,181,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,3764,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,6018,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION (21604787),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,3370,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,111,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,4540,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,144,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,61,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES (21603728),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,3521,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,725,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,44,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,131,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,425,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,denominator,binary,NA,count,15206,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: POTASSIUM (21600875),binary,NA,count,655,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,107,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,302,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,541,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,63,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,256,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,51,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,168,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: POTASSIUM (21600875),binary,NA,count,695,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,517,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,998,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,151,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTI-PARATHYROID AGENTS (21602785),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: BLOOD AND RELATED PRODUCTS (21601137),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,282,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,557,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANABOLIC STEROIDS (21600915),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ESTROGENS (21602514),binary,NA,count,99,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,456,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,1095,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,442,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIFIBRINOLYTICS (21601033),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: BETA BLOCKING AGENTS AND OTHER DIURETICS (21601718),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,136,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,636,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: HYPOTHALAMIC HORMONES (21602709),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: CALCIUM (21600858),binary,NA,count,65,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: OTHER ANTIHYPERTENSIVES (21600438),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,267,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,147,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,484,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,779,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,582,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,16874,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,119,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,782,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: CORTICOSTEROIDS (21605164),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,1898,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,412,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,159,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,312,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,888,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION (21602558),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: OTHER HEMATOLOGICAL AGENTS (21601226),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,528,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,438,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,47,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,266,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,234,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,441,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: VITAMIN K AND OTHER HEMOSTATICS (21601043),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,denominator,binary,NA,count,16653,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,393,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,118,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,171,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,612,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,362,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,90,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS (21604125)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,666,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,242,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,51,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIFIBRINOLYTICS (21601033),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,171,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,1153,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,116,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,75,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,44,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,88,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,122,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,343,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: DRUGS FOR TREATMENT OF LEPRA (21603121),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,109,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,1514,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,226,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,409,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,172,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,63,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,820,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,1639,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ESTROGENS (21602514),binary,NA,count,939,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: ECTOPARASITICIDES, INCL. SCABICIDES (21604968)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS (21600933),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,117,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,548,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,756,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,9565,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,454,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,928,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,145,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,4301,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ALLERGENS (21605214),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,428,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,120,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: ECTOPARASITICIDES, INCL. SCABICIDES (21604968)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,179,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIPSORIATICS FOR SYSTEMIC USE (21602044),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,147,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,193,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"ATC 3rd: LIPID MODIFYING AGENTS, COMBINATIONS (21601898)",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION (21602558),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,3521,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: LIPID MODIFYING AGENTS, COMBINATIONS (21601898)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,787,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,2271,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,880,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,1848,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION (21604787),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,81,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,72,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,2157,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,220,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: ANTIPSORIATICS FOR SYSTEMIC USE (21602044),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: SURGICAL AIDS (21605112),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,5504,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,978,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,18807,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,63,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS (21604125)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: CALCIUM (21600858),binary,NA,count,408,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS (21601730)",binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,215,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,0 to 0,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: OTHER HEMATOLOGICAL AGENTS (21601226),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,1302,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,145,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,93,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,107,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS (21600933),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,519,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,434,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION (21602558),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,258,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: LIPID MODIFYING AGENTS, COMBINATIONS (21601898)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,175,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,0 to 0,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: ANDROGENS (21602506),binary,NA,count,77,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,1709,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,100,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,453,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,189,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: SPECIFIC ANTIRHEUMATIC AGENTS (21604021),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,663,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,550,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,88,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: OTHER PLAIN VITAMIN PREPARATIONS (21600840),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,437,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,1903,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,160,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,269,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,53,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: POTASSIUM (21600875),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,62,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: SPECIFIC ANTIRHEUMATIC AGENTS (21604021),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,174,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: OTHER RESPIRATORY SYSTEM PRODUCTS (21603531),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,48,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"ATC 3rd: LIPID MODIFYING AGENTS, COMBINATIONS (21601898)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES (21603728),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,129,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,214,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,62,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,163,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: ANTIADRENAL PREPARATIONS (21602748),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,166,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,645,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,2689,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,1756,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: CALCIUM (21600858),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,2917,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,314,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,61,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,69,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,88,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,denominator,binary,NA,count,17991,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,513,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,0 to 0,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: ANDROGENS (21602506),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,1295,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,1484,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION (21602558),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,48,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,730,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,2411,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,44,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,804,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,"ATC 3rd: LIPID MODIFYING AGENTS, COMBINATIONS (21601898)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: OPIOIDS (21604254),binary,NA,count,1263,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,299,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,63,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: ANDROGENS (21602506),binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,488,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,289,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,134,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,64,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,305,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,63,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE (21602318),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,68,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,100,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,121,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,176,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,102,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,395,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"ATC 3rd: ECTOPARASITICIDES, INCL. SCABICIDES (21604968)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,413,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,603,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,1692,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: LOCAL ANESTHETICS (21605096),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: POSTERIOR PITUITARY LOBE HORMONES (21602697),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: OPIOIDS (21604254),binary,NA,count,1324,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,491,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,48,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,56,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,256,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,408,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,605,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,299,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,3616,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,151,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,44,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: OTHER HEMATOLOGICAL AGENTS (21601226),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE (21602318),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: HYPOTHALAMIC HORMONES (21602709),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,166,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,1091,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,438,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,338,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,1301,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: POSTERIOR PITUITARY LOBE HORMONES (21602697),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIFIBRINOLYTICS (21601033),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,94,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,713,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,48,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: VITAMIN K AND OTHER HEMOSTATICS (21601043),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,132,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS (21600933),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,56,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,199,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,102,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,1270,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,366,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,7004,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,583,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION (21604787),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: ALKYLATING AGENTS (21601388),binary,NA,count,183,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: ENZYMES (21601997),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,243,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,85,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: OTHER PLAIN VITAMIN PREPARATIONS (21600840),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: CALCIUM (21600858),binary,NA,count,466,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,0 to 0,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: POSTERIOR PITUITARY LOBE HORMONES (21602697),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,276,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,65,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: POTASSIUM (21600875),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: ANABOLIC STEROIDS (21600915),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,47,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,0 to 0,denominator,binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,100,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,498,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,1630,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,18859,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,549,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: ECTOPARASITICIDES, INCL. SCABICIDES (21604968)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,171,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,73,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,1000,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,102,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: OTHER OTOLOGICALS (21605180),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,194,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS (21600933),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: BETA BLOCKING AGENTS AND OTHER DIURETICS (21601718),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,4107,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,350,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: ESTROGENS (21602514),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: ECTOPARASITICIDES, INCL. SCABICIDES (21604968)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,190,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,71,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,101,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,197,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,471,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,134,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,4771,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,2453,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,392,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,64,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,434,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,"ATC 3rd: ECTOPARASITICIDES, INCL. SCABICIDES (21604968)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,denominator,binary,NA,count,18751,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,809,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: OCULAR VASCULAR DISORDER AGENTS (21605119),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,750,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,231,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,83,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: ESTROGENS (21602514),binary,NA,count,484,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,1835,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,933,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,115,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,53,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,denominator,binary,NA,count,14816,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,89,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,434,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,843,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,71,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,579,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,0 to 0,denominator,binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,629,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,920,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: BLOOD AND RELATED PRODUCTS (21601137),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,468,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,0 to 0,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,319,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: GONADOTROPINS AND OTHER OVULATION STIMULANTS (21602597),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,96,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,44,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,0 to 0,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,113,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANABOLIC STEROIDS (21600915),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: DRUGS FOR TREATMENT OF LEPRA (21603121),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,340,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,51,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,479,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,422,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,70,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,184,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: MEDICATED DRESSINGS (21602262),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,602,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,0 to 0,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: ALKYLATING AGENTS (21601388),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,901,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: ALLERGENS (21605214),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,166,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS (21601730)",binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,0 to 0,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION (21602558),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,372,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,99,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,185,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: CALCIUM (21600858),binary,NA,count,604,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,372,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,212,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,202,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,555,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,590,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,535,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: UTEROTONICS (21602430),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,0 to 0,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES (21603728),binary,NA,count,75,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,232,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: LIPID MODIFYING AGENTS, COMBINATIONS (21601898)",binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,78,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,251,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,141,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,0 to 0,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION (21600451),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ALKYLATING AGENTS (21601388),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,619,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,562,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: ESTROGENS (21602514),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,1055,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: OPIOIDS (21604254),binary,NA,count,1190,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,0 to 0,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,83,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,112,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS (21604911),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANDROGENS (21602506),binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: CALCIUM (21600858),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: BLOOD AND RELATED PRODUCTS (21601137),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,288,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,115,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,330,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,788,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: OTHER ANTIHYPERTENSIVES (21600438),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,448,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,3802,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,0 to 0,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,4074,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,denominator,binary,NA,count,2453,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,1403,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,109,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTACIDS (21600047),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,0 to 0,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: INTESTINAL ADSORBENTS (21600627),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,631,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"ATC 3rd: BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS (21601730)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,610,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,225,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,1083,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,105,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,1759,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,319,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,128,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,0 to 0,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,denominator,binary,NA,count,70,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,1724,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,317,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,130,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,170,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,473,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,771,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,8096,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,134,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: OTHER ANTIHYPERTENSIVES (21600438),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,2070,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,138,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,75,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: HYPOTHALAMIC HORMONES (21602709),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,18043,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,3287,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,183,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,810,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: MEDICATED DRESSINGS (21602262),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,250,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,440,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: GONADOTROPINS AND OTHER OVULATION STIMULANTS (21602597),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,70,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,785,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,53,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,171,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,1307,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,329,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,0 to 0,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,68,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,121,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,367,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,799,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: OTHER PLAIN VITAMIN PREPARATIONS (21600840),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,909,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,91,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,185,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,115,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTI-PARATHYROID AGENTS (21602785),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,2454,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,303,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,452,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,57,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,79,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,282,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS (21600933),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,170,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,223,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,262,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,1436,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: GLYCOGENOLYTIC HORMONES (21602776),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,207,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,255,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: CALCIUM (21600858),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,686,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,72,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,108,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,4671,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,0 to 0,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,0 to 0,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,305,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: OPIOIDS (21604254),binary,NA,count,121,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,151,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,106,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,107,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,208,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ESTROGENS (21602514),binary,NA,count,575,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: OPIOIDS (21604254),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,124,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,129,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: OTHER RESPIRATORY SYSTEM PRODUCTS (21603531),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,0 to 0,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: ANTACIDS (21600047),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,57,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: LIVER THERAPY, LIPOTROPICS (21600521)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,64,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: CALCIUM (21600858),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: GLYCOGENOLYTIC HORMONES (21602776),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,0 to 0,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,411,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,404,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,80,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,741,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,0 to 0,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,1838,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: GONADOTROPINS AND OTHER OVULATION STIMULANTS (21602597),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: EMOLLIENTS AND PROTECTIVES (21601969),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,246,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,1876,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,364,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION (21604787),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,629,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,67,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIPSORIATICS FOR SYSTEMIC USE (21602044),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,117,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIPSORIATICS FOR SYSTEMIC USE (21602044),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,90,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,0 to 0,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: ANTACIDS (21600047),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,266,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,"ATC 3rd: BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS (21601730)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,187,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: ANTIFIBRINOLYTICS (21601033),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,71,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,3211,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,158,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,513,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,160,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,150,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,163,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: MEDICATED DRESSINGS (21602262),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,377,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,311,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,318,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS (21602745)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,480,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,3960,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,2754,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,123,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,1185,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,3396,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: BETA BLOCKING AGENTS AND OTHER DIURETICS (21601718),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,241,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,930,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,1055,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,65,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,505,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: LOCAL ANESTHETICS (21605096),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,1115,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,79,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,216,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,849,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,18010,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,333,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: OTHER DIURETICS (21601556),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: ANTACIDS (21600047),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,64,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: OPIOIDS (21604254),binary,NA,count,939,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: EMOLLIENTS AND PROTECTIVES (21601969),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,160,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: ANTIADRENAL PREPARATIONS (21602748),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,4951,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,2538,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,44,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,1886,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,64,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,79,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,"ATC 3rd: BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS (21601730)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,498,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM (21601848),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: ANTIFIBRINOLYTICS (21601033),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,672,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,8333,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,97,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,560,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,65,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,4484,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,1074,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,0 to 0,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,136,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION (21604787),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES (21602683),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: OTHER ANTIHYPERTENSIVES (21600438),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTACIDS (21600047),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,150,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,1518,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: ANTACIDS (21600047),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,4017,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: BETA BLOCKING AGENTS AND OTHER DIURETICS (21601718),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,130,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,542,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,2462,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,130,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,0 to 0,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,383,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: POTASSIUM (21600875),binary,NA,count,700,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,119,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,229,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,68,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,122,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,394,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,213,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,156,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ENZYMES (21601997),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS (21604125)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: GLYCOGENOLYTIC HORMONES (21602776),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,119,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,405,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,44,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,383,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,denominator,binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,425,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: OTHER OTOLOGICALS (21605180),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,53,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: OPIOIDS (21604254),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,0 to 0,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: OTHER ANTIHYPERTENSIVES (21600438),binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,2113,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,0 to 0,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,138,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,95,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,149,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,382,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: LOCAL ANESTHETICS (21605096),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,5432,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,4901,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,242,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: OTHER DIURETICS (21601556),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: BETA BLOCKING AGENTS AND OTHER DIURETICS (21601718),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,2727,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,176,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,154,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: VITAMIN K AND OTHER HEMOSTATICS (21601043),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,106,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,82,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,800,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,3559,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: ANDROGENS (21602506),binary,NA,count,149,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES (21602683),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: CALCIUM (21600858),binary,NA,count,262,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,104,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,31787,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,437,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,5969,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: ANTI-PARATHYROID AGENTS (21602785),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,3153,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,90,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: OTHER OTOLOGICALS (21605180),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,85,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,464,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,137,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: OTHER DIURETICS (21601556),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,243,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: OTHER RESPIRATORY SYSTEM PRODUCTS (21603531),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,447,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,107,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,72,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: ESTROGENS (21602514),binary,NA,count,1475,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ESTROGENS (21602514),binary,NA,count,608,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,2027,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,90,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,470,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,753,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE (21602318),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,184,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,0 to 0,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,84,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,455,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,314,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: OTHER PLAIN VITAMIN PREPARATIONS (21600840),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,2172,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: CORTICOSTEROIDS (21605164),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: OTHER HEMATOLOGICAL AGENTS (21601226),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,1032,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH ANALGESICS (21600220),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,520,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: ESTROGENS (21602514),binary,NA,count,61,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,295,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,73,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,465,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,664,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,235,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,2499,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,253,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,115,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,0 to 0,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ENZYMES (21601997),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: GLYCOGENOLYTIC HORMONES (21602776),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: POTASSIUM (21600875),binary,NA,count,527,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,269,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,1629,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,3071,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANDROGENS (21602506),binary,NA,count,44,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,1609,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM (21601848),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,157,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: CORTICOSTEROIDS (21605164),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,463,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: MEDICATED DRESSINGS (21602262),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"ATC 3rd: MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS (21604125)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: OTHER PLAIN VITAMIN PREPARATIONS (21600840),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,7823,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,266,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: VITAMIN K AND OTHER HEMOSTATICS (21601043),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,3872,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,1068,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,105,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,245,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,438,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,2003,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: CORTICOSTEROIDS (21605164),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,201,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: POTASSIUM (21600875),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,766,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,544,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,denominator,binary,NA,count,31662,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,0 to 0,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,0 to 0,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH ANALGESICS (21600220),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: MEDICATED DRESSINGS (21602262),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,82,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,3715,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,563,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,48,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,76,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,1690,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,171,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,346,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: BETA BLOCKING AGENTS AND OTHER DIURETICS (21601718),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,185,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,1249,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,352,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM (21601848),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,837,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: ANTIPSORIATICS FOR SYSTEMIC USE (21602044),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,183,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTI-PARATHYROID AGENTS (21602785),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,71,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,109,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,552,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,206,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,142,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,677,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,663,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,2556,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,91,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES (21602683),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,498,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,895,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,1075,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,4260,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,1008,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,639,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS (21601730)",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: POSTERIOR PITUITARY LOBE HORMONES (21602697),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,788,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,130,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,918,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: AMPHENICOLS (21602813),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,230,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: HYPOTHALAMIC HORMONES (21602709),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,141,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,1118,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: DRUGS FOR TREATMENT OF LEPRA (21603121),binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,155,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: OTHER OTOLOGICALS (21605180),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,0 to 0,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,78,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,denominator,binary,NA,count,116,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,309,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,118,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,447,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ALKYLATING AGENTS (21601388),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: BETA BLOCKING AGENTS AND OTHER DIURETICS (21601718),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,135,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,1066,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,115,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,1143,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,82,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,1615,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,217,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,3103,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: OPIOIDS (21604254),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,552,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,1339,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,220,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION (21600451),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: VITAMIN K AND OTHER HEMOSTATICS (21601043),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,123,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: OTHER HEMATOLOGICAL AGENTS (21601226),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE (21602318),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,14912,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,1260,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,1563,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: CORTICOSTEROIDS (21605164),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: ANTACIDS (21600047),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,2964,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,53,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,130,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,334,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,294,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIADRENAL PREPARATIONS (21602748),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,7742,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,51,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIFIBRINOLYTICS (21601033),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: DRUGS FOR TREATMENT OF LEPRA (21603121),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM (21601848),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS (21602745)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,66,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: ANTI-PARATHYROID AGENTS (21602785),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: POTASSIUM (21600875),binary,NA,count,828,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: POTASSIUM (21600875),binary,NA,count,675,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,163,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,569,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,97,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,229,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,2385,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: DRUGS FOR TREATMENT OF LEPRA (21603121),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,90,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,839,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,100,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES (21602683),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,80,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,116,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,701,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,173,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,1096,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,320,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION (21602558),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: POTASSIUM (21600875),binary,NA,count,51,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,116,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: DRUGS FOR TREATMENT OF LEPRA (21603121),binary,NA,count,53,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,0 to 0,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,84,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: LIPID MODIFYING AGENTS, COMBINATIONS (21601898)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ANTIPSORIATICS FOR SYSTEMIC USE (21602044),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ALLERGENS (21605214),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,172,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: OTHER RESPIRATORY SYSTEM PRODUCTS (21603531),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,156,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,1034,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,2922,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,273,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,497,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: OTHER OTOLOGICALS (21605180),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE (21602318),binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,475,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: GLYCOGENOLYTIC HORMONES (21602776),binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,610,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: AMPHENICOLS (21602813),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,293,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: LIPID MODIFYING AGENTS, COMBINATIONS (21601898)",binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,202,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,317,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ANTIADRENAL PREPARATIONS (21602748),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,denominator,binary,NA,count,48992,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,124,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE (21602318),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,82,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,313,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ENZYMES (21601997),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,3862,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,145,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM (21601848),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,95,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ANABOLIC STEROIDS (21600915),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,544,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,518,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,975,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,185,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION (21600451),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,196,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,426,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,325,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: OPIOIDS (21604254),binary,NA,count,3906,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,1776,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,6294,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,1911,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: RENAL SYSTEM (21605462),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS (21601730)",binary,NA,count,47,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: OTHER RESPIRATORY SYSTEM PRODUCTS (21603531),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,339,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS (21604911),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH ANALGESICS (21600220),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,11545,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: HYPOTHALAMIC HORMONES (21602709),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,272,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,244,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,287,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,91,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,119,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: OTHER HEMATOLOGICAL AGENTS (21601226),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,1279,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION (21604787),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,67,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,2951,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,715,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,2989,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES (21602683),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,1058,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: OTHER ANTIHYPERTENSIVES (21600438),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,35888,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: BLOOD AND RELATED PRODUCTS (21601137),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,1038,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: RENAL SYSTEM (21605462),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,647,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,1024,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,226,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,2629,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,2388,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,143,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,1129,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,243,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,207,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,603,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: OCULAR VASCULAR DISORDER AGENTS (21605119),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: GLYCOGENOLYTIC HORMONES (21602776),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: CICATRIZANTS (21601986),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,157,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,410,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,5507,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: ECTOPARASITICIDES, INCL. SCABICIDES (21604968)",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,1966,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ANTACIDS (21600047),binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,144,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,148,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,488,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,1049,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,102,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: OTHER PLAIN VITAMIN PREPARATIONS (21600840),binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,1811,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,665,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,1494,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,1264,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,1862,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,440,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: OTHER ANTIHYPERTENSIVES (21600438),binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,315,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,2619,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,492,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,286,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,195,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,183,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ALKYLATING AGENTS (21601388),binary,NA,count,339,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: VITAMIN K AND OTHER HEMOSTATICS (21601043),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,2888,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,403,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,1644,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,167,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: OTHER OTOLOGICALS (21605180),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,474,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANTITREMATODALS (21604928),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION (21604787),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,1132,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,520,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: OCULAR VASCULAR DISORDER AGENTS (21605119),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,675,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,71,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,1259,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,595,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,9471,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,92,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,226,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: CORTICOSTEROIDS (21605164),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,79,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: POTASSIUM (21600875),binary,NA,count,1847,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,6677,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,83,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,1044,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION (21602558),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,96,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,65,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,1485,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,3409,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,731,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANTI-PARATHYROID AGENTS (21602785),binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,243,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM (21601848),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,5291,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,2430,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,97,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,4171,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: UTEROTONICS (21602430),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,136,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,444,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,1598,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,4281,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,109,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,1048,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,1918,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANTIFIBRINOLYTICS (21601033),binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,1452,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,1407,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,238,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: CALCIUM (21600858),binary,NA,count,1048,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,1368,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,129,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ALKYLATING AGENTS (21601388),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,585,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,1259,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,1649,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,1644,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,164,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,772,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,310,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,35886,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: SPECIFIC ANTIRHEUMATIC AGENTS (21604021),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,1009,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: BETA BLOCKING AGENTS AND OTHER DIURETICS (21601718),binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS (21601730)",binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,690,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,75,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,66,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,18009,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,101,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,1295,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,1482,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,517,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,7710,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,160,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,2486,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,80,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,470,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,390,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,7876,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,174,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ESTROGENS (21602514),binary,NA,count,1261,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: POSTERIOR PITUITARY LOBE HORMONES (21602697),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,2010,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: CORTICOSTEROIDS (21605164),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,67,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,751,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION (21600451),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,1019,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,431,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION (21602558),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,8777,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ULTRASOUND CONTRAST MEDIA (21605437),binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,347,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS (21604125)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANTACIDS (21600047),binary,NA,count,57,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,1321,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,4636,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,862,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,4515,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,1679,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: EMOLLIENTS AND PROTECTIVES (21601969),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,291,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,2458,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,668,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: HYPOTHALAMIC HORMONES (21602709),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,1449,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,687,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,56,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ENZYMES (21601997),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,1390,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: BETA BLOCKING AGENTS AND OTHER DIURETICS (21601718),binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANTIADRENAL PREPARATIONS (21602748),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: MEDICATED DRESSINGS (21602262),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,3164,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,3114,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,434,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,56,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS (21604125)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: ECTOPARASITICIDES, INCL. SCABICIDES (21604968)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: MEDICATED DRESSINGS (21602262),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,1074,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,7563,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,1548,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,1326,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,257,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: POTASSIUM (21600875),binary,NA,count,1516,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,93,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,61,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,64,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,89,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,1617,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,315,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES (21603728),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: OPIOIDS (21604254),binary,NA,count,4282,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,3785,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,49497,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,4579,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,946,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,1310,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,105,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,13700,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,448,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,1368,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,890,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,2483,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: LIVER THERAPY, LIPOTROPICS (21600521)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,4112,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,244,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ANTIFIBRINOLYTICS (21601033),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: VITAMIN K AND OTHER HEMOSTATICS (21601043),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,1184,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ESTROGENS (21602514),binary,NA,count,2504,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,747,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS (21600933),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,315,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,1472,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,177,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,12999,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,345,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,5761,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,2462,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,217,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,105,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS (21602745)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,4458,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,329,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,371,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,330,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,76,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,330,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,929,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,2143,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,247,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,2028,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,9640,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,623,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,224,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,120,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS (21600933),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,107,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,93,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,886,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANTIPSORIATICS FOR SYSTEMIC USE (21602044),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES (21602683),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,17350,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,1112,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: OTHER DIURETICS (21601556),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,743,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,12507,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: GONADOTROPINS AND OTHER OVULATION STIMULANTS (21602597),binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: CALCIUM (21600858),binary,NA,count,1040,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,204,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: EMOLLIENTS AND PROTECTIVES (21601969),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: SPECIFIC ANTIRHEUMATIC AGENTS (21604021),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,293,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,209,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,1138,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH ANALGESICS (21600220),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,205,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,575,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,93,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: BLOOD AND RELATED PRODUCTS (21601137),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,591,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,2607,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,152,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: OTHER DIURETICS (21601556),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,2004,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,211,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,190,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,673,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,108,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,85,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,67,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,2195,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ANTI-PARATHYROID AGENTS (21602785),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,3714,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,487,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,denominator,binary,NA,count,36827,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,1086,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,1053,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: INTESTINAL ADSORBENTS (21600627),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,811,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,211,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,7206,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,135,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,425,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: DRUGS FOR TREATMENT OF LEPRA (21603121),binary,NA,count,76,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS (21604911),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,7947,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,2534,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,4865,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: DRUGS FOR TREATMENT OF LEPRA (21603121),binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: OTHER PLAIN VITAMIN PREPARATIONS (21600840),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,172,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,1352,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: LOCAL ANESTHETICS (21605096),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ANDROGENS (21602506),binary,NA,count,194,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,347,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: LOCAL ANESTHETICS (21605096),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,365,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,9651,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: POSTERIOR PITUITARY LOBE HORMONES (21602697),binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,1170,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,8604,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,51,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,176,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: LIVER THERAPY, LIPOTROPICS (21600521)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,470,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,88,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,4173,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,2521,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: UTEROTONICS (21602430),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,2035,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,847,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: GONADOTROPINS AND OTHER OVULATION STIMULANTS (21602597),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,267,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,1413,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,415,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,166,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,167,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,1100,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,877,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: OTHER HEMATOLOGICAL AGENTS (21601226),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANABOLIC STEROIDS (21600915),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,405,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,260,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,94,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS (21602745)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,429,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,727,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,2640,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: LIPID MODIFYING AGENTS, COMBINATIONS (21601898)",binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,1147,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,3017,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANDROGENS (21602506),binary,NA,count,330,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,3281,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ULTRASOUND CONTRAST MEDIA (21605437),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES (21603728),binary,NA,count,168,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,445,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,5285,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,4290,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,57,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,3360,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,96,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: LIPID MODIFYING AGENTS, COMBINATIONS (21601898)",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,878,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,2576,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,222,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: GLYCOGENOLYTIC HORMONES (21602776),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,171,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS (21600933),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,2318,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,593,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,351,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: CICATRIZANTS (21601986),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,816,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS (21602745)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,1358,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTI-PARATHYROID AGENTS (21602785),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: EMOLLIENTS AND PROTECTIVES (21601969),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,412,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,602,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: MEDICATED DRESSINGS (21602262),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTI-PARATHYROID AGENTS (21602785),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS (21602745)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE (21602318),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,306,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,608,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ALKYLATING AGENTS (21601388),binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: POTASSIUM (21600875),binary,NA,count,137,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,312,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,1177,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,158,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,117,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,351,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,870,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,91,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,9349,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,269,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,640,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,1349,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,73,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,718,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION (21600451),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: CALCIUM (21600858),binary,NA,count,510,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,454,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,888,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,3128,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES (21603728),binary,NA,count,96,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,502,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,171,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTITREMATODALS (21604928),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,1566,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,438,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,690,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,4338,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIADRENAL PREPARATIONS (21602748),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,510,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,225,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,308,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH ANALGESICS (21600220),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: LIPID MODIFYING AGENTS, COMBINATIONS (21601898)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,342,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION (21600451),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,75,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,1771,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,149,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,586,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,310,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,89,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS (21604911),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,140,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,153,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES (21603728),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,582,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,323,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES (21603728),binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,234,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,65,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,4038,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,206,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,5322,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,143,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,2038,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,132,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,1809,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,329,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,623,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,53,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: LIVER THERAPY, LIPOTROPICS (21600521)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER ANTIHYPERTENSIVES (21600438),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTACIDS (21600047),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM (21601848),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,131,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,137,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: DRUGS FOR TREATMENT OF LEPRA (21603121),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,212,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: OPIOIDS (21604254),binary,NA,count,1764,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION (21602558),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,61,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,169,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,656,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS (21601730)",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,356,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,163,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,95,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,512,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,56,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,3721,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,458,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: VITAMIN K AND OTHER HEMOSTATICS (21601043),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,67,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,1417,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,68,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,209,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,580,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,162,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,300,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: OPIOIDS (21604254),binary,NA,count,1963,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,654,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: GLYCOGENOLYTIC HORMONES (21602776),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER RESPIRATORY SYSTEM PRODUCTS (21603531),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,102,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: LIPID MODIFYING AGENTS, COMBINATIONS (21601898)",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIPSORIATICS FOR SYSTEMIC USE (21602044),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,587,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,79,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTACIDS (21600047),binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,1205,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,192,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,132,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,620,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,1441,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIFIBRINOLYTICS (21601033),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,75,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,1283,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,210,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,521,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: BETA BLOCKING AGENTS AND OTHER DIURETICS (21601718),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,324,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS (21601730)",binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,88,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,147,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,129,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,439,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER HEMATOLOGICAL AGENTS (21601226),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,282,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,571,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,374,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,92,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,3269,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,599,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,378,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM (21601848),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,2574,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,271,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,1688,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIADRENAL PREPARATIONS (21602748),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,240,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: OCULAR VASCULAR DISORDER AGENTS (21605119),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,9057,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH ANALGESICS (21600220),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIPSORIATICS FOR SYSTEMIC USE (21602044),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,186,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANABOLIC STEROIDS (21600915),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,70,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,287,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH ANALGESICS (21600220),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: OTHER HEMATOLOGICAL AGENTS (21601226),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,556,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,6727,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,844,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,18198,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,74,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,62,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,117,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,1962,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,877,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,1513,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,80,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,96,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,1188,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,677,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,239,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,146,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: CORTICOSTEROIDS (21605164),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,138,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: GONADOTROPINS AND OTHER OVULATION STIMULANTS (21602597),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,111,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,84,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: BETA BLOCKING AGENTS AND OTHER DIURETICS (21601718),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,213,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ALKYLATING AGENTS (21601388),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,993,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: POSTERIOR PITUITARY LOBE HORMONES (21602697),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,denominator,binary,NA,count,9560,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,53,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,1192,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,67,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,128,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,149,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,51,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,509,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,1787,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,657,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: POSTERIOR PITUITARY LOBE HORMONES (21602697),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,200,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: ULTRASOUND CONTRAST MEDIA (21605437),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,131,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,56,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,434,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,554,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,79,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,1448,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,925,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES (21602683),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,178,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: LIPID MODIFYING AGENTS, COMBINATIONS (21601898)",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTI-PARATHYROID AGENTS (21602785),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,131,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,147,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,383,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: ECTOPARASITICIDES, INCL. SCABICIDES (21604968)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,57,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OTHER PLAIN VITAMIN PREPARATIONS (21600840),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANABOLIC STEROIDS (21600915),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,79,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,184,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,3357,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,535,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,511,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,179,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,949,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,71,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,110,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,96,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,316,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS (21601730)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM (21601848),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,124,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: LOCAL ANESTHETICS (21605096),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,2562,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,614,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS (21601730)",binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,94,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,407,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,53,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,73,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,1064,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTI-PARATHYROID AGENTS (21602785),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIPSORIATICS FOR SYSTEMIC USE (21602044),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,110,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,526,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,131,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,4682,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,121,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,493,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,221,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: EMOLLIENTS AND PROTECTIVES (21601969),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,98,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: CORTICOSTEROIDS (21605164),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANDROGENS (21602506),binary,NA,count,66,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ENZYMES (21601997),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: VITAMIN K AND OTHER HEMOSTATICS (21601043),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,170,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,80,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,98,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,680,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES (21602683),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,287,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: RENAL SYSTEM (21605462),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANDROGENS (21602506),binary,NA,count,70,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION (21600451),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: OTHER OTOLOGICALS (21605180),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: ECTOPARASITICIDES, INCL. SCABICIDES (21604968)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,601,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: LIVER THERAPY, LIPOTROPICS (21600521)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,80,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,543,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,592,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,164,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,2339,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,3162,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,362,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,2479,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OTHER ANTIHYPERTENSIVES (21600438),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,254,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,398,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,766,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,1163,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,78,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,109,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,3153,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: LIVER THERAPY, LIPOTROPICS (21600521)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,18177,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER HEMATOLOGICAL AGENTS (21601226),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,157,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,145,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS (21604911),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: AMPHENICOLS (21602813),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: LOCAL ANESTHETICS (21605096),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,1533,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIPSORIATICS FOR SYSTEMIC USE (21602044),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,319,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,93,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,1147,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,110,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ULTRASOUND CONTRAST MEDIA (21605437),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,107,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,314,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,314,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,2200,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: BLOOD AND RELATED PRODUCTS (21601137),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,67,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIFIBRINOLYTICS (21601033),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,109,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ENZYMES (21601997),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,525,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,67,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,695,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: GONADOTROPINS AND OTHER OVULATION STIMULANTS (21602597),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: OTHER ANTIHYPERTENSIVES (21600438),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,297,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,2464,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,1675,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,121,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,128,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS (21600933),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,63,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,458,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,7028,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,326,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,198,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: BLOOD AND RELATED PRODUCTS (21601137),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,123,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: BETA BLOCKING AGENTS AND OTHER DIURETICS (21601718),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,181,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,190,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,121,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: CALCIUM (21600858),binary,NA,count,459,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,138,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,176,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,458,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ESTROGENS (21602514),binary,NA,count,510,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,2287,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS (21600933),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,650,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,574,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,163,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: INTESTINAL ADSORBENTS (21600627),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,692,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,1073,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,72,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,229,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,455,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,117,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,64,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,44,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,67,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,1584,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,634,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,1294,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,467,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,1965,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,218,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,145,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,83,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,367,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,2109,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: POTASSIUM (21600875),binary,NA,count,258,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,195,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,1042,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,6322,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,164,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,2409,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION (21604787),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,243,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,564,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,117,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,1310,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,1556,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,192,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,1408,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: EMOLLIENTS AND PROTECTIVES (21601969),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: ESTROGENS (21602514),binary,NA,count,633,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: CORTICOSTEROIDS (21605164),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ESTROGENS (21602514),binary,NA,count,448,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,1017,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,1072,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,48,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,193,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,44,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,1014,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,214,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: DRUGS FOR TREATMENT OF LEPRA (21603121),binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE (21602318),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: GLYCOGENOLYTIC HORMONES (21602776),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION (21604787),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,47,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,225,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,3489,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: ECTOPARASITICIDES, INCL. SCABICIDES (21604968)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,729,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ENZYMES (21601997),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,468,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ESTROGENS (21602514),binary,NA,count,943,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: CALCIUM (21600858),binary,NA,count,460,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,83,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ALLERGENS (21605214),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,986,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ALKYLATING AGENTS (21601388),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: OTHER DIURETICS (21601556),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,276,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,385,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTACIDS (21600047),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,1548,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,53,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: VITAMIN K AND OTHER HEMOSTATICS (21601043),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,238,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,293,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,104,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,1825,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,407,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,219,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,268,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,78,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION (21602558),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,757,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: OTHER OTOLOGICALS (21605180),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,370,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,952,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,92,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,981,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,57,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,145,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,143,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS (21604125)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,96,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,94,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: CORTICOSTEROIDS (21605164),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: BETA BLOCKING AGENTS AND OTHER DIURETICS (21601718),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,87,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,973,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,161,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTACIDS (21600047),binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE (21602318),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OTHER ANTIHYPERTENSIVES (21600438),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: EMOLLIENTS AND PROTECTIVES (21601969),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,82,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTACIDS (21600047),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,1164,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,3656,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,156,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,456,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE (21602318),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,51,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,574,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES (21602683),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,87,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,67,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,405,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,232,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: ALKYLATING AGENTS (21601388),binary,NA,count,140,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,145,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: GONADOTROPINS AND OTHER OVULATION STIMULANTS (21602597),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER OTOLOGICALS (21605180),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: OTHER ANTIHYPERTENSIVES (21600438),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,376,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANDROGENS (21602506),binary,NA,count,89,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,560,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: RENAL SYSTEM (21605462),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,297,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,579,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: LOCAL ANESTHETICS (21605096),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,47,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,14349,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: LOCAL ANESTHETICS (21605096),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,299,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,412,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,106,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ULTRASOUND CONTRAST MEDIA (21605437),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,150,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,178,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIADRENAL PREPARATIONS (21602748),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ALKYLATING AGENTS (21601388),binary,NA,count,154,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,283,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,222,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,95,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: EMOLLIENTS AND PROTECTIVES (21601969),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,225,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,294,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,579,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES (21602683),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,2069,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,361,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,3861,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,96,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,1381,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: GLYCOGENOLYTIC HORMONES (21602776),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,22792,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,82,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,169,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,313,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,97,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,626,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE (21602318),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,109,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,852,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,72,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,199,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,239,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: GLYCOGENOLYTIC HORMONES (21602776),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,3935,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,245,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ULTRASOUND CONTRAST MEDIA (21605437),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,362,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,243,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: BLOOD AND RELATED PRODUCTS (21601137),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,323,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,180,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: OPIOIDS (21604254),binary,NA,count,361,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,1236,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,148,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,95,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,504,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,1233,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: CALCIUM (21600858),binary,NA,count,439,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,1258,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,621,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,79,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ENZYMES (21601997),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE (21602318),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: POTASSIUM (21600875),binary,NA,count,625,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS (21600933),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,92,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OTHER HEMATOLOGICAL AGENTS (21601226),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,1062,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANABOLIC STEROIDS (21600915),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,205,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,2199,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: POSTERIOR PITUITARY LOBE HORMONES (21602697),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,87,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,67,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,172,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,118,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,84,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,3466,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTACIDS (21600047),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,14333,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,192,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,682,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION (21602558),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,730,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: HYPOTHALAMIC HORMONES (21602709),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,1212,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,160,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,586,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: HYPOTHALAMIC HORMONES (21602709),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,84,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: DRUGS FOR TREATMENT OF LEPRA (21603121),binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,4640,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,137,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,822,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER OTOLOGICALS (21605180),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS (21602745)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,248,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,409,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,130,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,91,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIFIBRINOLYTICS (21601033),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,601,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: OTHER RESPIRATORY SYSTEM PRODUCTS (21603531),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,238,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,713,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,212,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,591,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,427,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OCULAR VASCULAR DISORDER AGENTS (21605119),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,522,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,179,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,385,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OTHER DIURETICS (21601556),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,116,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION (21602558),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,199,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,426,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,987,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,983,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: CORTICOSTEROIDS (21605164),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,159,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,132,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: EMOLLIENTS AND PROTECTIVES (21601969),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,120,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,232,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ALKYLATING AGENTS (21601388),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,1006,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,1181,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,123,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,308,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,1865,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,439,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,3308,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES (21602683),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,356,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,850,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,1741,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OTHER OTOLOGICALS (21605180),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,3753,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER PLAIN VITAMIN PREPARATIONS (21600840),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: DRUGS FOR TREATMENT OF LEPRA (21603121),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,124,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM (21601848),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,126,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,170,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,130,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,116,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS (21601730)",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,69,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,890,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: POSTERIOR PITUITARY LOBE HORMONES (21602697),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,81,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,196,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,594,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,85,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,606,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,5572,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,4726,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,876,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,1632,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,542,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OPIOIDS (21604254),binary,NA,count,1582,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,84,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,562,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,1670,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS (21604911),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS (21604125)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,110,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,298,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,1312,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OTHER RESPIRATORY SYSTEM PRODUCTS (21603531),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,97,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: ECTOPARASITICIDES, INCL. SCABICIDES (21604968)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,2933,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: SPECIFIC ANTIRHEUMATIC AGENTS (21604021),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,399,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,377,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,771,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIADRENAL PREPARATIONS (21602748),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,310,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,348,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,880,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,472,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,828,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,103,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,274,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,257,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,69,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,524,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,65,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,87,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,617,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,1050,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH ANALGESICS (21600220),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,999,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,152,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM (21601848),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,177,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM (21601848),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,573,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ULTRASOUND CONTRAST MEDIA (21605437),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER PLAIN VITAMIN PREPARATIONS (21600840),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: ENZYMES (21601997),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,501,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: HYPOTHALAMIC HORMONES (21602709),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,247,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,311,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,133,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,314,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,155,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,1426,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OTHER PLAIN VITAMIN PREPARATIONS (21600840),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,3709,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,331,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,74,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,187,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,204,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: LOCAL ANESTHETICS (21605096),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,denominator,binary,NA,count,18134,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,1153,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,87,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,1315,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION (21600451),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: LIVER THERAPY, LIPOTROPICS (21600521)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES (21603728),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,113,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,344,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,3000,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: UTEROTONICS (21602430),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,226,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,446,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANDROGENS (21602506),binary,NA,count,194,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: UTEROTONICS (21602430),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: DRUGS FOR TREATMENT OF LEPRA (21603121),binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,201,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,447,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: VITAMIN K AND OTHER HEMOSTATICS (21601043),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS (21604911),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,144,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,1132,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,128,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,1748,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: MEDICATED DRESSINGS (21602262),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,476,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,1209,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS (21600933),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,119,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,denominator,binary,NA,count,22789,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,390,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,1324,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: HYPOTHALAMIC HORMONES (21602709),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,51,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,252,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,121,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: POSTERIOR PITUITARY LOBE HORMONES (21602697),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: OTHER PLAIN VITAMIN PREPARATIONS (21600840),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,223,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: OPIOIDS (21604254),binary,NA,count,583,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,365,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: BLOOD AND RELATED PRODUCTS (21601137),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,198,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANDROGENS (21602506),binary,NA,count,82,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: SPECIFIC ANTIRHEUMATIC AGENTS (21604021),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,87,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANDROGENS (21602506),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,473,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,266,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,169,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,1017,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,691,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,381,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,119,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER RESPIRATORY SYSTEM PRODUCTS (21603531),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,117,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,187,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,146,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: POTASSIUM (21600875),binary,NA,count,754,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,3428,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OPIOIDS (21604254),binary,NA,count,1935,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,2310,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTI-PARATHYROID AGENTS (21602785),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,176,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: POSTERIOR PITUITARY LOBE HORMONES (21602697),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: GONADOTROPINS AND OTHER OVULATION STIMULANTS (21602597),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,48,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,474,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,72,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ALLERGENS (21605214),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,57,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,467,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIFIBRINOLYTICS (21601033),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,66,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,2729,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,2682,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,477,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,1683,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OTHER OTOLOGICALS (21605180),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,denominator,binary,NA,count,3516,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: CALCIUM (21600858),binary,NA,count,141,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: SPECIFIC ANTIRHEUMATIC AGENTS (21604021),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,63,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,220,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,180,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,4281,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,7592,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION (21604787),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,4145,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,212,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,5997,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,82,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: LOCAL ANESTHETICS (21605096),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS (21602745)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,165,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,86,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES (21603728),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,3932,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,84,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,834,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,93,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,101,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,147,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,263,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,498,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,denominator,binary,NA,count,15177,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: POTASSIUM (21600875),binary,NA,count,764,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,121,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,468,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS (21602745)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,936,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,81,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,341,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,104,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,48,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,97,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,434,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,65,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: POTASSIUM (21600875),binary,NA,count,825,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,619,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,1223,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,272,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTI-PARATHYROID AGENTS (21602785),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,88,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: BLOOD AND RELATED PRODUCTS (21601137),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,44,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,367,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,693,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANABOLIC STEROIDS (21600915),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,90,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ESTROGENS (21602514),binary,NA,count,118,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,676,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,712,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,1238,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: UTEROTONICS (21602430),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIFIBRINOLYTICS (21601033),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: BETA BLOCKING AGENTS AND OTHER DIURETICS (21601718),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,227,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,730,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: HYPOTHALAMIC HORMONES (21602709),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: CALCIUM (21600858),binary,NA,count,79,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER ANTIHYPERTENSIVES (21600438),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: RENAL SYSTEM (21605462),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,275,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,325,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION (21604787),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,574,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,1233,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,79,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,57,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,691,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,17186,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,327,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,1131,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: GLYCOGENOLYTIC HORMONES (21602776),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: CORTICOSTEROIDS (21605164),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ULTRASOUND CONTRAST MEDIA (21605437),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,2258,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,493,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,188,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,368,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,1414,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION (21602558),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OTHER HEMATOLOGICAL AGENTS (21601226),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,77,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,920,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,523,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,102,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,305,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,387,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,576,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: VITAMIN K AND OTHER HEMOSTATICS (21601043),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS (21604911),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,denominator,binary,NA,count,16643,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,445,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,51,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: OTHER PLAIN VITAMIN PREPARATIONS (21600840),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,128,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,279,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,794,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,459,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,107,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS (21604125)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,822,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,663,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: LIVER THERAPY, LIPOTROPICS (21600521)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,139,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,184,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIFIBRINOLYTICS (21601033),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,253,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,1542,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,136,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,101,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,56,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,138,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,322,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,70,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,573,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: DRUGS FOR TREATMENT OF LEPRA (21603121),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,137,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,2158,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: GONADOTROPINS AND OTHER OVULATION STIMULANTS (21602597),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,476,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,445,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,232,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,187,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,1130,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,1844,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,105,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ESTROGENS (21602514),binary,NA,count,1113,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: BLOOD AND RELATED PRODUCTS (21601137),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: ECTOPARASITICIDES, INCL. SCABICIDES (21604968)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS (21600933),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,574,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,672,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,1129,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,9519,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,51,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,515,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,1092,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,168,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,4833,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,84,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ALLERGENS (21605214),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,519,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,75,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,73,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OCULAR VASCULAR DISORDER AGENTS (21605119),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,53,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,175,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: ECTOPARASITICIDES, INCL. SCABICIDES (21604968)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,255,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH ANALGESICS (21600220),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIPSORIATICS FOR SYSTEMIC USE (21602044),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,169,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,102,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,308,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: LIPID MODIFYING AGENTS, COMBINATIONS (21601898)",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION (21602558),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,977,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,2660,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION (21604787),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,109,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,498,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: CALCIUM (21600858),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,89,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,926,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,149,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,105,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OTHER HEMATOLOGICAL AGENTS (21601226),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,2813,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,148,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,5435,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,47,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,344,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 30,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ANTIPSORIATICS FOR SYSTEMIC USE (21602044),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 30,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,350,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: OPIOIDS (21604254),binary,NA,count,202,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,602,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,137,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,173,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,7505,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,314,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,1342,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,18952,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ESTROGENS (21602514),binary,NA,count,691,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,131,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: OPIOIDS (21604254),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS (21604125)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: CALCIUM (21600858),binary,NA,count,477,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,213,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS (21601730)",binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,419,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,150,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OTHER RESPIRATORY SYSTEM PRODUCTS (21603531),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,1 to 30,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OTHER HEMATOLOGICAL AGENTS (21601226),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,79,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 30,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,160,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: ANTACIDS (21600047),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,84,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,2021,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,210,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,214,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,272,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: LIVER THERAPY, LIPOTROPICS (21600521)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS (21600933),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,100,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: CALCIUM (21600858),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,681,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH ANALGESICS (21600220),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: GLYCOGENOLYTIC HORMONES (21602776),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 30,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,816,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,585,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION (21602558),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,51,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,348,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIADRENAL PREPARATIONS (21602748),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: LIPID MODIFYING AGENTS, COMBINATIONS (21601898)",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,454,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,115,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,972,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,497,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 30,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: ANDROGENS (21602506),binary,NA,count,116,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,1 to 30,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,2412,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,1935,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,473,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: GONADOTROPINS AND OTHER OVULATION STIMULANTS (21602597),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: ENZYMES (21601997),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,517,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: EMOLLIENTS AND PROTECTIVES (21601969),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,437,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,215,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: SPECIFIC ANTIRHEUMATIC AGENTS (21604021),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,2116,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,447,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 30,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,772,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION (21604787),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,745,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 30,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,634,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,98,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,140,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OTHER PLAIN VITAMIN PREPARATIONS (21600840),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIPSORIATICS FOR SYSTEMIC USE (21602044),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,663,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,2152,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,260,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIPSORIATICS FOR SYSTEMIC USE (21602044),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,106,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,189,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,497,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,101,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: POTASSIUM (21600875),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,159,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 30,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: SPECIFIC ANTIRHEUMATIC AGENTS (21604021),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,193,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: LOCAL ANESTHETICS (21605096),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,83,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,64,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: ANTACIDS (21600047),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,329,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,216,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,"ATC 3rd: BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS (21601730)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: EMOLLIENTS AND PROTECTIVES (21601969),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: OTHER RESPIRATORY SYSTEM PRODUCTS (21603531),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,255,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: ANTIFIBRINOLYTICS (21601033),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,61,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: RENAL SYSTEM (21605462),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,93,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"ATC 3rd: LIPID MODIFYING AGENTS, COMBINATIONS (21601898)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,3728,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES (21603728),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,253,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,558,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,286,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,156,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,191,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,581,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,366,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,186,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: MEDICATED DRESSINGS (21602262),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,324,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,664,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,508,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ANTIADRENAL PREPARATIONS (21602748),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,222,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,802,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,3049,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,1974,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: OTHER OTOLOGICALS (21605180),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,535,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: CALCIUM (21600858),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS (21602745)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,3459,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,62,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,535,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,88,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,153,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,449,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,107,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,171,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: RENAL SYSTEM (21605462),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,75,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,4666,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,101,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,3032,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,817,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,denominator,binary,NA,count,17970,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,599,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,1427,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 30,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: ANDROGENS (21602506),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,51,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: GONADOTROPINS AND OTHER OVULATION STIMULANTS (21602597),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,1453,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,4341,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: BETA BLOCKING AGENTS AND OTHER DIURETICS (21601718),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,586,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,1406,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,53,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,1924,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: GLYCOGENOLYTIC HORMONES (21602776),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,44,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,1693,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,76,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,738,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION (21602558),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,123,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,2742,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,807,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,57,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: LOCAL ANESTHETICS (21605096),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,1257,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,89,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,925,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,"ATC 3rd: LIPID MODIFYING AGENTS, COMBINATIONS (21601898)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,115,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,246,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: OPIOIDS (21604254),binary,NA,count,2213,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS (21602745)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,376,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH ANALGESICS (21600220),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,1140,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,16816,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS (21604911),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,370,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: OTHER DIURETICS (21601556),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,73,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: ANDROGENS (21602506),binary,NA,count,44,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,84,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,580,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ANTACIDS (21600047),binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,110,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,74,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: OPIOIDS (21604254),binary,NA,count,1786,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 30,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: EMOLLIENTS AND PROTECTIVES (21601969),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,196,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: ANTIADRENAL PREPARATIONS (21602748),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,371,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,5513,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,44,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,2945,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,53,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,161,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,144,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,2161,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 30,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,74,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,185,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,"ATC 3rd: BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS (21601730)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: UTEROTONICS (21602430),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,589,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,334,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: ANTI-PARATHYROID AGENTS (21602785),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM (21601848),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,67,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ANTIFIBRINOLYTICS (21601033),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,113,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS (21604911),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE (21602318),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,813,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: BLOOD AND RELATED PRODUCTS (21601137),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,64,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 30,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,9295,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,198,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,164,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,170,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,235,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,175,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,619,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,137,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,51,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,165,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,5073,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,1224,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION (21600451),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION (21602558),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: OCULAR VASCULAR DISORDER AGENTS (21605119),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: ENZYMES (21601997),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,120,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,622,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,153,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,1 to 30,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,232,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION (21604787),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"ATC 3rd: ECTOPARASITICIDES, INCL. SCABICIDES (21604968)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,520,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES (21602683),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: LIVER THERAPY, LIPOTROPICS (21600521)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OTHER ANTIHYPERTENSIVES (21600438),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,758,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,1891,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: LOCAL ANESTHETICS (21605096),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTACIDS (21600047),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,214,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 30,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,1777,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: POSTERIOR PITUITARY LOBE HORMONES (21602697),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: ENZYMES (21601997),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: CICATRIZANTS (21601986),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OPIOIDS (21604254),binary,NA,count,2105,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,4515,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,686,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,114,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,138,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,305,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,658,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES (21603728),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,715,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,455,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,70,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,4090,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,171,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,89,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: OTHER HEMATOLOGICAL AGENTS (21601226),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: CORTICOSTEROIDS (21605164),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,138,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE (21602318),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: HYPOTHALAMIC HORMONES (21602709),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: BETA BLOCKING AGENTS AND OTHER DIURETICS (21601718),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,134,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,255,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,826,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,2736,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,1308,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,150,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,494,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,65,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,396,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,1 to 30,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: HYPOTHALAMIC HORMONES (21602709),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,66,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,427,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: POTASSIUM (21600875),binary,NA,count,834,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ULTRASOUND CONTRAST MEDIA (21605437),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,328,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,1787,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: POSTERIOR PITUITARY LOBE HORMONES (21602697),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,609,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIFIBRINOLYTICS (21601033),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,157,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,115,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,837,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,142,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,291,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES (21603728),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,571,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: VITAMIN K AND OTHER HEMOSTATICS (21601043),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,47,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,155,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS (21600933),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,53,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,121,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,93,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,247,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: OCULAR VASCULAR DISORDER AGENTS (21605119),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,235,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,201,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ENZYMES (21601997),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS (21604125)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: GLYCOGENOLYTIC HORMONES (21602776),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,825,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,130,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,453,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,1441,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,440,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,486,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,denominator,binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,489,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,77,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OTHER OTOLOGICALS (21605180),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"ATC 3rd: LIVER THERAPY, LIPOTROPICS (21600521)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: OPIOIDS (21604254),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,7910,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 30,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: OTHER ANTIHYPERTENSIVES (21600438),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,2368,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,1 to 30,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,776,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,230,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,47,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,152,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,185,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION (21604787),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: ALKYLATING AGENTS (21601388),binary,NA,count,321,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,475,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: LOCAL ANESTHETICS (21605096),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ENZYMES (21601997),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,6918,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,5454,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,95,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,254,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,146,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: OTHER PLAIN VITAMIN PREPARATIONS (21600840),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: CALCIUM (21600858),binary,NA,count,537,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 30,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: POSTERIOR PITUITARY LOBE HORMONES (21602697),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,278,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: POSTERIOR PITUITARY LOBE HORMONES (21602697),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: OTHER DIURETICS (21601556),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,523,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: BETA BLOCKING AGENTS AND OTHER DIURETICS (21601718),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,3082,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,394,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,235,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: POTASSIUM (21600875),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,96,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,402,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ANABOLIC STEROIDS (21600915),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: RENAL SYSTEM (21605462),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,111,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: VITAMIN K AND OTHER HEMOSTATICS (21601043),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,114,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,174,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,1200,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,4086,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 30,denominator,binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ANDROGENS (21602506),binary,NA,count,216,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,111,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES (21602683),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: CALCIUM (21600858),binary,NA,count,332,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,120,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE (21602318),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,31920,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 30,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,500,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,6661,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ANTI-PARATHYROID AGENTS (21602785),binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,3532,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,122,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OTHER OTOLOGICALS (21605180),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS (21602745)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES (21603728),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,623,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,1847,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,478,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,572,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,18984,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,594,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,1144,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: ECTOPARASITICIDES, INCL. SCABICIDES (21604968)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,296,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,294,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OTHER DIURETICS (21601556),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,1233,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,234,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,667,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: OTHER OTOLOGICALS (21605180),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,374,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,256,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OTHER RESPIRATORY SYSTEM PRODUCTS (21603531),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,560,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS (21600933),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,129,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: BETA BLOCKING AGENTS AND OTHER DIURETICS (21601718),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,5384,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,85,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,111,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ESTROGENS (21602514),binary,NA,count,1740,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,470,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: ESTROGENS (21602514),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,101,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: ECTOPARASITICIDES, INCL. SCABICIDES (21604968)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ESTROGENS (21602514),binary,NA,count,692,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,2435,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,213,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,263,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,137,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,285,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: BLOOD AND RELATED PRODUCTS (21601137),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,1238,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,267,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,934,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,544,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,521,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,5794,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,2425,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,100,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,467,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE (21602318),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,617,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,244,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: LIVER THERAPY, LIPOTROPICS (21600521)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,"ATC 3rd: ECTOPARASITICIDES, INCL. SCABICIDES (21604968)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,1 to 30,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,denominator,binary,NA,count,18728,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,1162,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 30,ATC 3rd: CALCIUM (21600858),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OCULAR VASCULAR DISORDER AGENTS (21605119),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,67,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,102,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,92,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,964,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,82,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,654,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,269,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,139,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: ESTROGENS (21602514),binary,NA,count,567,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,2614,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,426,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: OTHER PLAIN VITAMIN PREPARATIONS (21600840),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,94,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,1424,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,200,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,2420,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,95,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: CORTICOSTEROIDS (21605164),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: OTHER HEMATOLOGICAL AGENTS (21601226),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,denominator,binary,NA,count,14793,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,164,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,506,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,1423,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: EMOLLIENTS AND PROTECTIVES (21601969),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,331,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 30,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,57,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,118,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,101,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,920,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,1 to 30,denominator,binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,1292,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH ANALGESICS (21600220),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,779,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: ESTROGENS (21602514),binary,NA,count,66,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 30,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,720,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,323,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,1345,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: VITAMIN K AND OTHER HEMOSTATICS (21601043),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,254,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,551,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: BLOOD AND RELATED PRODUCTS (21601137),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,1218,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,256,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,982,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 30,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,3103,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,56,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,428,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,331,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,197,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: GONADOTROPINS AND OTHER OVULATION STIMULANTS (21602597),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,160,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,79,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 30,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 30,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,151,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANABOLIC STEROIDS (21600915),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ENZYMES (21601997),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: DRUGS FOR TREATMENT OF LEPRA (21603121),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: GLYCOGENOLYTIC HORMONES (21602776),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: POTASSIUM (21600875),binary,NA,count,673,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,494,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,471,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,2229,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,3378,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANDROGENS (21602506),binary,NA,count,70,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,96,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,72,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,1770,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM (21601848),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,1132,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,263,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,475,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: CORTICOSTEROIDS (21605164),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,510,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,394,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: MEDICATED DRESSINGS (21602262),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"ATC 3rd: MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS (21604125)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,1069,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OTHER PLAIN VITAMIN PREPARATIONS (21600840),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,8657,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,1 to 30,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,329,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: BLOOD AND RELATED PRODUCTS (21601137),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: VITAMIN K AND OTHER HEMOSTATICS (21601043),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,4271,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,99,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,1282,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,140,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ALKYLATING AGENTS (21601388),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,269,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ULTRASOUND CONTRAST MEDIA (21605437),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,1079,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,897,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ALLERGENS (21605214),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,2472,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,68,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,248,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,61,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: CORTICOSTEROIDS (21605164),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,547,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: POTASSIUM (21600875),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,915,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS (21601730)",binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 30,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION (21602558),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,886,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: ANTACIDS (21600047),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,784,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,159,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,denominator,binary,NA,count,31625,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,1 to 30,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,1 to 30,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,53,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,73,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH ANALGESICS (21600220),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: MEDICATED DRESSINGS (21602262),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,247,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,71,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,95,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: CALCIUM (21600858),binary,NA,count,711,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,532,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,275,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,85,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,4884,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,615,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,249,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,729,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,678,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,657,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,1 to 30,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: UTEROTONICS (21602430),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES (21603728),binary,NA,count,161,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,61,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,130,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,1879,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,495,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,449,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,572,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: BETA BLOCKING AGENTS AND OTHER DIURETICS (21601718),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION (21600451),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,78,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: LIPID MODIFYING AGENTS, COMBINATIONS (21601898)",binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,444,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,1301,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,393,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,207,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM (21601848),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,1152,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,516,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,528,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 30,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: ANTIPSORIATICS FOR SYSTEMIC USE (21602044),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: ULTRASOUND CONTRAST MEDIA (21605437),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,321,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,117,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION (21600451),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ALKYLATING AGENTS (21601388),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,739,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTI-PARATHYROID AGENTS (21602785),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,645,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: ESTROGENS (21602514),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: ANTIADRENAL PREPARATIONS (21602748),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,1671,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OPIOIDS (21604254),binary,NA,count,1850,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,161,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,203,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,1 to 30,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,775,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,150,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,335,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,142,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,159,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,639,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS (21604911),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,57,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANDROGENS (21602506),binary,NA,count,76,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,822,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: CALCIUM (21600858),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: BLOOD AND RELATED PRODUCTS (21601137),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,753,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,111,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,3046,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,337,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,272,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,740,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,1108,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,209,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES (21602683),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,64,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,870,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,1264,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,1698,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: OTHER ANTIHYPERTENSIVES (21600438),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,5537,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,1192,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,562,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,763,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,4351,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ULTRASOUND CONTRAST MEDIA (21605437),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 30,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,48,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,4582,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS (21601730)",binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: POSTERIOR PITUITARY LOBE HORMONES (21602697),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,denominator,binary,NA,count,2451,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,1559,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,498,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTACIDS (21600047),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,916,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,74,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 30,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,197,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,137,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: INTESTINAL ADSORBENTS (21600627),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,770,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,1024,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: AMPHENICOLS (21602813),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: CORTICOSTEROIDS (21605164),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"ATC 3rd: BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS (21601730)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,385,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,699,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,259,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: HYPOTHALAMIC HORMONES (21602709),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,84,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,247,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,236,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,1409,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,115,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,166,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,1413,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,2176,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,160,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: DRUGS FOR TREATMENT OF LEPRA (21603121),binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,171,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,370,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,149,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 30,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,denominator,binary,NA,count,70,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: OTHER OTOLOGICALS (21605180),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,1940,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 30,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,97,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,348,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,99,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,157,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,denominator,binary,NA,count,116,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,355,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,180,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: ULTRASOUND CONTRAST MEDIA (21605437),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,479,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: LOCAL ANESTHETICS (21605096),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,278,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ALKYLATING AGENTS (21601388),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,611,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,76,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,955,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,74,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,65,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: BETA BLOCKING AGENTS AND OTHER DIURETICS (21601718),binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,166,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,1545,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,588,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,1524,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,8853,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 30,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,151,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,1928,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,253,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,156,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OTHER ANTIHYPERTENSIVES (21600438),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,3844,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,2726,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,234,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: OPIOIDS (21604254),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,687,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,1540,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,97,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,237,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION (21600451),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,98,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: HYPOTHALAMIC HORMONES (21602709),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: VITAMIN K AND OTHER HEMOSTATICS (21601043),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,166,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,16787,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: OTHER HEMATOLOGICAL AGENTS (21601226),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE (21602318),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,15031,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,1958,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,3726,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,2275,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: CORTICOSTEROIDS (21605164),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: ANTACIDS (21600047),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,427,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,3437,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,908,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: MEDICATED DRESSINGS (21602262),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,347,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: MEDICATED DRESSINGS (21602262),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,205,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,1073,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,389,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: GONADOTROPINS AND OTHER OVULATION STIMULANTS (21602597),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,48,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,57,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,342,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIADRENAL PREPARATIONS (21602748),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,8443,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,75,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,994,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIFIBRINOLYTICS (21601033),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,61,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,334,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: DRUGS FOR TREATMENT OF LEPRA (21603121),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ANTITREMATODALS (21604928),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,121,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,1561,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM (21601848),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,596,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 30,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS (21602745)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,350,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,112,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: ANTI-PARATHYROID AGENTS (21602785),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,161,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: POTASSIUM (21600875),binary,NA,count,976,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,446,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: POTASSIUM (21600875),binary,NA,count,794,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,80,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,189,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,1055,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,734,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,190,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: OTHER PLAIN VITAMIN PREPARATIONS (21600840),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,377,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,1073,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,73,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,106,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,234,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,2683,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: DRUGS FOR TREATMENT OF LEPRA (21603121),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,141,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTI-PARATHYROID AGENTS (21602785),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,106,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,1253,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,2745,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,184,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,47,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES (21602683),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,175,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,338,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,114,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,48,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,629,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: ECTOPARASITICIDES, INCL. SCABICIDES (21604968)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,66,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,229,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,827,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 30,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,253,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,343,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: GONADOTROPINS AND OTHER OVULATION STIMULANTS (21602597),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS (21600933),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,288,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,354,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,331,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,1597,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,1443,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,127,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,604,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION (21602558),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: POTASSIUM (21600875),binary,NA,count,66,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,148,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS (21604911),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: DRUGS FOR TREATMENT OF LEPRA (21603121),binary,NA,count,69,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,214,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 30,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: LIPID MODIFYING AGENTS, COMBINATIONS (21601898)",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: GLYCOGENOLYTIC HORMONES (21602776),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,349,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: LOCAL ANESTHETICS (21605096),binary,NA,count,90,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANDROGENS (21602506),binary,NA,count,287,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,1524,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: LOCAL ANESTHETICS (21605096),binary,NA,count,99,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,1377,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,13434,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: POSTERIOR PITUITARY LOBE HORMONES (21602697),binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,6003,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,12097,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: BETA BLOCKING AGENTS, OTHER COMBINATIONS (21601738)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,303,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,1344,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: LIVER THERAPY, LIPOTROPICS (21600521)",binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,2971,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,275,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,7885,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,6174,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: UTEROTONICS (21602430),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,278,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,4786,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,1009,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: AMPHENICOLS (21602813),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: GONADOTROPINS AND OTHER OVULATION STIMULANTS (21602597),binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,540,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,2168,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,879,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,1066,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,747,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,132,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: SURGICAL AIDS (21605112),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,1715,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,2225,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: OTHER HEMATOLOGICAL AGENTS (21601226),binary,NA,count,63,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANABOLIC STEROIDS (21600915),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,534,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,399,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,199,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS (21602745)",binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,2352,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,5299,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,1287,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: LIPID MODIFYING AGENTS, COMBINATIONS (21601898)",binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,1659,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,9395,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,53,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANDROGENS (21602506),binary,NA,count,513,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,4808,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ULTRASOUND CONTRAST MEDIA (21605437),binary,NA,count,240,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES (21603728),binary,NA,count,229,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,2114,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,6660,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: CARDIOVASCULAR SYSTEM (21605509),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,9095,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTIPSORIATICS FOR SYSTEMIC USE (21602044),binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,199,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ALLERGENS (21605214),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,453,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: OTHER RESPIRATORY SYSTEM PRODUCTS (21603531),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,594,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,3456,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,10854,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,404,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,1801,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: OTHER OTOLOGICALS (21605180),binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,1299,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE (21602318),binary,NA,count,62,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: GLYCOGENOLYTIC HORMONES (21602776),binary,NA,count,166,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,1140,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: CICATRIZANTS (21601986),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: AMPHENICOLS (21602813),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,863,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: LIPID MODIFYING AGENTS, COMBINATIONS (21601898)",binary,NA,count,51,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,1079,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,1226,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTIADRENAL PREPARATIONS (21602748),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: SURGICAL AIDS (21605112),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,denominator,binary,NA,count,49033,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,167,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: OTHER THERAPEUTIC RADIOPHARMACEUTICALS (21605585),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE (21602318),binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,151,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,495,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,73,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ENZYMES (21601997),binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,4872,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,276,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM (21601848),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,722,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANABOLIC STEROIDS (21600915),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,1515,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,5244,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,731,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,400,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION (21600451),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,768,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: OPIOIDS (21604254),binary,NA,count,9196,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,1372,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,1761,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,7750,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,7844,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,2989,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: RENAL SYSTEM (21605462),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: OTHER RESPIRATORY SYSTEM PRODUCTS (21603531),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS (21601730)",binary,NA,count,56,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,713,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS (21604911),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH ANALGESICS (21600220),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,14044,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: HYPOTHALAMIC HORMONES (21602709),binary,NA,count,66,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,388,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,800,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,458,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,128,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,351,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,78,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,1833,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: OTHER HEMATOLOGICAL AGENTS (21601226),binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION (21604787),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,143,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,6820,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: IMMUNE SERA (21601246),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,873,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,4632,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES (21602683),binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,1505,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: OTHER ANTIHYPERTENSIVES (21600438),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,36161,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: BLOOD AND RELATED PRODUCTS (21601137),binary,NA,count,57,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,1537,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: RENAL SYSTEM (21605462),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,3053,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,1461,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,887,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,7419,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,5826,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,296,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: CARDIOVASCULAR SYSTEM (21605509),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,6123,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,662,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,859,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,2274,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: OCULAR VASCULAR DISORDER AGENTS (21605119),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: GLYCOGENOLYTIC HORMONES (21602776),binary,NA,count,161,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: CICATRIZANTS (21601986),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,391,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,2079,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,7701,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: ECTOPARASITICIDES, INCL. SCABICIDES (21604968)",binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,8649,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,194,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,1337,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTACIDS (21600047),binary,NA,count,165,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,1808,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,2802,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,915,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,268,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: OTHER PLAIN VITAMIN PREPARATIONS (21600840),binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,4165,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,3759,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,1991,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,3603,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,16289,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,863,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: OTHER ANTIHYPERTENSIVES (21600438),binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,1650,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,5042,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,790,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,1053,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,1613,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,1351,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: X-RAY CONTRAST MEDIA, NON-IODINATED (21605414)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: VITAMIN K AND OTHER HEMOSTATICS (21601043),binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ALKYLATING AGENTS (21601388),binary,NA,count,451,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,3931,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,814,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,2385,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,251,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,233,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: OTHER OTOLOGICALS (21605180),binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,1438,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTITREMATODALS (21604928),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION (21604787),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,2086,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,2291,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: OCULAR VASCULAR DISORDER AGENTS (21605119),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,2097,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,89,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,3749,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,81,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,1850,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,11780,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,205,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,302,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: CORTICOSTEROIDS (21605164),binary,NA,count,68,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,253,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: POTASSIUM (21600875),binary,NA,count,2876,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,11292,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,1852,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,382,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ALLERGENS (21605214),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTITREMATODALS (21604928),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION (21602558),binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,104,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,2811,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,294,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,4310,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,1065,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTI-PARATHYROID AGENTS (21602785),binary,NA,count,106,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,573,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM (21601848),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,3714,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,6750,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,252,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,7229,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,73,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: UTEROTONICS (21602430),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,457,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,2186,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,2909,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,5237,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,991,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,1579,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,6905,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTIFIBRINOLYTICS (21601033),binary,NA,count,150,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,2814,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,1795,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,1352,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,4101,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: CALCIUM (21600858),binary,NA,count,1608,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,1052,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ALKYLATING AGENTS (21601388),binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,57,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,4338,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,2157,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,12859,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,2124,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: COMBINATIONS OF ANTIBACTERIALS (21603035),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,2538,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,770,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,625,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,36121,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,192,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: SPECIFIC ANTIRHEUMATIC AGENTS (21604021),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,1704,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: BETA BLOCKING AGENTS AND OTHER DIURETICS (21601718),binary,NA,count,63,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS (21601730)",binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,2577,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,133,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,94,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,21158,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,135,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,1641,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,62,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,4939,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,2023,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: COMBINATIONS OF ANTIBACTERIALS (21603035),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,14029,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,373,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,99,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,5865,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,173,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,1388,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,1279,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,10852,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,623,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ESTROGENS (21602514),binary,NA,count,1937,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,5805,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: POSTERIOR PITUITARY LOBE HORMONES (21602697),binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,262,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: CORTICOSTEROIDS (21605164),binary,NA,count,74,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,2197,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION (21600451),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,4021,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,1201,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION (21602558),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,9749,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,510,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ULTRASOUND CONTRAST MEDIA (21605437),binary,NA,count,273,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS (21604125)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,159,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,3179,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTACIDS (21600047),binary,NA,count,195,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,5614,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,1083,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,5602,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,2427,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: EMOLLIENTS AND PROTECTIVES (21601969),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,648,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,3044,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,172,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,2787,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: HYPOTHALAMIC HORMONES (21602709),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,2544,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,2049,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,302,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,283,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ENZYMES (21601997),binary,NA,count,73,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,2792,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: BETA BLOCKING AGENTS AND OTHER DIURETICS (21601718),binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTIADRENAL PREPARATIONS (21602748),binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,158,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: MEDICATED DRESSINGS (21602262),binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,83,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,5274,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,7449,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,1235,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,99,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS (21604125)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: ECTOPARASITICIDES, INCL. SCABICIDES (21604968)",binary,NA,count,63,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: MEDICATED DRESSINGS (21602262),binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,1341,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,10420,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,2024,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,2160,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,938,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: POTASSIUM (21600875),binary,NA,count,2365,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,472,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,132,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,118,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,321,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,200,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,4214,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,1475,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES (21603728),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: OPIOIDS (21604254),binary,NA,count,10860,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,7444,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,49527,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,8526,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,127,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,1217,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,2330,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,246,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,24715,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,1004,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,3103,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,3537,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,4673,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: LIVER THERAPY, LIPOTROPICS (21600521)",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,4893,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,190,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,773,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTIFIBRINOLYTICS (21601033),binary,NA,count,76,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,175,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: INTESTINAL ADSORBENTS (21600627),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: X-RAY CONTRAST MEDIA, NON-IODINATED (21605414)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,61,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: VITAMIN K AND OTHER HEMOSTATICS (21601043),binary,NA,count,84,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,1577,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ESTROGENS (21602514),binary,NA,count,3709,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,1397,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS (21600933),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,183,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,1511,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,1851,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,702,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,16237,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,6513,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,567,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,3756,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,617,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,116,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS (21602745)",binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,82,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,6556,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,1705,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,512,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,1545,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,769,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,2849,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,660,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,3723,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,749,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,5093,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,11773,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,217,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,3057,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,639,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS (21600933),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,157,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: IMMUNE SERA (21601246),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,256,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,152,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,1030,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTIPSORIATICS FOR SYSTEMIC USE (21602044),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,19404,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES (21602683),binary,NA,count,72,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,4357,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: OTHER DIURETICS (21601556),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,20835,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,1473,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: GONADOTROPINS AND OTHER OVULATION STIMULANTS (21602597),binary,NA,count,82,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: CALCIUM (21600858),binary,NA,count,1514,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,1029,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: EMOLLIENTS AND PROTECTIVES (21601969),binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: SPECIFIC ANTIRHEUMATIC AGENTS (21604021),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,1073,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,1099,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,209,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,2987,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,921,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH ANALGESICS (21600220),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,163,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,921,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: BLOOD AND RELATED PRODUCTS (21601137),binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,735,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,3298,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,374,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: OTHER DIURETICS (21601556),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,4388,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,401,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,328,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,863,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,616,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,152,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,449,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,107,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,63,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,167,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,5344,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTI-PARATHYROID AGENTS (21602785),binary,NA,count,53,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,5513,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,87,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,691,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,1477,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,denominator,binary,NA,count,36863,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,1390,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: INTESTINAL ADSORBENTS (21600627),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,1057,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,355,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,12306,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,246,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,1312,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: DRUGS FOR TREATMENT OF LEPRA (21603121),binary,NA,count,137,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,320,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS (21604911),binary,NA,count,53,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,3367,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,9808,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,5877,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: DRUGS FOR TREATMENT OF LEPRA (21603121),binary,NA,count,85,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: OTHER PLAIN VITAMIN PREPARATIONS (21600840),binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,1010,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,1672,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,487,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,3377,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: UTEROTONICS (21602430),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,522,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,1100,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: LIPID MODIFYING AGENTS, COMBINATIONS (21601898)",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,3319,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,88,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,416,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: GLYCOGENOLYTIC HORMONES (21602776),binary,NA,count,68,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,733,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,2606,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS (21600933),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,412,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,935,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: CICATRIZANTS (21601986),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,1024,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: RENAL SYSTEM (21605462),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS (21602745)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,7854,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTI-PARATHYROID AGENTS (21602785),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: EMOLLIENTS AND PROTECTIVES (21601969),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,107,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,250,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,935,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,1029,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: MEDICATED DRESSINGS (21602262),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTI-PARATHYROID AGENTS (21602785),binary,NA,count,51,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS (21602745)",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE (21602318),binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,1622,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,789,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ALKYLATING AGENTS (21601388),binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: POTASSIUM (21600875),binary,NA,count,231,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,707,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,2336,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: SURGICAL AIDS (21605112),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,252,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,236,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: SURGICAL AIDS (21605112),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,258,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,484,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,3591,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: LIVER THERAPY, LIPOTROPICS (21600521)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,555,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,11003,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,1103,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,1122,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,4537,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,116,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,638,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,3445,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION (21600451),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: CALCIUM (21600858),binary,NA,count,785,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,64,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,97,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,103,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,4949,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,2237,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,4358,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES (21603728),binary,NA,count,123,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,1371,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,708,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTITREMATODALS (21604928),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,1790,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,5505,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,773,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,859,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIADRENAL PREPARATIONS (21602748),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,586,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,666,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,379,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH ANALGESICS (21600220),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: LIPID MODIFYING AGENTS, COMBINATIONS (21601898)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,647,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,354,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION (21600451),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,2086,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,327,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,1231,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,66,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,804,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,342,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS (21604911),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,151,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,197,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,920,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH ANALGESICS (21600220),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES (21603728),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: CARDIOVASCULAR SYSTEM (21605509),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: GONADOTROPINS AND OTHER OVULATION STIMULANTS (21602597),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: BETA BLOCKING AGENTS AND OTHER DIURETICS (21601718),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,3011,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,404,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES (21603728),binary,NA,count,75,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,442,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,224,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,4845,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,987,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,8354,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,779,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,2603,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,294,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,2570,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,633,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,1014,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,182,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: LIVER THERAPY, LIPOTROPICS (21600521)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER ANTIHYPERTENSIVES (21600438),binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,106,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTACIDS (21600047),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS (21604125)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: OCULAR VASCULAR DISORDER AGENTS (21605119),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: LIPID MODIFYING AGENTS, COMBINATIONS (21601898)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS (21601730)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,65,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM (21601848),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,238,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,719,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: DRUGS FOR TREATMENT OF LEPRA (21603121),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,621,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: OPIOIDS (21604254),binary,NA,count,4542,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION (21602558),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,277,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,263,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,1161,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS (21604911),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,364,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS (21601730)",binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,198,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,1070,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,369,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,654,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,125,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,107,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,5145,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,327,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,2183,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: VITAMIN K AND OTHER HEMOSTATICS (21601043),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,123,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,1609,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,85,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,594,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,79,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,3385,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,73,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,94,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,870,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,367,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,83,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,133,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: OPIOIDS (21604254),binary,NA,count,4835,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,1235,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,178,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: GLYCOGENOLYTIC HORMONES (21602776),binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER RESPIRATORY SYSTEM PRODUCTS (21603531),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,643,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: LIPID MODIFYING AGENTS, COMBINATIONS (21601898)",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIPSORIATICS FOR SYSTEMIC USE (21602044),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,1115,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,298,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTACIDS (21600047),binary,NA,count,93,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,91,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,1491,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: VITAMIN K AND OTHER HEMOSTATICS (21601043),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER DIURETICS (21601556),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,78,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANABOLIC STEROIDS (21600915),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,432,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,650,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,1123,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,4848,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,125,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIFIBRINOLYTICS (21601033),binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,313,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,2659,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,453,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,857,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: BETA BLOCKING AGENTS AND OTHER DIURETICS (21601718),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,489,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS (21601730)",binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,218,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,414,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,432,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,76,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,605,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,117,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,574,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER HEMATOLOGICAL AGENTS (21601226),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,66,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,1181,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,1974,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,502,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,187,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,113,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,142,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,5731,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,1900,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,1613,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM (21601848),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,3708,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,2187,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,726,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIADRENAL PREPARATIONS (21602748),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,47,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,775,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OCULAR VASCULAR DISORDER AGENTS (21605119),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,10213,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH ANALGESICS (21600220),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIPSORIATICS FOR SYSTEMIC USE (21602044),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: CICATRIZANTS (21601986),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,580,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANABOLIC STEROIDS (21600915),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,122,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,154,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,321,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,546,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH ANALGESICS (21600220),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OTHER HEMATOLOGICAL AGENTS (21601226),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,1458,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,179,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,7401,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,1100,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,18303,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,214,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ENZYMES (21601997),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,226,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,174,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTITREMATODALS (21604928),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,2514,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,2828,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,2072,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,116,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,232,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,1963,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,830,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,999,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,626,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,91,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: CORTICOSTEROIDS (21605164),binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,113,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,623,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: GONADOTROPINS AND OTHER OVULATION STIMULANTS (21602597),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,185,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,240,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: BETA BLOCKING AGENTS AND OTHER DIURETICS (21601718),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,598,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ALKYLATING AGENTS (21601388),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,1428,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: POSTERIOR PITUITARY LOBE HORMONES (21602697),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,denominator,binary,NA,count,9561,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,160,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,4463,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OTHER HEMATOLOGICAL AGENTS (21601226),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,89,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,65,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,166,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,313,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,601,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,384,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,1497,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,3323,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,3419,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,57,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: POSTERIOR PITUITARY LOBE HORMONES (21602697),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,261,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ULTRASOUND CONTRAST MEDIA (21605437),binary,NA,count,118,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: INTESTINAL ADSORBENTS (21600627),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,738,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,368,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,593,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,742,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: X-RAY CONTRAST MEDIA, NON-IODINATED (21605414)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,478,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,2260,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,1489,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,134,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES (21602683),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,712,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: LIPID MODIFYING AGENTS, COMBINATIONS (21601898)",binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: CICATRIZANTS (21601986),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,56,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTI-PARATHYROID AGENTS (21602785),binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,175,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,130,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,322,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,1162,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES (21603728),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: ECTOPARASITICIDES, INCL. SCABICIDES (21604968)",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,456,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER PLAIN VITAMIN PREPARATIONS (21600840),binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANABOLIC STEROIDS (21600915),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,127,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,3382,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,536,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,632,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,767,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,282,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,97,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,1161,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,260,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,214,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,1560,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,135,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS (21601730)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIADRENAL PREPARATIONS (21602748),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM (21601848),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,245,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: LOCAL ANESTHETICS (21605096),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,3122,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,785,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS (21601730)",binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,103,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,627,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,469,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,129,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,530,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,1317,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTI-PARATHYROID AGENTS (21602785),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,111,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIPSORIATICS FOR SYSTEMIC USE (21602044),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,255,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,1083,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,178,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,9235,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,177,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,793,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,815,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,80,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: EMOLLIENTS AND PROTECTIVES (21601969),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: X-RAY CONTRAST MEDIA, NON-IODINATED (21605414)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,51,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,239,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,3486,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,138,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: CORTICOSTEROIDS (21605164),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANDROGENS (21602506),binary,NA,count,120,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ENZYMES (21601997),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: VITAMIN K AND OTHER HEMOSTATICS (21601043),binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,475,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,177,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: CICATRIZANTS (21601986),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,449,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,987,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS (21604125)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES (21602683),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,141,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,777,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: RENAL SYSTEM (21605462),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANDROGENS (21602506),binary,NA,count,109,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION (21600451),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OTHER OTOLOGICALS (21605180),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: ECTOPARASITICIDES, INCL. SCABICIDES (21604968)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,817,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: RENAL SYSTEM (21605462),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: LIVER THERAPY, LIPOTROPICS (21600521)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,162,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,951,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,275,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,1139,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,3692,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,4288,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,1270,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,3046,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER ANTIHYPERTENSIVES (21600438),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,640,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,579,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,2090,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,2024,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,111,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,372,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,700,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,3910,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: LIVER THERAPY, LIPOTROPICS (21600521)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,18279,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER HEMATOLOGICAL AGENTS (21601226),binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,64,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,361,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,265,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS (21604911),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: AMPHENICOLS (21602813),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: LOCAL ANESTHETICS (21605096),binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,115,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,1850,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIPSORIATICS FOR SYSTEMIC USE (21602044),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,537,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,189,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,2908,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,233,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ULTRASOUND CONTRAST MEDIA (21605437),binary,NA,count,92,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,150,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,1709,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,69,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,1374,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,2769,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: BLOOD AND RELATED PRODUCTS (21601137),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,154,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,83,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,65,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIFIBRINOLYTICS (21601033),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,532,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ENZYMES (21601997),binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: BETA BLOCKING AGENTS, OTHER COMBINATIONS (21601738)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,954,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,95,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,1690,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: GONADOTROPINS AND OTHER OVULATION STIMULANTS (21602597),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OTHER ANTIHYPERTENSIVES (21600438),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,399,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,102,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,4099,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,2613,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,228,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,187,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,100,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,513,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS (21600933),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,101,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,140,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,685,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,8196,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,637,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,499,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: BLOOD AND RELATED PRODUCTS (21601137),binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,414,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: BETA BLOCKING AGENTS AND OTHER DIURETICS (21601718),binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,740,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,939,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,390,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: CALCIUM (21600858),binary,NA,count,694,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,102,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: X-RAY CONTRAST MEDIA, NON-IODINATED (21605414)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,189,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,286,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,597,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ESTROGENS (21602514),binary,NA,count,755,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,2740,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS (21600933),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,1578,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,726,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,535,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: INTESTINAL ADSORBENTS (21600627),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,1205,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,2509,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,226,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,1221,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,537,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,186,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,123,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,67,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,120,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,3379,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,1964,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,1956,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,2345,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,224,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,594,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,82,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,175,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,905,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,551,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,475,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,301,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,213,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,2532,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: POTASSIUM (21600875),binary,NA,count,439,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,496,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION (21600451),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: HYPOTHALAMIC HORMONES (21602709),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,1461,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,7782,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,521,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,3240,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,70,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,370,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION (21604787),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,224,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,314,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,857,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER DIURETICS (21601556),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,348,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,3652,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,1986,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,74,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,478,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,81,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,1721,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: EMOLLIENTS AND PROTECTIVES (21601969),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ESTROGENS (21602514),binary,NA,count,990,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: CORTICOSTEROIDS (21605164),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,341,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ESTROGENS (21602514),binary,NA,count,706,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,2782,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,1895,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,102,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,87,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,143,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,803,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,1443,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,315,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: DRUGS FOR TREATMENT OF LEPRA (21603121),binary,NA,count,47,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE (21602318),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: GLYCOGENOLYTIC HORMONES (21602776),binary,NA,count,57,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION (21604787),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,409,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,326,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,6181,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,159,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: ECTOPARASITICIDES, INCL. SCABICIDES (21604968)",binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,1674,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ENZYMES (21601997),binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,643,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ESTROGENS (21602514),binary,NA,count,1400,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: CALCIUM (21600858),binary,NA,count,647,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,353,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,158,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,67,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ALLERGENS (21605214),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,1540,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ALKYLATING AGENTS (21601388),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OTHER DIURETICS (21601556),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,1817,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,608,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,51,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTACIDS (21600047),binary,NA,count,56,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,3004,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: VITAMIN K AND OTHER HEMOSTATICS (21601043),binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,834,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,1495,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,605,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,2326,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: MEDICATED DRESSINGS (21602262),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,2072,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,559,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,441,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,100,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION (21602558),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,93,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER THERAPEUTIC RADIOPHARMACEUTICALS (21605585),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,47,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,974,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,94,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OTHER OTOLOGICALS (21605180),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,556,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,57,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,2117,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,391,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,2026,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,111,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,225,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,379,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS (21604125)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,133,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,299,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: AMPHENICOLS (21602813),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: BETA BLOCKING AGENTS AND OTHER DIURETICS (21601718),binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: CORTICOSTEROIDS (21605164),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,131,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,1528,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,220,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTACIDS (21600047),binary,NA,count,101,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE (21602318),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER ANTIHYPERTENSIVES (21600438),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: EMOLLIENTS AND PROTECTIVES (21601969),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,100,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,151,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTACIDS (21600047),binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,1692,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,139,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,4888,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,434,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,1025,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,44,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,77,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE (21602318),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,70,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,71,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,71,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,2535,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES (21602683),binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,386,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,726,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,320,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,316,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ALKYLATING AGENTS (21601388),binary,NA,count,193,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,629,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: GONADOTROPINS AND OTHER OVULATION STIMULANTS (21602597),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER OTOLOGICALS (21605180),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OTHER ANTIHYPERTENSIVES (21600438),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,462,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANDROGENS (21602506),binary,NA,count,141,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,85,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,1854,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,61,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: RENAL SYSTEM (21605462),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,1943,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,732,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: LOCAL ANESTHETICS (21605096),binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,202,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,14465,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: IMMUNE SERA (21601246),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: LOCAL ANESTHETICS (21605096),binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,357,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,619,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,142,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,472,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,512,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ULTRASOUND CONTRAST MEDIA (21605437),binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,459,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,253,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIADRENAL PREPARATIONS (21602748),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ALKYLATING AGENTS (21601388),binary,NA,count,199,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,985,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,80,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,773,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,124,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,273,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: EMOLLIENTS AND PROTECTIVES (21601969),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,688,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,718,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES (21602683),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,3991,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,1040,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,5828,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,204,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,1802,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: GLYCOGENOLYTIC HORMONES (21602776),binary,NA,count,76,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,22799,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,113,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,457,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,402,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,146,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,1032,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE (21602318),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,228,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,1096,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,81,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,175,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,893,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,349,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER DIURETICS (21601556),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: GLYCOGENOLYTIC HORMONES (21602776),binary,NA,count,77,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,4772,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,1693,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ULTRASOUND CONTRAST MEDIA (21605437),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,539,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,67,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,1284,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,801,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: BLOOD AND RELATED PRODUCTS (21601137),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,73,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,2613,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OPIOIDS (21604254),binary,NA,count,901,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,328,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,439,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,364,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: CICATRIZANTS (21601986),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,665,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,2199,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,57,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,67,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: CALCIUM (21600858),binary,NA,count,637,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,1986,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,1762,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,413,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ENZYMES (21601997),binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE (21602318),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: POTASSIUM (21600875),binary,NA,count,966,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS (21600933),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,177,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER HEMATOLOGICAL AGENTS (21601226),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,3189,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANABOLIC STEROIDS (21600915),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,500,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,2714,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: CARDIOVASCULAR SYSTEM (21605509),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: POSTERIOR PITUITARY LOBE HORMONES (21602697),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: SURGICAL AIDS (21605112),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,281,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,199,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,271,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,230,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,579,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,62,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,155,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,4895,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTACIDS (21600047),binary,NA,count,57,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,14476,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,1018,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,2143,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION (21602558),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,1386,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: HYPOTHALAMIC HORMONES (21602709),binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,2414,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,238,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,308,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,861,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,84,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: HYPOTHALAMIC HORMONES (21602709),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,411,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: DRUGS FOR TREATMENT OF LEPRA (21603121),binary,NA,count,74,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,6251,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: OCULAR VASCULAR DISORDER AGENTS (21605119),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,451,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,1225,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER OTOLOGICALS (21605180),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS (21602745)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,724,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,597,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,508,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,151,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIFIBRINOLYTICS (21601033),binary,NA,count,47,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,1727,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,398,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OTHER RESPIRATORY SYSTEM PRODUCTS (21603531),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,693,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,1102,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,458,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,1797,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,1080,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,83,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OCULAR VASCULAR DISORDER AGENTS (21605119),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,1304,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,738,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,153,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,271,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,487,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER DIURETICS (21601556),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,335,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION (21602558),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,191,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,309,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,532,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,2066,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,1476,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: CORTICOSTEROIDS (21605164),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,318,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,141,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,324,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,47,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,186,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: EMOLLIENTS AND PROTECTIVES (21601969),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,604,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,366,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ALKYLATING AGENTS (21601388),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,2995,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,161,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,2462,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,502,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,547,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: UTEROTONICS (21602430),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,2281,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,557,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,5736,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES (21602683),binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,348,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,980,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,1084,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,2602,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER OTOLOGICALS (21605180),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,5197,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,120,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,67,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER PLAIN VITAMIN PREPARATIONS (21600840),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: DRUGS FOR TREATMENT OF LEPRA (21603121),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,543,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM (21601848),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION (21600451),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,170,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,102,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,347,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,213,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,149,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,82,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS (21601730)",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,118,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,61,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,1302,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: POSTERIOR PITUITARY LOBE HORMONES (21602697),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,267,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,318,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,76,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,730,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,97,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,190,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,57,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,743,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,1147,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,6669,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,129,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,5824,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,1104,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,1959,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,1021,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OPIOIDS (21604254),binary,NA,count,3460,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,112,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,794,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,2071,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,583,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS (21604911),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,257,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS (21604125)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,229,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,1157,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,2008,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,63,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: COMBINATIONS OF ANTIBACTERIALS (21603035),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: RENAL SYSTEM (21605462),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER RESPIRATORY SYSTEM PRODUCTS (21603531),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ALLERGENS (21605214),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,135,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: ECTOPARASITICIDES, INCL. SCABICIDES (21604968)",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,3321,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: SPECIFIC ANTIRHEUMATIC AGENTS (21604021),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,512,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,474,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,1026,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIADRENAL PREPARATIONS (21602748),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,324,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,432,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,1800,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,3459,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,96,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,5217,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,1240,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,139,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,431,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,560,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,908,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,88,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,753,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,171,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,159,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,2190,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,2355,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH ANALGESICS (21600220),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,1259,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,728,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM (21601848),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,506,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM (21601848),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,1767,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ULTRASOUND CONTRAST MEDIA (21605437),binary,NA,count,111,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER PLAIN VITAMIN PREPARATIONS (21600840),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ENZYMES (21601997),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,1600,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: HYPOTHALAMIC HORMONES (21602709),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,389,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,1066,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,383,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,627,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,837,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,3359,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER PLAIN VITAMIN PREPARATIONS (21600840),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,4527,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,534,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,239,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,843,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,85,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,352,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: LOCAL ANESTHETICS (21605096),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: COMBINATIONS OF ANTIBACTERIALS (21603035),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,6338,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,denominator,binary,NA,count,18170,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,446,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,1969,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION (21600451),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: LIVER THERAPY, LIPOTROPICS (21600521)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES (21603728),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,460,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,438,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: MEDICATED DRESSINGS (21602262),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,3654,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: UTEROTONICS (21602430),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,403,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,831,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,175,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANDROGENS (21602506),binary,NA,count,284,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: UTEROTONICS (21602430),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: DRUGS FOR TREATMENT OF LEPRA (21603121),binary,NA,count,47,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,632,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTITREMATODALS (21604928),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,570,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: VITAMIN K AND OTHER HEMOSTATICS (21601043),binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS (21604911),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,269,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,1423,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,403,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,199,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,162,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,3880,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,63,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,114,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,61,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,325,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIPSORIATICS FOR SYSTEMIC USE (21602044),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: MEDICATED DRESSINGS (21602262),binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,898,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,2966,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,68,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS (21600933),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: IMMUNE SERA (21601246),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,454,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,denominator,binary,NA,count,22790,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,1403,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,2638,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: HYPOTHALAMIC HORMONES (21602709),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,88,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,471,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,475,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: POSTERIOR PITUITARY LOBE HORMONES (21602697),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,288,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OTHER PLAIN VITAMIN PREPARATIONS (21600840),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,191,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OPIOIDS (21604254),binary,NA,count,1725,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,1363,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: BLOOD AND RELATED PRODUCTS (21601137),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,370,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANDROGENS (21602506),binary,NA,count,115,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: SPECIFIC ANTIRHEUMATIC AGENTS (21604021),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,84,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANDROGENS (21602506),binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,106,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,1224,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,919,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,895,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,1278,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,1854,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,1442,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER RESPIRATORY SYSTEM PRODUCTS (21603531),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,383,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,149,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,119,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,333,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,230,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,74,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,540,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,81,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: POTASSIUM (21600875),binary,NA,count,1168,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: MEDICATED DRESSINGS (21602262),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,163,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,3784,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OPIOIDS (21604254),binary,NA,count,4593,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,51,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,2737,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTI-PARATHYROID AGENTS (21602785),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,702,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,318,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: POSTERIOR PITUITARY LOBE HORMONES (21602697),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: GONADOTROPINS AND OTHER OVULATION STIMULANTS (21602597),binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,62,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,61,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,780,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,356,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ALLERGENS (21605214),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,301,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,1087,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIFIBRINOLYTICS (21601033),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,107,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,214,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,4434,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,3395,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,57,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,199,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,57,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,689,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,2011,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER OTOLOGICALS (21605180),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,denominator,binary,NA,count,3516,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: CALCIUM (21600858),binary,NA,count,230,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: SPECIFIC ANTIRHEUMATIC AGENTS (21604021),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,128,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,335,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,5179,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,239,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,12121,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION (21604787),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,232,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,5774,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,799,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,10518,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,196,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: LOCAL ANESTHETICS (21605096),binary,NA,count,53,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ALLERGENS (21605214),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS (21602745)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,263,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,463,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES (21603728),binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,4356,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,530,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,1187,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,450,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,453,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,803,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,1095,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,649,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,denominator,binary,NA,count,15177,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: POTASSIUM (21600875),binary,NA,count,1176,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,170,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,1410,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS (21602745)",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,1936,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,64,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,142,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,760,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,209,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,403,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,542,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,1499,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,77,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: POTASSIUM (21600875),binary,NA,count,1261,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,84,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,1197,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,1903,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,1281,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTI-PARATHYROID AGENTS (21602785),binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,311,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,82,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: BLOOD AND RELATED PRODUCTS (21601137),binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,53,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,662,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,1422,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANABOLIC STEROIDS (21600915),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,361,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ESTROGENS (21602514),binary,NA,count,192,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,1835,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,2072,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,1627,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: UTEROTONICS (21602430),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIFIBRINOLYTICS (21601033),binary,NA,count,76,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,91,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: BETA BLOCKING AGENTS AND OTHER DIURETICS (21601718),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,544,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS (21602745)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,80,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,921,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: HYPOTHALAMIC HORMONES (21602709),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: CALCIUM (21600858),binary,NA,count,129,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER ANTIHYPERTENSIVES (21600438),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,286,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: RENAL SYSTEM (21605462),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,536,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,1141,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION (21604787),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,706,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,3021,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,473,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,208,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,949,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,17207,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,1433,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,2346,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,243,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: GLYCOGENOLYTIC HORMONES (21602776),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,104,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: CORTICOSTEROIDS (21605164),binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ULTRASOUND CONTRAST MEDIA (21605437),binary,NA,count,127,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,77,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,3248,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,92,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,686,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,409,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,3521,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,472,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION (21602558),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER HEMATOLOGICAL AGENTS (21601226),binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,220,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,2379,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,702,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,385,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,366,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTITREMATODALS (21604928),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,178,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,1336,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,1041,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: VITAMIN K AND OTHER HEMOSTATICS (21601043),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS (21604911),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,denominator,binary,NA,count,16682,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,637,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,125,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OTHER PLAIN VITAMIN PREPARATIONS (21600840),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,160,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,149,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,962,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,1570,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,706,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,152,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS (21604125)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,1038,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,3083,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: LIVER THERAPY, LIPOTROPICS (21600521)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,397,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,1104,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIFIBRINOLYTICS (21601033),binary,NA,count,48,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,785,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,3096,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,209,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,199,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,92,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,322,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,1310,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,371,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,1661,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: DRUGS FOR TREATMENT OF LEPRA (21603121),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,151,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,142,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,217,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,3805,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,92,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: GONADOTROPINS AND OTHER OVULATION STIMULANTS (21602597),binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,2049,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,566,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,403,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: BETA BLOCKING AGENTS, OTHER COMBINATIONS (21601738)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,1141,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,82,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,2126,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,2468,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ESTROGENS (21602514),binary,NA,count,1603,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,276,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: BLOOD AND RELATED PRODUCTS (21601137),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,65,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: ECTOPARASITICIDES, INCL. SCABICIDES (21604968)",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS (21600933),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,3089,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,1115,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,2887,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,9521,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,662,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,97,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,91,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,1606,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,222,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: MEDICATED DRESSINGS (21602262),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,56,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,5987,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,316,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ALLERGENS (21605214),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,789,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,264,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,382,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OCULAR VASCULAR DISORDER AGENTS (21605119),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,74,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: COMBINATIONS OF ANTIBACTERIALS (21603035),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,467,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: ECTOPARASITICIDES, INCL. SCABICIDES (21604968)",binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,158,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,497,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH ANALGESICS (21600220),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIPSORIATICS FOR SYSTEMIC USE (21602044),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: CARDIOVASCULAR SYSTEM (21605509),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,74,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,209,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,1085,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,531,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: LIPID MODIFYING AGENTS, COMBINATIONS (21601898)",binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION (21602558),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,134,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,1272,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,139,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,5040,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION (21604787),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,117,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: X-RAY CONTRAST MEDIA, NON-IODINATED (21605414)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,261,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER HEMATOLOGICAL AGENTS (21601226),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,4934,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,842,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANTIPSORIATICS FOR SYSTEMIC USE (21602044),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,14405,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,2461,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,18998,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,576,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS (21604125)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: CALCIUM (21600858),binary,NA,count,707,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS (21601730)",binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,1752,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,1 to 365,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER HEMATOLOGICAL AGENTS (21601226),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,1 to 365,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,543,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 365,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,977,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,5166,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,51,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,274,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,1046,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,1379,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS (21600933),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,1158,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,1435,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION (21602558),binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,640,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIADRENAL PREPARATIONS (21602748),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: LIPID MODIFYING AGENTS, COMBINATIONS (21601898)",binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,51,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,2624,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 365,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ANDROGENS (21602506),binary,NA,count,165,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,57,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,152,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,2396,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,2401,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 365,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,127,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,678,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,264,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: SPECIFIC ANTIRHEUMATIC AGENTS (21604021),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,70,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 365,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: CICATRIZANTS (21601986),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,1018,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,820,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 365,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,440,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER PLAIN VITAMIN PREPARATIONS (21600840),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,1503,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,2701,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,263,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,1794,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,363,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: POTASSIUM (21600875),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,670,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: SPECIFIC ANTIRHEUMATIC AGENTS (21604021),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,322,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,556,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: OTHER RESPIRATORY SYSTEM PRODUCTS (21603531),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,1 to 365,ATC 3rd: CORTICOSTEROIDS (21605164),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,126,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: LIPID MODIFYING AGENTS, COMBINATIONS (21601898)",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: UTEROTONICS (21602430),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 365,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES (21603728),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,48,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,823,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,764,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,722,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,275,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANTIADRENAL PREPARATIONS (21602748),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,423,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,1506,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,3673,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,2380,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: CALCIUM (21600858),binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,1 to 365,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,4503,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,193,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,1072,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,925,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,796,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,430,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,83,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,73,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,151,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,875,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,denominator,binary,NA,count,17984,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,117,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 365,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: ANDROGENS (21602506),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,94,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,1882,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,108,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: CARDIOVASCULAR SYSTEM (21605509),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: ANABOLIC STEROIDS (21600915),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,1 to 365,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,44,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,219,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: GLYCOGENOLYTIC HORMONES (21602776),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,2149,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 365,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,443,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION (21602558),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,3416,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,998,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,51,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,1321,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"ATC 3rd: LIPID MODIFYING AGENTS, COMBINATIONS (21601898)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: OPIOIDS (21604254),binary,NA,count,6195,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,533,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,97,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: ANDROGENS (21602506),binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: COMBINATIONS OF ANTIBACTERIALS (21603035),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,119,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,761,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 365,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,739,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,236,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,677,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,110,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"ATC 3rd: X-RAY CONTRAST MEDIA, NON-IODINATED (21605414)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 365,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,412,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,93,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,1003,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS (21604911),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE (21602318),binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,83,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: BLOOD AND RELATED PRODUCTS (21601137),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,942,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,441,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,350,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: ANTIFIBRINOLYTICS (21601033),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,640,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION (21600451),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: OCULAR VASCULAR DISORDER AGENTS (21605119),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,153,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,2160,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,750,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,69,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: ECTOPARASITICIDES, INCL. SCABICIDES (21604968)",binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,949,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,1306,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,78,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,2356,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: LOCAL ANESTHETICS (21605096),binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 365,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,47,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: POSTERIOR PITUITARY LOBE HORMONES (21602697),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ENZYMES (21601997),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OPIOIDS (21604254),binary,NA,count,4878,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,99,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,1712,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,64,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,570,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,864,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,486,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,1945,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,1056,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,1209,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,5029,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,221,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,51,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,353,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: OTHER HEMATOLOGICAL AGENTS (21601226),binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,106,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,554,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE (21602318),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: HYPOTHALAMIC HORMONES (21602709),binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,748,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,1991,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,571,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,493,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,641,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,107,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 365,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,4058,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: POSTERIOR PITUITARY LOBE HORMONES (21602697),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,244,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIFIBRINOLYTICS (21601033),binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,570,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,1243,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,831,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 365,ATC 3rd: POTASSIUM (21600875),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,47,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: VITAMIN K AND OTHER HEMOSTATICS (21601043),binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,216,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,236,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: BLOOD AND RELATED PRODUCTS (21601137),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS (21600933),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,391,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,364,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,138,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,220,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,1935,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,781,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,9980,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,1741,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,92,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION (21604787),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ALKYLATING AGENTS (21601388),binary,NA,count,417,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,318,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ENZYMES (21601997),binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,265,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,484,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: OTHER PLAIN VITAMIN PREPARATIONS (21600840),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS (21600933),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,61,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: CALCIUM (21600858),binary,NA,count,772,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 365,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: POSTERIOR PITUITARY LOBE HORMONES (21602697),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: POSTERIOR PITUITARY LOBE HORMONES (21602697),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,1535,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,63,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,1081,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: POTASSIUM (21600875),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,308,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANABOLIC STEROIDS (21600915),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,549,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,76,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 365,denominator,binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,154,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 365,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 365,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,72,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,90,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES (21603728),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,948,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,2254,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,19029,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: CARDIOVASCULAR SYSTEM (21605509),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,63,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,754,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: BETA BLOCKING AGENTS, OTHER COMBINATIONS (21601738)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: ECTOPARASITICIDES, INCL. SCABICIDES (21604968)",binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,935,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,1644,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: X-RAY CONTRAST MEDIA, NON-IODINATED (21605414)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,1587,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,333,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,5444,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,110,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: OTHER OTOLOGICALS (21605180),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,292,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,113,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS (21600933),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: BETA BLOCKING AGENTS AND OTHER DIURETICS (21601718),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,8567,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,640,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,936,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: ESTROGENS (21602514),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,536,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: ECTOPARASITICIDES, INCL. SCABICIDES (21604968)",binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,592,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,280,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,1878,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,513,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,3229,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,762,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,7444,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,2425,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,280,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,594,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,1486,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"ATC 3rd: ECTOPARASITICIDES, INCL. SCABICIDES (21604968)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,denominator,binary,NA,count,18750,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,2625,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OCULAR VASCULAR DISORDER AGENTS (21605119),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: ANDROGENS (21602506),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,180,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,2132,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,181,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,393,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,47,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,432,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,104,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,117,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ESTROGENS (21602514),binary,NA,count,855,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,5069,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,526,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,3258,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,730,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,63,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,denominator,binary,NA,count,14811,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,235,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,719,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,3308,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: EMOLLIENTS AND PROTECTIVES (21601969),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,2554,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,99,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,548,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,217,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,2353,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,1 to 365,denominator,binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,109,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,147,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,888,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 365,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,2549,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,64,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: BLOOD AND RELATED PRODUCTS (21601137),binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,4199,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 365,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,114,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,851,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,81,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,165,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: GONADOTROPINS AND OTHER OVULATION STIMULANTS (21602597),binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,430,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,258,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 365,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,90,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,81,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,322,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANABOLIC STEROIDS (21600915),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER DIURETICS (21601556),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: DRUGS FOR TREATMENT OF LEPRA (21603121),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,1400,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: CICATRIZANTS (21601986),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,525,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,432,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,81,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,73,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,4245,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,567,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,257,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: EMOLLIENTS AND PROTECTIVES (21601969),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,1676,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: MEDICATED DRESSINGS (21602262),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,2600,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: COMBINATIONS OF ANTIBACTERIALS (21603035),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,1 to 365,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,538,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ALKYLATING AGENTS (21601388),binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,1657,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 365,ATC 3rd: DRUGS FOR TREATMENT OF LEPRA (21603121),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ALLERGENS (21605214),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,811,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,65,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,96,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS (21601730)",binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 365,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION (21602558),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,2123,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,502,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,157,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,101,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,526,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,296,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: RENAL SYSTEM (21605462),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: CALCIUM (21600858),binary,NA,count,1068,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,1225,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,383,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,221,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,465,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,1542,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,952,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,815,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,1 to 365,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: UTEROTONICS (21602430),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES (21603728),binary,NA,count,215,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,76,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,2475,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION (21600451),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,341,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: LIPID MODIFYING AGENTS, COMBINATIONS (21601898)",binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER THERAPEUTIC RADIOPHARMACEUTICALS (21605585),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,270,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,1126,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,69,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,1681,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,2744,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 365,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ULTRASOUND CONTRAST MEDIA (21605437),binary,NA,count,133,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,379,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION (21600451),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ALKYLATING AGENTS (21601388),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,1079,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,872,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 365,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: ESTROGENS (21602514),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OPIOIDS (21604254),binary,NA,count,4180,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,4552,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,1 to 365,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,250,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,368,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,460,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS (21604911),binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,336,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 365,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANDROGENS (21602506),binary,NA,count,119,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: CALCIUM (21600858),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: BLOOD AND RELATED PRODUCTS (21601137),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,65,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,491,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,504,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,1271,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,1905,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,2351,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,169,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: OTHER ANTIHYPERTENSIVES (21600438),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,64,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,166,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,780,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,5471,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 365,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,62,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,5612,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,70,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,denominator,binary,NA,count,2452,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,1864,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,2823,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTACIDS (21600047),binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,101,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 365,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,102,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,282,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,547,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: INTESTINAL ADSORBENTS (21600627),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,1449,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: CORTICOSTEROIDS (21605164),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS (21601730)",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,831,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,323,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,2611,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,1598,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,283,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,3222,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,446,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,438,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,175,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 365,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,denominator,binary,NA,count,70,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,2408,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,406,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,545,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,221,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,916,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,1020,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,1932,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,9790,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: SURGICAL AIDS (21605112),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,194,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER ANTIHYPERTENSIVES (21600438),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,100,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,4548,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,861,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,445,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,241,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: HYPOTHALAMIC HORMONES (21602709),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,17014,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,4725,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,266,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: SURGICAL AIDS (21605112),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,1914,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,1231,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: MEDICATED DRESSINGS (21602262),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,609,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,4770,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: GONADOTROPINS AND OTHER OVULATION STIMULANTS (21602597),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,505,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: ANDROGENS (21602506),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,1596,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,80,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,1207,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANTITREMATODALS (21604928),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,458,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,2415,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,1790,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 365,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,1564,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,339,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,570,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,2035,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: OTHER PLAIN VITAMIN PREPARATIONS (21600840),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,1608,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,155,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,330,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,273,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTI-PARATHYROID AGENTS (21602785),binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,72,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,3355,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,588,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,241,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 365,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,555,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,1458,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,136,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,1033,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 365,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 365,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,441,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: GONADOTROPINS AND OTHER OVULATION STIMULANTS (21602597),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS (21600933),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,699,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,1114,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,416,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,1971,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,591,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS (21604911),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: GLYCOGENOLYTIC HORMONES (21602776),binary,NA,count,96,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,1233,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,212,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,1387,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: CALCIUM (21600858),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,1626,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,264,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,62,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ANTITREMATODALS (21604928),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,285,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,7815,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,53,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 365,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,454,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 365,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: OPIOIDS (21604254),binary,NA,count,449,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,2876,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,360,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,279,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,931,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ESTROGENS (21602514),binary,NA,count,1078,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: OPIOIDS (21604254),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,795,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,202,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER RESPIRATORY SYSTEM PRODUCTS (21603531),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 365,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: ANTACIDS (21600047),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,162,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: LIVER THERAPY, LIPOTROPICS (21600521)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,249,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: CALCIUM (21600858),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH ANALGESICS (21600220),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: GLYCOGENOLYTIC HORMONES (21602776),binary,NA,count,61,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 365,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,1348,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,577,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,57,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,228,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,2016,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,1 to 365,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,131,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,4307,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: GONADOTROPINS AND OTHER OVULATION STIMULANTS (21602597),binary,NA,count,62,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: ENZYMES (21601997),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: EMOLLIENTS AND PROTECTIVES (21601969),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,1281,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,2488,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,762,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: AMPHENICOLS (21602813),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,1 to 365,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION (21604787),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,1095,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,225,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIPSORIATICS FOR SYSTEMIC USE (21602044),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,1053,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIPSORIATICS FOR SYSTEMIC USE (21602044),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,149,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 365,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: LOCAL ANESTHETICS (21605096),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,351,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ANTACIDS (21600047),binary,NA,count,102,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,517,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,1753,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,"ATC 3rd: BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS (21601730)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: EMOLLIENTS AND PROTECTIVES (21601969),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,99,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,193,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,516,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ANTIFIBRINOLYTICS (21601033),binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,69,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: RENAL SYSTEM (21605462),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,151,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: SURGICAL AIDS (21605112),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 365,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,4996,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,86,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,2707,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,710,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,1184,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,48,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,229,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: MEDICATED DRESSINGS (21602262),binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,1326,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,2261,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,1562,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: OTHER OTOLOGICALS (21605180),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,1639,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS (21602745)",binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,698,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,286,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: RENAL SYSTEM (21605462),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,121,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,497,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,6504,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,3349,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,6856,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,2107,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: GONADOTROPINS AND OTHER OVULATION STIMULANTS (21602597),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,8365,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: BETA BLOCKING AGENTS AND OTHER DIURETICS (21601718),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,2328,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,3243,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,171,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,63,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,104,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,6858,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,230,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,100,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,1865,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,198,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: LOCAL ANESTHETICS (21605096),binary,NA,count,47,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,1492,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,141,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,805,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,293,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS (21602745)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH ANALGESICS (21600220),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,2573,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,17005,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,110,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS (21604911),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,526,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: OTHER DIURETICS (21601556),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,311,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANTACIDS (21600047),binary,NA,count,119,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,409,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,102,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: OPIOIDS (21604254),binary,NA,count,4288,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,119,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: EMOLLIENTS AND PROTECTIVES (21601969),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,422,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ANTIADRENAL PREPARATIONS (21602748),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,6701,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,3981,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,90,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: X-RAY CONTRAST MEDIA, NON-IODINATED (21605414)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,3069,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 365,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,102,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,870,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"ATC 3rd: BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS (21601730)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: UTEROTONICS (21602430),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,934,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: ANTI-PARATHYROID AGENTS (21602785),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM (21601848),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANTIFIBRINOLYTICS (21601033),binary,NA,count,96,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ALLERGENS (21605214),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,44,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,1263,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 365,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,10745,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,655,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,818,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,409,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,122,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,378,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,6260,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,1607,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION (21602558),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: ENZYMES (21601997),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,1 to 365,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,927,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION (21604787),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES (21602683),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: LIVER THERAPY, LIPOTROPICS (21600521)",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER ANTIHYPERTENSIVES (21600438),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,82,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTACIDS (21600047),binary,NA,count,70,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,460,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,2447,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: CICATRIZANTS (21601986),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: CARDIOVASCULAR SYSTEM (21605509),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: ANTACIDS (21600047),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,5655,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES (21603728),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,160,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,329,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: CORTICOSTEROIDS (21605164),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 365,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: BETA BLOCKING AGENTS AND OTHER DIURETICS (21601718),binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,299,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,2118,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,3289,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,317,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,213,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,189,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,1 to 365,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,47,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: HYPOTHALAMIC HORMONES (21602709),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,51,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,516,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: POTASSIUM (21600875),binary,NA,count,1288,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: IMMUNE SERA (21601246),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ULTRASOUND CONTRAST MEDIA (21605437),binary,NA,count,105,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,1399,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,2421,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,494,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,1441,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES (21603728),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,1533,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,69,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,661,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,389,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: OCULAR VASCULAR DISORDER AGENTS (21605119),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,362,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ENZYMES (21601997),binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS (21604125)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: GLYCOGENOLYTIC HORMONES (21602776),binary,NA,count,99,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,5972,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,562,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,244,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,149,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,70,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,692,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,denominator,binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,713,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,159,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER OTOLOGICALS (21605180),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: LIVER THERAPY, LIPOTROPICS (21600521)",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: OPIOIDS (21604254),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 365,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: OTHER ANTIHYPERTENSIVES (21600438),binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,2712,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,1 to 365,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 365,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,402,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,464,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,362,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,635,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: LOCAL ANESTHETICS (21605096),binary,NA,count,64,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,11476,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,6063,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,380,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: AMPHENICOLS (21602813),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES (21602683),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,361,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: OTHER DIURETICS (21601556),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: BETA BLOCKING AGENTS AND OTHER DIURETICS (21601718),binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,3947,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,487,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,1890,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: RENAL SYSTEM (21605462),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: VITAMIN K AND OTHER HEMOSTATICS (21601043),binary,NA,count,47,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,209,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,818,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,2695,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,5594,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANDROGENS (21602506),binary,NA,count,353,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: CALCIUM (21600858),binary,NA,count,533,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES (21602683),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,185,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE (21602318),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,31938,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ALLERGENS (21605214),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,658,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,8160,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 365,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANTI-PARATHYROID AGENTS (21602785),binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,4309,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,269,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER OTOLOGICALS (21605180),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS (21602745)",binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,1961,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,915,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,104,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,1 to 365,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,10224,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER DIURETICS (21601556),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,668,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER RESPIRATORY SYSTEM PRODUCTS (21603531),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,911,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,84,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,216,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,51,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,109,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ESTROGENS (21602514),binary,NA,count,2533,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: ALKYLATING AGENTS (21601388),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,3481,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ESTROGENS (21602514),binary,NA,count,1064,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,921,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: INTESTINAL ADSORBENTS (21600627),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: BLOOD AND RELATED PRODUCTS (21601137),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,5490,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,1395,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE (21602318),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,528,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: LIVER THERAPY, LIPOTROPICS (21600521)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,1 to 365,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,63,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 365,ATC 3rd: CALCIUM (21600858),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,614,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,374,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,118,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES (21603728),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,1220,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,820,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: OTHER PLAIN VITAMIN PREPARATIONS (21600840),binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,51,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,2967,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,799,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: CORTICOSTEROIDS (21605164),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,80,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,1 to 365,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: OTHER HEMATOLOGICAL AGENTS (21601226),binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 365,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,2342,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,1468,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH ANALGESICS (21600220),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: ESTROGENS (21602514),binary,NA,count,102,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,383,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: VITAMIN K AND OTHER HEMOSTATICS (21601043),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,1320,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,688,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,3159,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,322,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,5107,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,620,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,728,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: CICATRIZANTS (21601986),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 365,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,53,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ENZYMES (21601997),binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: GLYCOGENOLYTIC HORMONES (21602776),binary,NA,count,65,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: POTASSIUM (21600875),binary,NA,count,1066,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,1473,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,4524,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,3785,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANDROGENS (21602506),binary,NA,count,104,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,2167,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM (21601848),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,150,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,868,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: CORTICOSTEROIDS (21605164),binary,NA,count,53,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,626,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS (21604125)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER PLAIN VITAMIN PREPARATIONS (21600840),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,10345,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,419,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: BLOOD AND RELATED PRODUCTS (21601137),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: VITAMIN K AND OTHER HEMOSTATICS (21601043),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,5138,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,1981,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,326,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,226,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,314,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ULTRASOUND CONTRAST MEDIA (21605437),binary,NA,count,161,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,3611,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,4219,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,82,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,539,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,203,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: CORTICOSTEROIDS (21605164),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,2236,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: POTASSIUM (21600875),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,1226,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: ANTACIDS (21600047),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,2082,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,209,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,denominator,binary,NA,count,31647,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,1 to 365,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,1 to 365,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,617,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH ANALGESICS (21600220),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: MEDICATED DRESSINGS (21602262),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,131,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS (21600680)",binary,NA,count,99,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,153,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,8743,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,758,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: ULTRASOUND CONTRAST MEDIA (21605437),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,87,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,385,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,2277,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,2299,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,557,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: BETA BLOCKING AGENTS AND OTHER DIURETICS (21601718),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,1996,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,1402,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,500,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM (21601848),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,387,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,2623,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ANTIPSORIATICS FOR SYSTEMIC USE (21602044),binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,1366,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,537,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTI-PARATHYROID AGENTS (21602785),binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,96,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: ANTIADRENAL PREPARATIONS (21602748),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: LOCAL ANESTHETICS (21605096),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,757,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,701,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,1543,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,1336,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: COMBINATIONS OF ANTIBACTERIALS (21603035),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,3240,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,173,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,112,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,1321,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,4186,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,1152,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,259,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,1149,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES (21602683),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,97,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,3120,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,2474,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,161,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,4366,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,9283,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,1702,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,990,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ULTRASOUND CONTRAST MEDIA (21605437),binary,NA,count,103,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS (21601730)",binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: POSTERIOR PITUITARY LOBE HORMONES (21602697),binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,83,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,1244,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS (21604125)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,293,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,593,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,98,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,65,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,250,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,1509,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: AMPHENICOLS (21602813),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,1104,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: HYPOTHALAMIC HORMONES (21602709),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,413,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,607,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,1 to 365,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,686,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,2200,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: DRUGS FOR TREATMENT OF LEPRA (21603121),binary,NA,count,71,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,252,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: OTHER OTOLOGICALS (21605180),binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 365,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,174,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,112,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,denominator,binary,NA,count,116,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,446,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,343,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: ULTRASOUND CONTRAST MEDIA (21605437),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,589,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: LOCAL ANESTHETICS (21605096),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ALKYLATING AGENTS (21601388),binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,411,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,91,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,476,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: BETA BLOCKING AGENTS AND OTHER DIURETICS (21601718),binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,269,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,3718,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: PROTEIN KINASE INHIBITORS (947753),binary,NA,count,61,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,103,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,2492,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,2937,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,426,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,malaria,1 to 365,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,2875,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,496,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,6321,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: OPIOIDS (21604254),binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: ULTRASOUND CONTRAST MEDIA (21605437),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,1317,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,1997,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,295,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION (21600451),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,336,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: VITAMIN K AND OTHER HEMOSTATICS (21601043),binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: OTHER HEMATOLOGICAL AGENTS (21601226),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE (21602318),binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,15043,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,5212,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,4536,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: CORTICOSTEROIDS (21605164),binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: ANTACIDS (21600047),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,4779,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,79,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: X-RAY CONTRAST MEDIA, NON-IODINATED (21605414)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: MEDICATED DRESSINGS (21602262),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,332,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,554,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,505,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIADRENAL PREPARATIONS (21602748),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,134,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,9555,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,152,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIFIBRINOLYTICS (21601033),binary,NA,count,51,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: IMMUNE SERA (21601246),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,290,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,malaria,1 to 365,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ANABOLIC STEROIDS (21600915),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: DRUGS FOR TREATMENT OF LEPRA (21603121),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM (21601848),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS (21602745)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,351,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ANTI-PARATHYROID AGENTS (21602785),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: POTASSIUM (21600875),binary,NA,count,1566,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANABOLIC STEROIDS (21600915),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: POTASSIUM (21600875),binary,NA,count,1188,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,719,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,288,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,828,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,1034,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,1171,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,449,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,56,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,3347,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: DRUGS FOR TREATMENT OF LEPRA (21603121),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,147,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,2960,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,44,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,159,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: ANTIPSORIATICS FOR SYSTEMIC USE (21602044),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,596,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES (21602683),binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OCULAR VASCULAR DISORDER AGENTS (21605119),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,633,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,78,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,114,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,114,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: OTHER ANTIANEMIC PREPARATIONS (21601131),binary,NA,count,109,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: ECTOPARASITICIDES, INCL. SCABICIDES (21604968)",binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,1134,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,790,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,2684,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS (21600835)",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,1989,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION (21602558),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: POTASSIUM (21600875),binary,NA,count,109,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,315,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: DRUGS FOR TREATMENT OF LEPRA (21603121),binary,NA,count,114,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,covid,1 to 365,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,1039,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: LIPID MODIFYING AGENTS, COMBINATIONS (21601898)",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION (21600451),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCodelistATC
